SEROTONIN RECEPTOR MODULATOR
Certain biphenyic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases.
Latest Janssen Pharmaceutica NV Patents:
This application claims the benefit of U.S. provisional patent application Ser. No. 61/109,903, filed Oct. 30, 2008.
FIELD OF THE INVENTIONThere is provided by the present invention compounds that are serotonin receptor modulators. More particularly, there is provided by the present invention certain compounds that are serotonin receptor modulators useful for the treatment of disease states mediated by serotonin receptor activity.
BACKGROUND OF THE INVENTIONSerotonin (5-hydroxytryptamine, 5-HT) is a major neurotransmitter eliciting effects via a multiplicity of receptors. To date, at least fifteen different 5-HT receptors have been identified, largely as the result of cDNA cloning. These receptors have been grouped into seven families (5-HT1 through 5-HT7) (Hoyer, D. et al. Pharmacol. Biochem. Behav., 2002, 71, 533-554).
Fourteen of the fifteen cloned 5-HT receptors are expressed in the brain. 5-HT is implicated in many disease states, particularly conditions of the central nervous system including; depression, anxiety, schizophrenia, eating disorders, obsessive compulsive disorder, learning and memory dysfunction, migraine, chronic pain, sensory perception, motor activity, temperature regulation, nociception, sexual behavior, hormone secretion, and cognition.
The identification of multiple 5-HT receptors has provided the opportunity to characterize existing therapeutic agents thought to act via the serotonergic system. Consequently, this has led to the realization that many drugs have non-selective properties (Roth, B. L. et al., Neuroscientist, 2000, 6(4), 252-262). For example, the antipsychotic drugs, clozapine, chlorpromazine, haloperidol and olanzapine exhibit affinities for multiple serotonin receptors in addition to other families of receptors. Similar behavior has been noted for antidepressants including imipramine, nortriptaline, fluoxetine and sertraline. Similarly, the anti-migraine agent sumatriptan exhibits high affinity for several serotonin receptors. While the lack of selectivity often contributes to a favorable therapeutic outcome, it can also cause undesirable and dose-limiting side effects (Stahl, S. M., Essential Psychopharmacology, 2nd ed., Cambridge University Press, Cambridge, U.K., 2000). For example, the inhibition of serotonin and norepinephrine uptake together with 5-HT2 receptor blockade is responsible for the therapeutic effects of the tricyclic antidepressants. In contrast, their blockade of histamine H1, muscarinic and alpha-adrenergic receptors can lead to sedation, blurred vision and orthostatic hypertension respectively. Likewise, the atypical antipsychotics, including olanzapine and clozapine, are considered to have positive therapeutic effects attributable to their actions at 5-HT2, D2 and 5-HT7 receptors. Conversely, their side effect liability is due to their affinities for a range of dopaminergic, serotonergic and adrenergic receptors.
Elucidating selective ligands has the potential to ameliorate untoward pharmacologies and provide novel efficacious therapies. More importantly, the ability to obtain compounds which portray receptor selectivity provides the prospect to target distinct therapeutic mechanisms and improve clinical responses with a single drug. Consequently, there remains a need for potent serotonin receptor modulators with desirable pharmaceutical properties.
SUMMARY OF THE INVENTIONCertain compounds have now been found to have 5HT-modulating activity, in particular 5HT7 and/or serotonin transporter modulating activity. In particular, the invention is directed to the general and preferred embodiments defined, respectively, and by the independent and dependent claims appended hereto, which are incorporated by reference herein.
Thus, in one general aspect, the invention relates to compounds of Formula (I):
wherein
R1 is —H, —C1-4alkyl, monocyclic cycloalkyl, phenyl, or benzyl;
m is 1, 2 or 3,
n is 1 or 2, with the proviso that if m is 2, then n is not 1;
R2 and R3 are each independently —H or —C1-4alkyl;
R4 is —H, F, C1-4alkyl, or R4 is —OH when L is —CH2—, —CF2—, or —CHF—, —OCH2—, or —OCH(CH3)—;
where
-
- where Rb is —H; a —C1-4alkyl group unsubstituted or substituted with OH or halo; —CO2C1-4alkyl; or —CO2H; and
- Rc and Rd are each independently —H, —C1-4alkyl, —O—C1-4alkyl, or halo; or Rc and Rd taken together form an oxime, a C1-4alkyl oxime, or a carbonyl group;
- or Rc and Rd taken together with the carbon to which they are attached form a C3-6cycloalkyl group;
i) a phenyl or phenoxy group, unsubstituted or substituted with one, two, or three Rg substituents;
-
- where each Rg substituent is selected from the group consisting of: —C1-6alkyl, —OH, —OC1-6alkyl, —CN, —NO2, —C(O)C1-6alkyl, —S(O)0-2—C1-6alkyl, —OS(O)0-2—C1-6alkyl, —SO2CF3, —SCF3, halo, —CF3, —OCF3, —CO2H, —CO2C1-6alkyl, —CH2OH, monocyclic cycloalkyl, phenyl, thiophenyl, benzhydryl, and oxadiazolyl;
- or two Rg substituents taken together form —OCH2O—, —OCF2O—, or —OCH2CH2O—;
ii) a naphthyl group, unsubstituted or substituted with C1-4alkyl or halo;
iii) a monocyclic heteroaryl group, unsubstituted or substituted with one, two, or three Rg substituents;
iv) a fused bicyclic heteroaryl group, unsubstituted or substituted with C1-4alkyl or halo;
v) a monocyclic cycloalkyl group, optionally fused to a phenyl ring, and unsubstituted or substituted with one or two substituents selected from the group consisting of: —C1-4alkyl, —OC1-4alkyl, halo, —CF3, oxime, —C1-4alkyl oxime, or phenyl; and
vi) a monocyclic heterocycloalkyl group, optionally fused to or substituted with phenyl;
X is C or N; andR6 or R7 are each independently —H, halo, —CF3, thiophene, or —C(O)N(Rx)Ry;
wherein Rx and Ry are each independently —H or —C1-4alkyl.
The invention also relates to stereoisomeric forms, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of compounds of Formula (I). In certain preferred embodiments, the compound of Formula (I) is a compound selected from those species described or exemplified in the detailed description below.
In a further general aspect, the invention relates to pharmaceutical compositions each comprising: (a) an effective amount of an agent selected from compounds of Formula (I) and stereoisomeric forms, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites thereof; and (b) a pharmaceutically acceptable excipient.
In another general aspect, the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition (collectively, “indications”) mediated by 5HT7 activity, comprising administering to the subject in need of such treatment an effective amount of a compound of Formula (I), or a stereoisomeric form, hydrate, solvate, pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite of such compound. In certain preferred embodiments of the inventive method, the disease, disorder, or medical condition is selected from: cognitive disorders, sleep disorders, psychiatric disorders, and other disorders.
Preferred embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.
DETAILED DESCRIPTION OF THE INVENTION AND ITS PREFERRED EMBODIMENTSThe invention may be more fully appreciated by reference to the following detailed description, including the following glossary of terms and the concluding examples. For the sake of brevity, the disclosures of the publications, including patents, cited in this specification are herein incorporated by reference.
The terms “including”, “containing” and “comprising” are used herein in their open, non-limiting sense.
The term “alkyl” refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain. Examples of alkyl groups include methyl (Me, which may also be structurally depicted by a bond, “/”), ethyl (Et), n-propyl (Pr), isopropyl (iPr), butyl (nBu), isobutyl (iBu), sec-butyl (sBu), tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and so on.
The term “cycloalkyl” refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle. Illustrative examples of cycloalkyl groups include the following entities (depicted without their bonds of attachment):
A “heterocycloalkyl” refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated or partially saturated and has from 3 to 12 ring atoms per ring structure selected from carbon atoms and up to three heteroatoms selected from nitrogen, oxygen, and sulfur. The ring structure may optionally contain up to two oxo groups on carbon or sulfur ring members. Illustrative examples (depicted without their bonds of attachment) include:
The term “heteroaryl” refers to a monocyclic, fused bicyclic, or fused polycyclic aromatic heterocycle (ring structure having ring atoms selected from carbon atoms and up to four heteroatoms selected from nitrogen, oxygen, and sulfur) having from 3 to 12 ring atoms per heterocycle. Illustrative examples of heteroaryl groups include the following entities (depicted without their bonds of attachment):
Those skilled in the art will recognize that the species of cycloalkyl, heterocycloalkyl, and heteroaryl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected.
The term “halogen” represents chlorine, fluorine, bromine or iodine. The term “halo” represents chloro, fluoro, bromo or iodo.
The term “substituted” means that the specified group or moiety bears one or more substituents. The term “unsubstituted” means that the specified group bears no substituents. The term “optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system. In cases where a specified moiety or group is not expressly noted as being optionally substituted or substituted with any specified substituent, it is understood that such a moiety or group is intended to be unsubstituted.
Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. It is understood that some compounds referred to herein are chiral and/or have geometric isomeric centers, for example E- and Z-isomers. All optical isomers and stereoisomers of the compounds of any general structural formula, and mixtures thereof, are considered within the scope of the formula. Thus, any general formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof. Furthermore, certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers. Additionally, any general formula given herein is intended to embrace hydrates, solvates, and polymorphs of such compounds, and mixtures thereof. Furthermore, certain compounds referred to herein can exist in solvated as well as unsolvated forms. It is understood that this invention encompasses all such solvated and unsolvated forms that possess the activity that characterizes the compounds of this invention.
In another example, a zwitterionic compound is encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its zwitterionic form. Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard IUPAC-endorsed names that are well known and part of standard sets of defined scientific names. In this regard, the name zwitterion is assigned the name identification CHEBI:27369 by the Chemical Entities of Biological Interest (ChEBI) dictionary of molecular entities. As generally well known, a zwitterion or zwitterionic compound is a neutral compound that has formal unit charges of opposite sign. Sometimes these compounds are referred to by the term “inner salts”. Other sources refer to these compounds as “dipolar ions”, although the latter term is regarded by still other sources as a misnomer. As a specific example, aminoethanoic acid (the amino acid glycine) has the formula H2NCH2COOH, and it exists in some media (in this case in neutral media) in the form of the zwitterion +H3NCH2COO−. Zwitterions, zwitterionic compounds, inner salts and dipolar ions in the known and well established meanings of these terms are within the scope of this invention, as would in any case be so appreciated by those of ordinary skill in the art. Because there is no need to name each and every embodiment that would be recognized by those of ordinary skill in the art, no structures of the zwitterionic compounds that are associated with the compounds of this invention are given explicitly herein. They are, however, part of the embodiments of this invention. No further examples in this regard are provided herein because the interactions and transformations in a given medium that lead to the various forms of a given compound are known by any one of ordinary skill in the art.
Any general formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures of the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2H, 3H, 11C, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 36Cl, and 125I, respectively. Such isotopically labeled compounds are useful in metabolic studies (preferably with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques (such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 15F or 11C labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
When referring to a formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the moiety for the variable appearing elsewhere. In other words, where a variable appears more than once in a formula, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula unless otherwise indicated.
By way of a first example on substituent terminology, if substituent S1example is one of S1 and S2, and substituent S2example is one of S3 and S4, then these assignments refer to embodiments of this invention given according to the choices S1example is S1 and S2example is S3; S1example is S1 and S2example is S4; S1example is S2 and S2example is S3; S1example is S2 and S2example is S4; and equivalents of each one of such choices. The shorter terminology “S1example is one of S1 and S2, and S2example is one of S3 and S4” is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing first example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein. The foregoing convention given herein for substituents extends, when applicable, to members such as R1, R2, A, X4, X5, X6, X7, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rl, Rm, and Ro, and any other generic substituent symbol used herein.
Furthermore, when more than one assignment is given for any member or substituent, embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof. By way of a second example on substituent terminology, if it is herein described that substituent Sexample is one of S1, S2, and S3, this listing refers to embodiments of this invention for which Sexample is S1; Sexample is S2; Sexample is S3; Sexample is one of S1 and S2; Sexample is one of S1 and S3; Sexample is one of S2 and S3; Sexample is one of S1, S2 and S3; and Sexample is any equivalent of each one of these choices. The shorter terminology “Sexample is one of S1, S2, and S3” is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing second example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein. The foregoing convention given herein for substituents extends, when applicable, to members such as as R1, R2, A, X4, X5, X6, X7, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rl, Rm, and Ro, and any other generic substituent symbol used herein.
The nomenclature “Ci-j” with j>i, when applied herein to a class of substituents, is meant to refer to embodiments of this invention for which each and every one of the number of carbon members, from i to j including i and j, is independently realized. By way of example, the term C1-3 refers independently to embodiments that have one carbon member (C1), embodiments that have two carbon members (C2), and embodiments that have three carbon members (C3).
The term Cn-malkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies n≦N≦m, with m>n. Any disubstituent referred to herein is meant to encompass the various attachment possibilities when more than one of such possibilities are allowed. For example, reference to disubstituent A-B-, where A≠B, refers herein to such disubstituent with A attached to a first substituted member and B attached to a second substituted member, and it also refers to such disubstituent with A attached to the second substituted member and B attached to the first substituted member.
The compounds of Formula (I) and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of the present invention are useful as serotonin receptor modulators in the methods of the invention.
A “pharmaceutically acceptable salt” is intended to mean a salt of a free acid or base of a compound represented by Formula (I), that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See, generally, G. S. Paulekuhn, et al., “Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database”, J. Med. Chem., 2007, 50:6665-72, S. M. Berge, et al., “Pharmaceutical Salts”, J Pharm Sci., 1977, 66:1-19, and Handbook of Pharmaceutical Salts, Properties, Selection, and Use, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002. Examples of pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. A compound of Formula (I) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates, methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.
When the compound of Formula (I) contains a basic nitrogen, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspartic acid, glutaric acid or glutamic acid, an aromatic acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid, a sulfonic acid, such as laurylsulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, any compatible mixture of acids such as those given as examples herein, and any other acid and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
When the compound of Formula (I) is an acid, such as a carboxylic acid or sulfonic acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology. Illustrative examples of suitable salts include organic salts derived from amino acids, such as N-methyl-D-glucamine, lysine, choline, glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as tromethamine, benzylamines, pyrrolidines, piperidine, morpholine, and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
The invention also relates to pharmaceutically acceptable prodrugs of the compounds of Formula (I), and treatment methods employing such pharmaceutically acceptable prodrugs. The term “prodrug” means a precursor of a designated compound that, following administration to a subject, yields the compound in vivo via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula (I). A “pharmaceutically acceptable prodrug” is a prodrug that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
Exemplary prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, covalently joined through an amide or ester bond to a free amino, hydroxy, or carboxylic acid group of a compound of Formula (I). Examples of amino acid residues include the twenty naturally occurring amino acids, commonly designated by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.
Additional types of prodrugs may be produced, for instance, by derivatizing free carboxyl groups of structures of Formula (I) as amides or alkyl esters. Representative pharmaceutically acceptable amides of the invention include those derived from ammonia, primary C1-6 alkyl amines and secondary di(C1-6alkyl) amines. Secondary amines include 5- or 6-membered heterocyclic or heteroaromatic ring moieties containing at least one nitrogen atom and optionally between 1 and 2 additional heteroatoms. Preferred amides are derived from ammonia, C1-3alkyl primary amines, and di(C1-2alkyl)amines. Representative pharmaceutically acceptable esters of the invention include C1-7alkyl, C6-7cycloalkyl, phenyl, and phenyl(C1-6)alkyl esters. Preferred esters include methyl esters. Prodrugs may also be prepared by derivatizing free hydroxy groups using groups including hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, following procedures such as those outlined in Fleisher et al., Adv. Drug Delivery Rev. 1996, 19, 115-130. Carbamate derivatives of hydroxy and amino groups may also yield prodrugs. Carbonate derivatives, sulfonate esters, and sulfate esters of hydroxy groups may also provide prodrugs. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester, optionally substituted with one or more ether, amine, or carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also useful to yield prodrugs. Prodrugs of this type may be prepared as described in Robinson et al., J Med Chem. 1996, 39 (1), 10-18. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including ether, amine, and carboxylic acid functionalities.
The present invention also relates to pharmaceutically active metabolites of the compounds of Formula (I), which may also be used in the methods of the invention. A “pharmaceutically active metabolite” means a pharmacologically active product of metabolism in the body of a compound of Formula (I) or salt thereof. Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini, et al., J Med Chem. 1997, 40, 2011-2016; Shan, et al., J Pharm Sci. 1997, 86 (7), 765-767; Bagshawe, Drug Dev Res. 1995, 34, 220-230; Bodor, Adv Drug Res. 1984, 13, 224-331; Bundgaard, Design of Prodrugs (Elsevier Press, 1985); and Larsen, Design and Application of Prodrugs, Drug Design and Development (Krogsgaard-Larsen, et al., eds., Harwood Academic Publishers, 1991).
The compounds of Formula (I) and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of the present invention are useful as modulators of the seratonin receptor in the methods of the invention. As such modulators, the compounds may act as antagonists, agonists, or inverse agonists. The term “modulators” include both inhibitors and activators, where “inhibitors” refer to compounds that decrease, prevent, inactivate, desensitize or down-regulate seratonin receptor expression or activity, and “activators” are compounds that increase, activate, facilitate, sensitize, or up-regulate seratonin receptor expression or activity.
Many of the compounds of the present invention are 5-HT7 modulators that act as 5-HT7 antagonists. As such, the compounds are useful in the treatment of 5-HT7-mediated disease in which a decrease, prevention, inactivation, desensitization or down-regulation of serotonin receptor expression or activity is required.
The term “treat” or “treating” as used herein is intended to refer to administration of an active agent or composition of the invention to a subject for the purpose of effecting a therapeutic or prophylactic benefit through modulation of serotonin receptor activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition mediated through modulation of serotonin receptor activity. The term “subject” refers to a mammalian patient in need of such treatment, such as a human.
In treatment methods according to the invention, an effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition. An “effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the compounds of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician.
The invention may be particularly useful in the treatment or prevention of diseases, disorders, or conditions mediated by serotonin receptor activity, such as: central nervous system disorders such as sleep disorders (including insomnia), depression/anxiety, generalized anxiety disorder, schizophrenia, bipolar disorders, cognitive disorders, mild cognitive impairment, Alzheimer's disease, Parkinson's disease, psychotic disorders, phobic disorders, obsessive-compulsive disorder, mood disorders, post-traumatic stress and other stress-related disorders, migraine, pain, eating disorders, obesity, sexual dysfunction, metabolic disturbances, hormonal imbalance, hot flashes associated with menopause, alcohol abuse, drug abuse, and addictive disorders including drug addiction and alcohol addiction. Further diseases associated with serotonin receptor activity for which the compounds may be useful for treating are nausea, inflammation, centrally mediated hypertension, sleep/wake disturbances, jetlag, and circadian rhythm abnormalities. The compounds may also be used in the treatment and prevention of hypotension, peripheral vascular disorders, cardiovascular shock, renal disorders, gastric motility, diarrhea, spastic colon, irritable bowel disorders, ischemias, septic shock, urinary incontinence and other disorders related to the gastrointestinal and vascular systems. In addition, compounds of the present invention may be used in methods for treating or preventing a range of ocular disorders including glaucoma, optic neuritis, diabetic retinopathy, retinal edema, and age-related macular degeneration. Symptoms or disease states are intended to be included within the scope of “medical conditions, disorders, or diseases.”
The compounds of the present invention are 5-HT7 modulators, many of which are 5-HT7 antagonists. As such, the compounds are useful in the treatment of 5-HT7 mediated disease states. Where the compounds possess substantial 5-HT7 modulating activity, they may be particularly useful in methods for treating depression/anxiety, sleep/wake disturbances, sleep disorders, jet lag, migraine, urinary incontinence, gastric motility, and irritable bowel disorders, hypertension, analgesic, and irritable bowel syndrome.
Particularly, as serotonin receptor modulators, the compounds of the present invention are useful in the treatment or prevention of depression, anxiety, sleep disorders, and circadian rhythm abnormalities.
The compounds of the invention are used, alone or in combination with one or more other active ingredients, to formulate pharmaceutical compositions of the invention. In addition, the compounds of the invention may be used in combination with additional active ingredients in the treatment of the above conditions. In an exemplary embodiment, additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by serotonin receptors or that are active against another target associated with the particular condition, disorder, or disease. Suitable examples include: H1 receptor antagonists, H2 receptor antagonists, H3 receptor antagonists, topiramate (TOPAMAX™), and neurotransmitter modulators such as norepinephrine reuptake inhibitors (NRIs), selective serotonin reuptake inhibitors (SSRIs), noradrenergic reuptake inhibitors, non-selective serotonin re-uptake inhibitors (NSSRIs), acetylcholinesterase inhibitors (such as tetrahydroaminoacridine, Donepezil (ARICEPT™), Rivastigmine, or Galantamine (REMINYL™)), modafinil, anti-psychotics, sedatives, monoamine oxidase inhibitors (MAOs), and tricyclic antidepressants (TCAs). The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of a compound according to the invention), decrease one or more side effects, or decrease the required dose of the compound according to the invention. In preferred embodiments, the combination method employs doses containing additional active ingredients in the range of about 20 to 300 mg per dose.
A pharmaceutical composition of the invention comprises: (a) an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite thereof; and (b) a pharmaceutically acceptable excipient.
A “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of a agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
Delivery forms of the pharmaceutical compositions containing one or more dosage units of the active agents may be prepared using suitable pharmaceutical excipients and compounding techniques known or that become available to those skilled in the art. It is anticipated that the compounds of the invention can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical administration, and inhalation. For oral administration, the compounds of the invention will generally be provided in the form of tablets or capsules or as an aqueous solution or suspension. Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate and lactose. Cornstarch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, compounds of the invention may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the compound of the invention with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
The active agents of this invention may also be administered by non-oral routes. For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.
For topical administration, the compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle. Another mode of administering the compounds of the invention may utilize a patch formulation to affect transdermal delivery.
Compounds of the invention may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.
Effective doses of the compounds of the present invention may be ascertained by conventional methods. The specific dosage level required for any particular patient will depend on a number of factors, including severity of the condition being treated, the route of administration and the weight of the patient. In general, however, it is anticipated that the daily dose (whether administered as a single dose or as divided doses) will be in the range 0.01 to 1000 mg per day, more usually from 1 to 500 mg per day, and most usually from 10 to 200 mg per day. Expressed as dosage per unit body weight, a typical dose will be expected to be between 0.0001 mg/kg and 15 mg/kg, especially between 0.01 mg/kg and 7 mg/kg, and most especially between 0.15 mg/kg and 2.5 mg/kg.
The invention includes also pharmaceutically acceptable salts of the compounds represented by Formula (I), preferably of those described below. Pharmaceutically acceptable salts of the specific compounds exemplified herein are especially preferred.
In certain embodiments of compounds of Formula (I), R1 is —H, —C1-4alkyl, monocyclic cycloalkyl, phenyl, or benzyl. In certain embodiments, R1 is —H, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —C(CH3)3, cyclopropyl, cyclobutyl, or benzyl. In further embodiments, R1 is —H.
In certain embodiments of compounds of Formula (I), m has the value of 1, 2 or 3 and n has the value of 1 or 2; however, if m is 2 then n is not 1. In preferred embodiments, m is 1 and n is 1. In further embodiments, m is 1 and n is 2. In further embodiments, m is 2 and n is 2. In further embodiments, m is 3 and n is 1.
In certain embodiments of compounds of Formula (I), R2 is —H or —C1-4 alkyl. In further embodiments, R2 is —H, or —CH3.
In certain embodiments of compounds of Formula (I), R3 is —H or —C1-4 alkyl. In further embodiments, R3 is —H, or —CH3.
In certain embodiments of compounds of Formula (I), R2 and R3 are each —H.
In certain embodiments of compounds of Formula (I), R4 is —H, F, —C1-4 alkyl or R4 may be —OH when L is —CH2—, —CF2—, —CHF—, —OCH2—, or —OCH(CH3)—. In further embodiments, R4 is hydrogen.
In certain embodiments of compounds of Formula (I), L is —O—, —CH2—, —OCH2—, —OCH(CH3)—, —CH2O—, —CF2—, or —CHF—. In certain embodiments, L is —O—.
In certain embodiments of compounds of Formula (I), Z is —O—, —C(O)—, —OCH(Rb)—, or —OCH2C(Rc)(Rd)—; where Rb is —H; a —C1-4alkyl group unsubstituted or substituted with OH or halo; —CO2C1-4alkyl; or —CO2H; and Rc and Rd are each independently —H, —C1-4alkyl, —O—C1-4alkyl, or halo. In certain embodiments of compounds of Formula (I), Rc and Rd taken together form an oxime, a C1-4 alkyl oxime, or a carbonyl group. In certain embodiments of compounds of Formula (I), Rc and Rd taken together with the carbon to which they are attached form a C3-6cycloalkyl group. In certain embodiments of compounds of Formula (I), Z is —O—, —C(O)—, —OCH2—, —OCH(CH3)—, —OCH(CH2CH3)—, —OCH(CH2OH)—, —OCH(CO2H)—, —OCH(CH2F)—, —OCH2CH2—, —OCH2CH(F)—, —OCH2CH(OCH3)—, —OCH2C(NOH)—, —OCH2C(NOCH3)—, —OCH2CF2—, —OCH2C(O)—, or
In further embodiments, Z is —O—, —OCH2—, or —OCH(CH3)—.
In certain embodiments of compounds of Formula (I), R5 is a phenyl or phenoxy group, unsubstituted or substituted with one, two, or three Rg substituents; where each Rg substituent is selected from the group consisting of —C1-6alkyl, —OH, —OC1-6alkyl, —CN, —NO2, —C(O)C1-6alkyl, —S(O)0-2—C1-6alkyl, —OS(O)0-2—C1-6alkyl, —SO2CF3, —SCF3, halo, —CF3, —OCF3, —CO2H, —CO2C1-6alkyl, —CH2OH, monocyclic cycloalkyl, phenyl, thiophenyl, benzhydryl, and oxadiazolyl. In further embodiments of compounds of Formula (I), two Rg substituents taken together form —OCH2O—, —OCF2O—, or —OCH2CH2O— group. In further embodiments, R5 is a naphthyl group, unsubstituted or substituted with C1-4alkyl or halo. In further embodiments, R5 is a monocyclic heteroaryl group, unsubstituted or substituted with one, two, or three Rg substituents. In further embodiments, R5 is a fused bicyclic heteroaryl group, unsubstituted or substituted with C1-4alkyl or halo. In further embodiments, R5 is a monocyclic cycloalkyl group, optionally fused to a phenyl ring, and unsubstituted or substituted with one or two substituents selected from the group consisting of: —C1-4alkyl, —OC1-4alkyl, halo, —CF3, oxime, —C1-4alkyl oxime, or phenyl. In further embodiments, R5 is a monocyclic heterocycloalkyl group, optionally fused to or substituted with phenyl. In further embodiments, R5 is cyclohexyl, 2-indanyl, or furanyl optionally substituted with one or more substituents individually selected from halo, —CH3, —CF3, —OCF3, or —CN.
In certain embodiments, R5 is selected from the group consisting of cyclopropyl, cyclobutyl, 3-phenyl-cyclobutyl, cyclopentyl, cyclohexyl, phenyl, 3- or 4-bromo-phenyl, 2-, 3- or 4-chloro-phenyl, 3,4-dichloro-phenyl, 3- or 4-cyano-phenyl, 2-, 3- or 4-fluoro-phenyl, 3-chloro-4-fluoro-phenyl, 4-chloro-3-fluoro-phenyl, 4-chloro-3-trifluoromethyl-phenyl, 3-chloro-4-trifluoromethoxy-phenyl, 2,4-difluoro-phenyl, 2-fluoro-4-trifluoromethyl-phenyl, 3-fluoro-4-trifluoromethyl-phenyl, 4-fluoro-3-trifluoromethyl-phenyl, 3- or 4-methyl-phenyl, 3- or 4-methylsulfanyl-phenyl, 3- or 4-methoxy-phenyl, 3-chloro-4-methoxy-phenyl, 3-methanesulfonyloxy-phenyl, 3- or 4-methoxy-phenyl, 3-trifluoromethoxy-phenyl, 2-, 3- or 4-trifluoromethyl-phenyl, 4-fluoro-3-trifluoromethyl-phenyl, 3- or 4-trifluoromethylsulfanyl-phenyl, 3-trifluoromethoxy-phenyl,
3-azetidinyl, 1-benzyl-azetidin-3-yl, 1-benzhydryl-azetidin-3-yl, 1-isopropyl-azetidin-3-yl, benzo[1,3]dioxol-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 2-benzofuranyl, 5-benzofuranyl, 2,3-dihydro-benzofuran-2-yl, 2-benzothiazolyl, 6-benzothiazolyl, 1H-benzotriazole-6-yl, 1-methyl-1H-benzotriazole-6-yl, 2- or 3-chromanyl, 2- or 3-furanyl, 5-trifluoromethyl-2-furanyl, 2-indanyl, tetrahydro-3-furanyl, 1-Hydroxyimino-indan-2-yl, 4-methoxy-2-indanyl, 5-fluoro-1-indanyl, 5-methyl-1-indanyl, 5- or 6-chloro-1-indanyl, 6-fluoro-1-indanyl, 6-trifluoromethyl-1-indanyl, 6-methyl-1-indanyl, 5-fluoro-2-indanyl, 5-methoxy-2-indanyl, [1,2,4]oxadiazole-5-yl, 3-cyclopropyl-[1,2,4]oxadiazole-5-yl, 3-cyclobutyl-[1,2,4]oxadiazole-5-yl, 3-isopropyl-[1,2,4]oxadiazole-5-yl, phenoxy, 4-piperidinyl, 2- or 3-pyrrolidinyl, 3-methyl-[1,2,4]oxadiazole-5-yl, 5-oxazolyl, 3-, 4- or 5-pyrazolyl, 4-trifluoromethyl-2-pyridinyl, 2-, 3- or 4-pyridinyl, 6-trifluoromethyl-2-pyridinyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, 1,2,3,4-tetrahydro-naphthalen-2-yl, 1-phenyl-3-azetidinyl, 4- or 5-thiazolyl, 2-methyl-thiazole-4-yl, 2-thiophen-2-yl-thiazole-4-yl,
and 5-methyl-isoxazole-3-yl.
In certain embodiments of compounds of Formula (I), R6 and R7 are each independently —H, halo, —CF3, thiophene, or —C(O)N(Rx)Ry; wherein Rx and Ry are each independently —H or —C1-4alkyl. In certain embodiments of compounds of Formula (I), R6 and R7 are each independently —H, halo, —CF3, thiophene-3-yl, or N,N-dimethyl-formamidyl. In certain embodiments, R6 is —H or halo. In certain embodiments, R6 is —H or halo and R7 is —H, halo, —CF3, thiophene-3-yl, or N,N-dimethyl-formamidyl.
Preferred compounds are selected from the group consisting of:
and stereoisomeric forms, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, and active metabolites thereof.
Exemplary chemical entities useful in methods of the invention will now be described by reference to illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. Unless otherwise specified, the variables in the formulas depicted in the schemes below are as defined above in reference to Formula (I). Reactions may be performed between the melting point and the reflux temperature of the solvent, and preferably between 0° C. and the reflux temperature of the solvent.
List of abbreviations: Ac=Acetyl, AlBN=azobisisobutyronitrile, Boc=tert-Butylcarbamoyl, m-CPBA=meta-chloroperoxybenzoic acid, DCE=dichloroethane, DEAD=diethyldiazodicarboxylate, DIBAL-H=diisobutyl aluminum hydride, DIEA=N,N-Diisopropylethylamine, DMA=N,N-Dimethylacetamide, DME=Ethylene glycol dimethyl ether, DMF=dimethylformamide, DMSO=Dimethyl sulfoxide, Et3N=triethylamine, Et2O=diethyl ether, EtOAc=Ethyl acetate, MeCN=acetonitrile, MeOH=methanol, MsCl=Methanesulfonyl chloride, TFA=trifluoroacetic acid, TFAA=trifluoroacetic acid anhydride, THF=tetrahydrofuran, TLC=thin layer chromatography, Q-Phos=1,2,3,4,5-pentaphenyl-1′-(di-tert-butylphosphino)ferrocene.
The compounds of formula (I) may be prepared by a number of reaction schemes. The following schemes represent certain synthesis steps for obtaining compounds of the invention. Persons skilled in the art will recognize that certain compounds are more advantageously produced by one scheme as compared to the other.
The amines in the compounds below may be protected, as indicated by P1, as an alkyl or benzyl amine, amide, carbamate or other groups such as described in “Protecting Groups in Organic Synthesis”, 3rd ed.; T. W. Greene and P. G. Wuts, John Wiley and Sons, 1999. Preferably, P1 is —C1-6Alkyl, —COOC1-6Alkyl, —(C═O)C1-6Alkyl, benzyl substituted or unsubstituted with —OC1-6Alkyl or C1-6Alkyl, or benzhydryl substituted or unsubstituted with —OC1-6Alkyl or —C1-6Alkyl). A further preferred protecting group is t-butyl carbamate (Boc) or trifluoroacetamide. This protecting group (P1) on the nitrogen may be removed or converted directly into the desired compounds using generally accepted methods known to one skilled in the art. More specifically a group such as a Boc group may be removed with an acid such as trifluoroacetic acid or hydrochloric acid and the like in a solvent such as CH2Cl2, EtOAc, THF, 1,4-dioxane, MeOH or EtOH. A group such as trifluoroacetamide was removed using a base such as NH3, NH4OH or K2CO3 in an alcoholic solvent such as MeOH or EtOH and the like.
Intermediates of the formula A5 were prepared according to Scheme A. The variable Z in the formula depicted in Scheme 1 are as defined above in reference to Formula (I) except Z cannot be —C(O)— in Scheme 1. Compounds of the formula A1 were treated with tert-butylamine in the presence of a dehydrating agent such as SiO2, CuSO4, Ti(OiPr)4, MgSO4 or molecular sieves in a suitable solvent such as THF, CH2Cl2, benzene, toluene, MeOH or EtOH. A preferred method uses MgSO4 in CH2Cl2 to give compounds of the formula A2. Compounds of the formula A2 were allowed to react with compounds of the formula A3 in a suitable solvent such as DMF, DMSO, NMP or THF in the presence of a base such as NaH, KOtBu or Cs2CO3, preferably NaH in DMF, to produce compounds of formula A4. Compounds of the formula A5 were obtained from compounds of the formula A4 upon basic hydrolysis of the compound obtained from the treatment of compounds of the formula A4 with an oxidant such as m-chloroperoxybenzoic acid (m-CPBA) in CH2Cl2. The hydrolysis is performed using a base such as NaOH or KOH in a solvent such as MeOH, EtOH or H2O.
Intermediates of the formula A4 were alternatively prepared according to Scheme B. Compounds of the formula A4 were alternatively obtained from compounds of the formula B1, where LG represents a chloride, bromide, iodide, mesylate or tosylate, upon treatment with a compound of the formula B2. The variable Z in the formulas depicted in Scheme 2 are as defined above in reference to Formula (I) except Z cannot be —C(O)— in Scheme 2. This type of reaction was carried out in a solvent such as DMF, DMA, THF or EtOH in the presence of bases such as NaHCO3, Na2CO3, K2CO3 or Cs2CO3. Alternatively, compounds of the formula A4 may also be obtained from compounds of the formula B1 when LG is OH using PPh3 or similar trialkyl or triaryl phosphine and diethyldiazodicarboxylate (DEAD), diisopropyldiazodicarboxylate (DIAD) or di-tert-butyldiazodicarboxylate (DBAD) in a solvent such as MeCN, DMF, THF or CH2Cl2 and the like. One skilled in the art will recognize this as a Mitsunobu reaction.
Intermediates of the formula C3 were prepared according to Scheme C. Compounds of the formula C3 were synthesized similar to compounds of the formula A5 (Scheme 1) from compounds of the formula C1. Compounds of the formula C2 were obtained from compounds of the formula C1 and compounds of the formula A2 (Scheme 1) in a suitable solvent such as DMF, DMSO, NMP or THF in the presence of a base such as NaH, KOtBu or Cs2CO3, preferably NaH in DMF. Compounds of the formula C3 were obtained from compounds of the formula C2 upon basic hydrolysis of the compound obtained from the treatment of compounds of the formula C2 with an oxidant such as m-chloroperoxybenzoic acid (m-CPBA) in CH2Cl2. The hydrolysis was performed using a base such as NaOH or KOH in a solvent such as MeOH, EtOH or H2O.
Intermediates of the formula C2 were alternatively prepared according to Scheme D using compounds of the formula D1. The amine in compounds of the formula C2 may be protected with a protecting group, as indicated by P1, with previously described protecting groups. Treatment of compounds of formula D1 with a nucleophile such as a compound of formula B2 (Scheme 2) in the presence of base such as pyridine, triethylamine, diisopropylamine, K2CO3, Cs2CO3 or Na2CO3 in a suitable solvent such as THF, CH2Cl2, DMF, MeCN, 1,4-dioxane or the like at a temperature ranging from rt to 100° C. provided compounds of the formula C2. Compounds of the formula D1 were obtained from compounds of the formula C1 when treated with methanesulfonyl chloride (MsCl) in the presence of a base such as pyridine, triethylamine or diisopropylamine and the like in a solvent such as CH2Cl2, THF or DCE.
Intermediates of the formula E2 were prepared according to Scheme E. Compounds of the formula E2 were obtained after addition of compounds of the formula E2 to compounds of the formula E1. One skilled in the art will recognize compounds of the formula E2 as Grignard reagents.
Intermediates of the formula F4 were prepared according to Scheme F. Compounds of the formula F4 were prepared from compounds of the formula F2, where LG represents a Cl or Br, and F3. Compounds of the formula F2 were prepared from compounds of the formula F1 upon treatment with an oxidizing agent such as m-CPBA in a solvent such as CH2Cl2.
Intermediates of the formula G7 were prepared according to Scheme G. Compounds of the formula G3 were synthesized from compounds of the formula G1 and compounds of the formula G2 using solvents such as Et2O, THF, CH2Cl2, or dioxane and the like. One skilled in the art will recognize G1 as a Weinreb amide (Nahm, S. et al., Tet. Lett., 1981, 22, 3815-3818) and G2 as a Grignard reagent. Compounds of the formula G4 were obtained from compounds of the formula G3 by partial reduction with hydride donors such as NaBH4 in alcoholic solvents such as MeOH, EtOH or i-PrOH and the like followed by further reduction using H2 in the presence of a hydrogenation catalyst such as Pd/C, PtO2 or Pd(OH)2 and the like at pressures up to 60 psi and temperatures ranging from rt to 60° C. in solvents such as MeOH, EtOH or i-PrOH and the like. The Boc protecting group in compounds of the formula G2 was exchanged for a trifluoroacetamide as shown in compounds of the formula G5 by treatment with acids such as trifluoroacetic acid or hydrochloric acid and the like in a solvent such as CH2Cl2, EtOAc, THF, 1,4-dioxane, MeOH or EtOH. Treatment of the intermediate from this reaction with trifluoroacetic anhydride (TFAA) in the presence of a base such as pyridine, triethylamine or diisopropylethylamine or the like in a solvent such as CH2Cl2, THF, DMF, MeOH, EtOH or the like yields compounds of the formula G5. Treatment of compounds of the formula G5 with an electrophilic bromine source such as Br2, NBS, NaBr/oxone or chlorine source such as Cl2, KCl/oxone or NCS and the like in a solvent such as MeOH, CH2Cl2, EtOH, DMF, acetone, H2O and the like or mixtures there of produces compounds of the formula G6. Treatment of compounds of the formula G6 with a reagent such as Lil in collidine, HBr in AcOH, or preferrably BBr3 in CH2Cl2, produces compounds of the formula G7.
Intermediates of the formula H6 were prepared according to Scheme H. Compounds of the formula H3 were obtained from compounds of the formula C3 upon treatment with compounds of the formula H1, representing an alkyl chloride, bromide, iodide, mesylate or tosylate in a solvent such as DMF, DMA, THF or EtOH in the presence of bases such as NaHCO3, Na2CO3, K2CO3 or Cs2CO3. Alternatively, compounds of the formula H3 may also be obtained from compounds of the formula H2 when X is OH using PPh3 or similar trialkyl or triaryl phosphine and diethyldiazodicarboxylate (DEAD), diisopropyldiazodicarboxylate (DIAD) or di-tert-butyldiazodicarboxylate (DBAD) in a solvent such as MeCN, DMF, THF or CH2Cl2 and the like. One skilled in the art will recognize this as a Mitsunobu reaction. The transformation when X is OH may also be performed using cyanomethylene-tri-n-butylphosphine in a solvent such as PhCH3 when heated in a microwave reactor at temperatures up to 120° C. When R5 is a substituted aryl or heteroaryl, compounds of the formula H3 were obtained using Cu(OAc)2 and base such as pyridine or Et3N and the like in the presence of dehydrating agents such as MgSO4 or 4 Å molecular sieves.
Compounds such as H6 were prepared from compounds of the formula H4 using methods such as reductive amination or alkylation. Thus treatment of H4 with a compound of formula H5 containing a carbonyl in the presence of a reductant such as NaBH4, NaBH3CN, NaBH(OAc)3 or hydrogen gas in the presence of a catalyst in a solvent such as CH2Cl2, THF, DCE, MeOH, EtOH or similar afforded compounds of the formula H6. One skilled in the art will recognize that the presence of Bronsted or Lewis acids may be required. Examples of acids may include AcOH, Ti(O-iPr)4, trifluoroacetic acid or hydrochloric acid and the like. One skilled in the art will also recognize that compounds of the formula H6 may be obtained from H4 upon treatment with an alkyl chloride, bromide, iodide, mesylate or tosylate and the like in a solvent such as DMF, DMA, THF or EtOH in the presence of bases such as NaHCO3, Na2CO3, K2CO3 or Cs2CO3. It will be generally recognized that compounds of the formula H6 represent a subset of compounds of the formula H4 where R1 is equal to H. Compounds of the formula H4 or H6 may be converted to their corresponding salts using methods generally accepted to those skilled in the art.
Intermediates of the formula H1 were prepared according to Scheme I when not commercially available.
Intermediates of the formula J4 were prepared according to Scheme J. Compounds of the formula J4 were prepared from compounds of the formula J1 and compounds of the formula J3 (prepared as in Scheme A) using cyanomethylene-tri-n-butylphosphine in a solvent such as PhCH3 when heated in a microwave reactor at temperatures up to 120° C. In this reaction scheme, the preferred protecting group, P1 is a benzhydryl group. Alternatively, compounds of the formula J4 were also synthesized from compounds of the formula D1 (Scheme D). Treatment of a compound of formula D1 with a nucleophile such as a compound of formula J3 in the presence of base such as pyridine, triethylamine, diisopropylamine, K2CO3, Cs2CO3 or Na2CO3 in a suitable solvent such as THF, CH2Cl2, DMF, MeCN, 1,4-dioxane or the like at a temperature ranging from rt to 100° C. provided compounds of the formula J4.
Intermediates of the formula K4 were prepared according to Scheme K. The variable Rn in the formulas depicted in Scheme K are —H or —C1-4alkyl. The variable Z in the formulas depicted in Scheme K are as defined above in reference to Formula (I) except Z cannot be —C(O)— in Scheme K. Compounds of the formula K2 were obtained from compounds of the formula K1 and compounds of the formula A4 in the presence of cyanomethylene-tri-n-butylphosphine in a solvent such as PhCH3 when heated in a microwave reactor at temperatures up to 120° C. Alternatively, when the protecting group on nitrogen was a benzhydryl as in compounds of the formula K3 compounds of the formula K4 were obtained using similar conditions.
Intermediates of the formula L4 were prepared according to Scheme L. The variable Z in the formulas depicted in Scheme L are as defined above in reference to Formula (I) except Z cannot be —C(O)— in Scheme L. The amine in compounds of the formula L3 may be protected, as indicated by P1, as discussed previously. Compounds of the formula L3 were prepared from compounds of the formula L2 and compounds of the formula C1 in the presence of base such as pyridine, triethylamine, diisopropylamine, K2CO3, Cs2CO3 or Na2CO3 in a suitable solvent such as THF, CH2Cl2, DMF, MeCN, 1,4-dioxane or the like at a temperature ranging from rt to 100° C. Compounds of the formula L2 were prepared from compounds of the formula L1 by treatment with a chlorinating agent such as SOCl2 in a solvent such as CH2Cl2. Compounds of the formula L1 were prepared from compounds of the formula A4 using a reducing agent such as NaBH4, LiBH4, Dibal-H, LiAlH4 and the like in a solvent such as CH2Cl2, THF, DCE, MeOH or EtOH and the like.
Intermediates of the formula M5 were prepared according to Scheme M. The variable Z in the formulas depicted in Scheme M are as defined above in reference to Formula (I) except Z cannot be —C(O)— in Scheme M. Compounds of the formula M4 may be prepared from compounds of the formula M3 and compounds of the formula C1 using a base such as NaH and the like in a solvent such as THF, DMF, NMP or DMSO at temperatures up to 145° C. in a microwave reactor. Compounds of the formula M3 may be prepared from compounds of the formula M1 and compounds of the formula M2 using a base such as NaH and the like in a solvent such as THF, DMF, NMP or DMSO and the like.
Compounds of the formula M5 may be obtained from compounds of the formula M4 by removal of the P1 group. The amine in compounds of the formula M4 may be protected, as indicated by P1, as described previously. A preferred protecting group is t-butyl carbamate (Boc) or trifluoroacetamide. It will be generally recognized that compounds of the formula M5 may be converted to their corresponding salts using methods generally accepted to those skilled in the art.
Intermediates of the formula N5 were prepared according to Scheme N. Compounds of the formula N5 may be obtained from compounds of the formula N4 by removal of the P1 group. The amine in compounds of the formula N4 may be protected, as indicated by P1, as described previously. A preferred protecting group is t-butyl carbamate (Boc) or trifluoroacetamide. It will be generally recognized that compounds of the formula N5 may be converted to their corresponding salts using methods generally accepted to those skilled in the art.
Compounds of the formula N4 were prepared from compounds of the formula N2 and compounds of the formula N3 in the presence of a base such as diisopropyethylamine, Et3N or pyridine and the like upon heating in a microwave reactor at temperatures up to 145° C. Precursors to compounds of the formula N2 were prepared from compounds of the formula N1 and bromomethyl acetate in a solvent such as DMF, DMA, THF or EtOH in the presence of bases such as NaHCO3, Na2CO3, K2CO3 or Cs2CO3. Subsequent hydrolysis using aqueous NaOH followed by formation of compounds of the formula N2 using oxalyl chloride in a solvent such as THF, CH2Cl2 or PhCH3 in the presence of a catalytic amount of DMF provided compounds of the formula N2.
Intermediates of the formula O6 were prepared according to Scheme O. The amine in compounds of the formula O5 may be protected, as indicated by P1 as described previously. A preferred protecting group is t-butyl carbamate (Boc) or trifluoroacetamide. Compounds of the formula O6 were obtained from compounds of the formula O5 by removal of the P1 group. It will be generally recognized that compounds of the formula O6 may be converted to their corresponding salts using methods generally accepted to those skilled in the art.
Compounds of the formula O5 were prepared form compounds of the formula O3 and compounds of the formula O4 using a base such as NaHCO3, Na2CO3, K2CO3 or Cs2CO3 in solvents such as MeOH, EtOH or iPrOH. Compounds of the formula O3 were prepared from compounds of the formula C3 and compounds of the formula O2 by heating the mixture up to 100° C. in a microwave reactor in a solvent such as DMF, DMA, THF or EtOH in the presence of bases such as NaHCO3, Na2CO3, K2CO3 or Cs2CO3. Compounds of the formula O2 were obtained by bromination of compounds of the formula O1 using (Bu)N4Br3 (TBABr3) in a solvent mixture of MeOH and CH2Cl2.
Intermediates of the formula P1 were prepared according to Scheme P. Compounds of the formula P1 were synthesized from compounds of the formula O3 using a hydride donor such as Et3SiH in the presence of an acid such as trifluoroacetic acid in a solvent such as DCE or CH2Cl2.
Intermediates of the formula Q5 were prepared according to Scheme Q. Compounds of the formula Q3 were prepared from compounds of the formula Q2 by oxidation with an oxidant such as the Dess-Martin periodinane in a solvent such as CH2Cl2. Compounds of the formula Q2 were prepared from compounds of the formula C2 (Scheme C) and compounds of the formula Q1 in solvents such as Et2O, THF, CH2Cl2, or dioxane and the like.
Compounds of the formula Q4 may be obtained from compounds of the formula Q3 by removal of the P1 group. The amine in compounds of the formula Q3 may be protected, as indicated by P1 as described previously. A preferred protecting group is t-butyl carbamate (Boc) or trifluoroacetamide. It will be generally recognized that compounds of the formula Q4 represent a subset of compounds of the formula Q5 where R6 is equal to H. Compounds of the formula Q4 or Q5 may be converted to their corresponding salts using methods generally accepted to those skilled in the art.
Compounds such as Q5 were prepared from compounds of the formula Q4 using methods such as reductive amination or alkylation. Thus treatment of Q4 with a compound containing a carbonyl in the presence of a reductant such as NaBH4, NaBH3CN, NaBH(OAc)3 or hydrogen gas in the presence of a catalyst in a solvent such as CH2Cl2, THF, DCE, MeOH, EtOH or similar afforded compounds of the formula Q5. One skilled in the art will recognize that the presence of Bronsted or Lewis acids may be required. Examples of acids may include AcOH, Ti(O-iPr)4, trifluoroacetic acid or hydrochloric acid and the like. One skilled in the art will also recognize that compounds of the formula Q5 may be obtained from Q4 upon treatment with an alkyl chloride, bromide, iodide, mesylate or tosylate and the like in a solvent such as DMF, DMA, THF or EtOH in the presence of bases such as NaHCO3, Na2CO3, K2CO3 or Cs2CO3.
Intermediates of the formula R3 were prepared according to Scheme R. Compounds of the formula R2 were synthesized from compounds of the formula R1 (prepared as outlined in Scheme G) using an oxidant such as m-CPBA in a solvent such as CH2Cl2. Compounds of the formula R3 may be obtained from compounds of the formula R2 by removal of the P1 group. The amine in compounds of the formula R2 may be protected, as indicated by P1 as described previously. A preferred protecting group is t-butyl carbamate (Boc) or trifluoroacetamide.
Intermediates of the formula S4 were prepared according to Scheme S. Compounds of the formula S2 were obtained from compounds of the formula S1 by bromination using NBS in the presence of AlBN in solvents such as CCl4 at refluxing temperatures. Compounds of the formula S3 were obtained from compounds of the formula N1 and compounds of the formula S2 in a solvent such as DMF, DMA, THF or EtOH in the presence of bases such as NaHCO3, Na2CO3, K2CO3 or Cs2CO3 followed by a work-up with neutral H2O. A preferred protecting group on compounds of the formula N1 was Boc.
Intermediates of the formula T2 were prepared according to Scheme T. Compounds of the formula T1 were obtained from compounds of the formula N1 and compounds of the formula S2 in a solvent such as DMF, DMA, THF or EtOH in the presence of bases such as NaHCO3, Na2CO3, K2CO3 or Cs2CO3 followed by a work-up with basic H2O where the pH was >10. A preferred protecting group on compounds of the formula N1 was Boc.
Intermediates of the formula U2 were prepared according to Scheme U. Compounds of the formula U2 were prepared from compounds of the formula U1 using reducing agents such as Dibal-H in solvents such as CH2Cl2, THF or PhCH3 and the like.
Intermediates of the formula V3 were prepared according to Scheme V. Compounds of the formula V2 were prepared from compounds of the formula V1 using reducing agents such as LiBH4 and the like in solvents such as CH2Cl2, THF or PhCH3 and the like. Compounds of the formula V3 were prepared from compounds of the formula V2 using acids such as trifluoroacetic acid or hydrochloric acid and the like in a solvent such as CH2Cl2, EtOAc, THF, 1,4-dioxane, MeOH or EtOH.
Intermediates of the formula W2 were prepared according to Scheme W. Compounds of the formula W1 were prepared from compounds of the formula V1 by hydrolysis using aqueous hydroxide bases such as NaOH or KOH and the like with an organic co-solvent such as THF or MeOH. A preferred protecting group on compounds of the formula V1 was Boc.
Intermediates of the formula X4 were prepared according to Scheme X. A preferred protecting group on compounds of the formula X1 was Boc. Compounds of the formula X3, were prepared from compounds of the formula X1 and compounds of the formula X2 by heating in a microwave reactor at temperatures up to 170° C. in the presence of Hermann's catalyst, Mo(CO)6 and bases such as Na2CO3 and the like.
Intermediates of the formula Y3 were prepared according to Scheme Y. A preferred protecting group on compounds of the formula X1 was Boc. Compounds of the formula Y2, were prepared from compounds of the formula X1 by treatment with compounds of the formula Y1 in the presence of a catalyst such as PdCl2(dppf), PdCl2(dppe) Pd2(dba)3, Pd(dba)2, PdCl2(PPh3)2, Pd(PPh3)4 in a solvent such as PhCH3, 1,4-dioxane, THF, DMA, DMF or DME in the presence of a base such as Na2CO3, K2CO3, Cs2CO3, CsF, KF, K3PO4, KOAc or the like and a ligand typically used in such reactions such as Q-Phos, dppf, dppe or PPh3 and the like at temperatures ranging from rt to 160° C. using conventional or microwave heating.
EXAMPLES ChemistryIn obtaining the compounds described in the examples below and the corresponding analytical data, the following experimental and analytical protocols were followed unless otherwise indicated.
Unless otherwise stated, reaction mixtures were magnetically stirred at room temperature (rt). Where solutions were “dried,” they were generally dried over a drying agent such as Na2SO4 or MgSO4 then filtered and concentrated. Where mixtures, solutions, and extracts were “concentrated”, they were typically concentrated on a rotary evaporator under reduced pressure.
Thin-layer chromatography (TLC) was performed using Merck silica gel 60 F254 2.5 cm×7.5 cm 250 μm or 5.0 cm×10.0 cm 250 μm pre-coated silica gel plates. Preparative thin-layer chromatography (PTLC) was performed using EM Science silica gel 60 F254 20 cm×20 cm 0.5 mm pre-coated plates with a 20 cm×4 cm concentrating zone.
Normal-phase flash column chromatography (FCC) was performed on silica gel (SiO2) eluting with 2 M NH3 in MeOH/CH2Cl2 or EtOAc in hexanes, unless otherwise noted.
Preparative reversed-phase HPLC (RP HPLC) was performed on a Hewlett Packard HPLC Series 1100, with a Phenomenex Luna C18 (5 μm, 4.6×150 mm) column. Detection was done at λ=230, 254 and 280 nm. The gradient was 10 to 99% acetonitrile/H2O (0.05% trifluoroacetic acid) over 5.0 min with a flow rate of 1 mL/min. Alternatively, HPLC was performed on a Dionex APS2000 LC/MS with a Phenomenex Gemini C18 (5 μm, 30×100 mm) column, and a gradient of 5 to 100% acetonitrile/H2O (20 mM NH4OH) over 16.3 min, and a flow rate of 30 mL/min. Preparative RP HPLC was also performed on an Agilent 1100 preparative system with a Waters X-Bridge C18 (5 μm, 30×100 mm) column, and a gradient of 5 to 99% acetonitrile/H2O (20 mM NH4OH) over 17 min, and a flow rate of 80 mL/min.
Mass spectra (MS) were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass corresponds to the exact mass.
Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers. The format of the 1H NMR data below is: chemical shift in ppm downfield of the tetramethylsilane reference or relative to residual protic solvent (multiplicity, coupling constant J in Hz, integration).
Chemical names were generated using ChemDraw Version 6.0.2 (CambridgeSoft, Cambridge, Mass.).
General ProceduresGeneral Procedure 1 (Removal of Boc Groups):
Boc groups were deprotected using TFA/CH2Cl2 (1:1) or 4M HCl in dioxane/EtOAc (1:1). The compounds were then either neutralized and extracted with CH2Cl2 or characterized as the hydrochloride or trifluoroacetate salt where indicated.
General Procedure 2 (Removal of Trifluoroacetamide Groups):
Trifluoroacetamide groups were deprotected using K2CO3 (1 eq.) in MeOH (0.2 M), 2M NH3 in MeOH or 5N NH4OH (aq.) in MeOH. After 15 h, H2O was added and the mixture extracted with EtOAc (2×). The combined organics were dried and concentrated. Purification using silica gel chromatography, reverse-phase HPLC or PTLC then provided the deprotected amines.
General Procedure 3 (Reductive Amination):
To amine in CH2Cl2 (0.1 M) was added ketone (1.2-5.0 eq.) and NaBH(OAc)3 (1.2 eq.). After 18 h, the reaction was typically treated with 5% Na2CO3 (aq.) and extracted with CH2Cl2 (2×). The combined organics were dried and purified using silica gel chromatography, reverse-phase HPLC or PTLC.
General Procedure 4 (Reductive Amination):
To amine in MeOH (0.1 M) was added ketone or aldehyde (1.2-5.0 eq.), AcOH (10 mol %) and NaCNBH3 (1.2 eq.). After 18 h, the reaction was typically treated with 5% Na2CO3 (aq.) and extracted with CH2Cl2 (2×). The combined organics were dried and purified using silica gel chromatography, reverse-phase HPLC or PTLC.
General Procedure 5 (NH to NMe):
To amine in MeOH (0.1 M) was added excess 37 wt % [H2CO]n in H2O and NaBHOAc3 (1.2 eq.). After 18 h, 5% Na2CO3 (aq.) was added and the mixture extracted with CH2Cl2. The combined organics were dried and purified using silica gel chromatography, reverse-phase HPLC or PTLC to yield the corresponding methylated analogs.
General Procedure 6 (Cu(OAc)2-Mediated Diary) Ether Synthesis):
To a phenol in DCE (0.1 M) was added arylboronic acid (2 eq.), Cu(OAc)2 (1 eq.), MgSO4 (2 eq) or 4 Å molecular sieves and Et3N (5 eq). The reactions were allowed to stir open to the air for 12-48 h, then filtered, concentrated and purified using silica gel chromatography, reverse-phase HPLC or PTLC.
General Procedure 7 (Mitsunobu Reaction):
To phenol (1 eq), alcohol (1 eq) and either PPh3 (1.2 eq) or resin-bound PPh3 in THF (0.2 M) at 0° C. or rt was added DEAD (1.1 eq) dropwise. After judged complete, the reactions were concentrated and purified using silica gel chromatography, reverse phase HPLC or PTLC.
Example 1 3-(2-Benzyloxy-5-bromo-phenoxy)-azetidineTo a CH2Cl2 (900 mL) solution of 4-bromo-2-fluoro-benzaldehyde (50.0 g, 246 mmol) was added tert-butylamine (42.3 mL, 29.3 g, 400 mmol) and MgSO4 (60.0 g, 499 mmol). After 48 h, the solution was filtered and concentrated to give 62.0 g (98%) of the title compound as a yellow liquid. 1H NMR (CDCl3): 8.48 (s, 1H), 7.89 (t, J=8.1 Hz, 1H), 7.32-7.25 (m, 2H), 1.29 (s, 9H).
Step B: Preparation of 3-(5-bromo-2-formyl-phenoxy)-azetidine-1-carboxylic acid tert-butyl esterTo a 0° C. DMF (720 mL) solution of the title compound of Step A (37.2 g, 144 mmol) and 3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester (25.0 g, 144 mmol) was added NaH (60 wt % in mineral oil, 7.50 g, 188 mmol) portionwise over 2 h. The reaction was then allowed to warm to rt. After 18 h, H2O was added and the reaction mixture was extracted with EtOAc (2×). The combined organic layers were washed with brine and concentrated to give a yellow liquid that was treated with THF (360 mL), H2O (360 mL) and AcOH (25 mL). After 5 h, this solution was made basic with 5% Na2CO3 (aq.) and extracted with EtOAc (2×). The combined organic layers were washed with brine and dried. The resulting solid was then triturated with 20% EtOAc in hexanes to give 41.9 g (82%) of the title compound as a white solid. 1H NMR (CDCl3): 10.43 (s, 1H), 7.74 (d, J=8.3 Hz, 1H), 7.26-7.23 (m, 1H), 6.77 (d, J=1.6 Hz, 1H), 5.01-4.95 (m, 1H), 4.39 (ddd, J=9.9, 6.3, 0.8 Hz, 2H), 4.08 (dd, J=6.4, 0.8 Hz, 2H), 1.46 (s, 9H).
Step C: Preparation of 3-(5-Bromo-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl esterTo a CH2Cl2 (280 mL) solution of the title compound of Step B (24.7 g, 69.4 mmol) was added 77% m-CPBA (23.3 g, 104 mmol). After 15 h, 10% Na2S2O5 (aq.) was added and the solution allowed to stir until the aqueous was KI paper negative then extracted with CH2Cl2 (2×). The combined organic layers were washed with saturated NaHCO3 (aq.), concentrated and treated with MeOH (220 mL) and 1N NaOH (220 mL). After 15 h, the reaction was partially concentrated to remove the MeOH, acidified with 1M KHSO4 (220 mL) and extracted with CH2Cl2 (2×). The combined organic layers were washed with brine and dried providing a brown solid that was triturated with EtOAc/hexanes giving 17.6 g (74%) of the title compound as a white solid. 1H NMR (CDCl3): 7.03 (dd, J=8.5, 2.1 Hz, 1H), 6.84 (d, J=8.5 Hz, 1H), 6.64 (d, J=2.2 Hz, 1H), 4.93-4.89 (m, 1H), 4.34 (dd, J=10.1, 6.8 Hz, 1H), 4.03 (dd, J=9.9, 3.7 Hz, 1H), 1.46 (s, 9H).
Step D: Preparation of 3-(2-benzyloxy-5-bromo-phenoxy)-azetidine-1-carboxylic acid tert-butyl esterTo a DMF (10 mL) solution of the title compound of Step C (0.52 g, 1.5 mmol), Cs2CO3 (0.54 g, 1.7 mmol) and KI (0.20 g, 1.20 mmol) was added benzyl bromide (0.20 mL, 0.29 g, 1.7 mmol). After 48 h, H2O was added and the mixture extracted with EtOAc (2×). The combined organics were washed with brine (2×) and dried. Silica gel chromatography (5-20% EtOAc in hexanes) gave 0.65 g (99%) of the title compound as a clear oil. 1H NMR (CDCl3): 7.42-7.36 (m, 3H), 7.34-7.31 (m, 2H), 7.03 (dd, J=8.6, 2.3 Hz, 1H), 6.81 (d, J=8.6 Hz, 1H), 6.70 (d, J=2.3 Hz, 1H), 5.09 (s, 2H), 4.88-4.83 (m, 1H), 4.26 (ddd, J=9.7, 6.5, 0.9 Hz, 2H), 4.05 (dd, J=9.8, 4.0 Hz, 2H), 1.45 (s, 9H).
Step E: Preparation of 3-(2-Benzyloxy-5-bromo-phenoxy)-azetidineSynthesized according to general procedure 1 from the title compound of Step D. MS (ESI): mass calcd. for C16H16BrNO2, 333.0; m/z found, 334.0 [M+H]+. 1H NMR (CDCl3): 7.08 (dd, J=8.6, 2.3 Hz, 1H), 6.77 (d, J=8.6 Hz, 1H), 6.67 (d, J=2.2 Hz, 1H), 4.86 (tt, J=6.5, 4.3 Hz, 1H), 4.29 (ddd, J=9.7, 6.5, 0.8 Hz, 2H), 4.08 (dd, J=10.1, 4.2 Hz, 2H), 3.85 (s, 3H), 1.44 (s, 9H).
Unless otherwise specified the compounds in Examples 2-74 were prepared similar to Example 1 using the appropriately substituted phenol and alkyl halide.
Example 2 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C16H15BrClNO2, 367.0; m/z found, 368.1 [M+H]+. 1H NMR (CDCl3): 7.47-7.43 (m, 1H), 7.31-7.27 (m, 3H), 7.00 (dd, J=8.6, 2.3 Hz, 1H), 6.78-6.73 (m, 2H), 5.06 (s, 2H), 5.01-4.95 (m, 1H), 3.94-3.83 (m, 4H).
The compounds in Examples 3-6 were prepared from the title compound of Example 2 using general procedure 3 or 4.
Example 3 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-1-cyclobutyl-azetidineMS (ESI): mass calcd. for C20H21BrClNO2, 422.7; m/z found, 423.9 [M+H]+. 1H NMR (CDCl3): 7.43 (s, 1H), 7.32-7.26 (m, 3H), 6.98 (dd, J=8.5, 2.3 Hz, 1H), 6.75 (dd, J=13.6, 5.4 Hz, 2H), 5.05 (s, 2H), 4.77-4.72 (m, 1H), 3.78-3.65 (m, 2H), 3.12-3.16 (m, 3H), 2.01-1.95 (m, 2H), 1.87-1.79 (m, 2H), 1.78-1.69 (m, 2H).
Example 4 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-1-propyl-azetidineMS (ESI): mass calcd. for C19H21BrClNO2, 410.7; m/z found, 411.9 [M+H]+. 1H NMR (CDCl3): 7.44 (s, 1H), 7.33-7.27 (m, 3H), 7.02-6.95 (m, 1H), 6.76 (dd, J=13.4, 5.4 Hz, 2H), 5.06 (s, 2H), 4.78-4.74 (m, 1H), 3.88-3.80 (m, 2H), 3.14-3.06 (m, 2H), 2.52-2.44 (m, 2H), 1.45-1.34 (m, 2H), 0.91 (t, J=7.4 Hz, 3H).
Example 5 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-1-isopropyl-azetidineMS (ESI): mass calcd. for C19H21BrClNO2, 410.7; m/z found, 411.9 [M+H]+. 1H NMR (CDCl3): 7.44 (s, 1H), 7.32-7.27 (m, 3H), 6.99 (dd, J=8.6, 2.3 Hz, 1H), 6.79 (d, J=2.3 Hz, 1H), 6.75 (d, J=8.6 Hz, 1H), 4.98 (s, 2H), 4.75-4.70 (m, 1H), 3.88-3.71 (m, 2H), 3.15-2.94 (m, 2H), 2.43-2.38 (m, 1H), 0.99-0.95 (m, 6H).
Example 6 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-1-ethyl-azetidineMS (ESI): mass calcd. for C18H19BrClNO2, 396.7; m/z found, 397.0 [M+H]+. 1H NMR (CDCl3): 7.44 (d, J=1.8, 1H), 7.35-7.26 (m, 3H), 6.99 (dd, J=8.6, 2.3 Hz, 1H), 6.76 (dd, J=14.8, 5.4 Hz, 2H), 5.06 (s, 2H), 4.78-4.73 (m, 1H), 3.87-3.79 (m, 2H), 3.11-3.08 (m, 2H), 2.55 (q, J=7.2, 2H), 1.00 (t, J=7.2 Hz, 3H).
Example 7 3-[5-Bromo-2-(3-trifluoromethoxy-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H15BrF3NO3, 417.0; m/z found, 418.1 [M+H]+. 1H NMR (CDCl3): 7.40 (t, J=8.1 Hz, 1H), 7.34-7.33 (m, 2H), 7.18-7.16 (m, 1H), 7.00 (dd, J=8.6, 2.3 Hz, 1H), 6.77 (d, J=8.6 Hz, 1H), 6.73 (d, J=2.3 Hz, 1H), 5.10 (s, 2H), 5.01-4.96 (m, 1H), 3.93-3.86 (m, 4H).
Example 8 3-[5-Bromo-2-(3-trifluoromethyl-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H15BrF3NO2, 401.0; m/z found, 401.9 [M+H]+. 1H NMR (CDCl3): 7.75 (s, 1H), 7.60 (t, J=7.2 Hz, 2H), 7.51 (t, J=7.7 Hz, 1H), 7.02 (dd, J=8.6, 2.3 Hz, 1H), 6.80 (d, J=8.6 Hz, 1H), 6.74 (d, J=2.3 Hz, 1H), 5.14 (s, 2H), 5.01-4.95 (m, 1H), 3.93-3.86 (m, 4H).
Example 9 3-[2-(Azetidin-3-yloxy)-4-bromo-phenoxymethyl]-benzonitrile1H NMR (CDCl3): 7.78 (s, 1H), 7.67-7.61 (m, 2H), 7.50 (t, J=7.7 Hz, 1H), 7.01 (dd, J=8.6, 2.3 Hz, 1H), 6.76 (d, J=8.6 Hz, 1H), 6.73 (d, J=2.3 Hz, 1H), 5.12 (s, 2H), 5.02-4.96 (m, 1H), 3.95-3.86 (m, 4H).
Example 10 3-[5-Bromo-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C15H13BrF3NO3, 391.0; m/z found, 392.1 [M+H]+. 1H NMR (CDCl3): 7.03 (dd, J=8.6, 2.3 Hz, 1H), 6.84 (d, J=8.6 Hz, 1H), 6.79-6.76 (m, 1H), 6.74 (d, J=2.3 Hz, 1H), 6.47 (d, J=3.3 Hz, 1H), 5.06 (s, 2H), 5.00-4.93 (m, 1H), 3.96-3.89 (m, 2H), 3.88-3.79 (m, 2H).
Example 11 3-[5-Bromo-2-(3-chloro-4-trifluoromethoxy-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H14BrClF3NO3, 451.0; m/z found, 452.0 [M+H]+. 1H NMR (CDCl3): 7.62-7.59 (m, 2H), 7.35-7.32 (m, 2H), 7.02 (dd, J=8.6, 2.3 Hz, 1H), 6.78 (d, J=8.6 Hz, 1H), 6.74 (d, J=2.3 Hz, 1H), 5.06 (s, 2H), 5.03-4.96 (m, 1H), 3.98-3.91 (m, 2H), 3.89-3.83 (m, 2H).
Example 12 3-[5-Bromo-2-(3-chloro-4-fluoro-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C16H14BrClFNO2, 385.0; m/z found, 386.1 [M+H]+. 1H NMR (CDCl3): 7.52 (dd, J=7.0, 2.1 Hz, 1H), 7.31-7.25 (m, 1H), 7.15 (dd, J=8.7, 8.6 Hz, 1H), 7.01 (dd, J=8.6, 2.3 Hz, 1H), 6.77 (d, J=8.6 Hz, 1H), 6.73 (d, J=2.3 Hz, 1H), 5.03 (s, 2H), 5.01-4.95 (m, 1H), 3.99-3.91 (m, 2H), 3.90-3.81 (m, 2H).
Example 13 3-[5-Bromo-2-(3-chloro-4-methoxy-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17BrClNO3, 397.0; m/z found, 398.1 [M+H]+. 1H NMR (CDCl3): 7.48 (d, J=2.1 Hz, 1H), 7.29-7.25 (m, 1H), 7.02 (dd, J=8.6, 2.3 Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 6.79 (d, J=8.6 Hz, 1H), 6.73 (d, J=2.3 Hz, 1H), 5.01 (s, 2H), 5.00-4.94 (m, 1H), 3.96-3.83 (m, 4H), 3.92 (s, 3H).
Example 14 3-[5-Bromo-2-(4-chloro-benzyloxy)-phenoxy]-azetidine trifluoroacetateMS (ESI): mass calcd. for C16H15BrClNO2, 367.00; m/z found, 368.1 [M+H]+. 1H NMR (CDCl3): 7.41-7.30 (m, 4H), 7.12 (dd, J=8.7, 2.3 Hz, 1H), 6.87 (d, J=2.3 Hz, 1H), 6.80 (d, J=8.7 Hz, 1H), 5.06-4.99 (m, 3H), 4.31-4.13 (m, 4H).
Example 15 3-[5-Bromo-2-(2-chloro-benzyloxy)-phenoxy]-azetidine trifluoroacetateMS (ESI): mass calcd. for C16H15BrClNO2, 367.0; m/z found, 368.1 [M+H]+. 1H NMR (CDCl3): 7.46 (dd, J=5.5, 3.8 Hz, 1H), 7.41 (dd, J=5.6, 3.7 Hz, 1H), 7.32-7.27 (m, 2H), 7.13 (dd, J=8.7, 2.2 Hz, 1H), 6.89 (d, J=2.3 Hz, 1H), 6.83 (d, J=8.7 Hz, 1H), 5.14 (s, 2H), 5.07-4.99 (m, 1H), 4.26-4.21 (m, 4H).
Example 16 3-[5-Bromo-2-(2-chloro-benzyloxy)-phenoxy]-1-methyl-azetidineSynthesized from the title compound of Example 15 according to general procedure 5. MS (ESI): mass calcd. for C17H17BrClNO2, 381.0; m/z found, 382.1 [M+H]+. 1H NMR (CDCl3): 7.59-7.51 (m, 1H), 7.39 (dd, J=7.4, 1.7 Hz, 1H), 7.32-7.23 (m, 2H), 7.00 (dd, J=8.6, 2.3 Hz, 1H), 6.78 (dd, J=5.4, 3.1 Hz, 2H), 5.19 (s, 2H), 4.78-4.73 (m, 1H), 3.92-3.78 (m, 2H), 3.21-3.11 (m, 2H), 2.42 (s, 3H).
Example 17 3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-azetidine trifluoroacetateMS (ESI): mass calcd. for C16H15BrFNO2, 351.0; m/z found, 352.1 [M+H]+. 1H NMR (CDCl3): 7.36 (dt, J=7.9, 5.9 Hz, 1H), 7.16 (d, J=7.6 Hz, 1H), 7.13-7.08 (m, 2H), 7.03 (dt, J=8.4, 2.1 Hz, 1H), 6.86 (d, J=2.2 Hz, 1H), 6.80 (d, J=8.7 Hz, 1H), 5.04 (s, 3H), 4.29-4.22 (m, 4H).
The compounds in Examples 18-21 were prepared from the title compound of Example 17 using general procedure 3 or 4.
Example 18 3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-1-ethyl-azetidineMS (ESI): mass calcd. for C18H19BrFNO2, 380.3; m/z found, 381.1 [M+H]+. 1H NMR (CDCl3): 7.35-7.31 (m, 1H), 7.17-7.15 (m, 2H), 7.00-6.97 (m, 2H), 6.76 (dd, J=16.1, 5.4 Hz, 2H), 5.08 (s, 2H), 4.78-4.74 (m, 1H), 3.85-3.82 (m, 2H), 3.13-3.05 (m, 2H), 2.57-2.53 (m, 2H), 1.00 (t, J=7.2 Hz, 3H).
Example 19 3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-1-propyl-azetidineMS (ESI): mass calcd. for C19H21BrFNO2, 394.3; m/z found, 395.1 [M+H]+. 1H NMR (CDCl3): 7.34-7.21 (m, 1H), 7.15-7.13 (m, 2H), 7.02-6.92 (m, 2H), 6.74 (dd, J=14.8, 5.4 Hz, 2H), 5.06 (s, 2H), 4.76-4.72 (m, 1H), 3.85-3.77 (m, 2H), 3.11-3.04 (m, 2H), 2.46 (dd, J=8.8, 6.0 Hz, 2H), 1.43-1.32 (m, 2H), 0.89 (t, J=7.4 Hz, 3H).
Example 20 3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-1-isopropyl-azetidineMS (ESI): mass calcd. for C19H21BrFNO2, 394.3; m/z found, 395.1 [M+H]+. 1H NMR (CDCl3): 7.34-7.30 (m, 1H), 7.18-7.12 (m, 2H), 7.02-6.94 (m, 2H), 6.80-6.71 (m, 2H), 5.07 (s, 2H), 4.74-4.69 (m, 1H), 3.85-3.78 (m, 2H), 3.12-3.06 (m, 2H), 2.43-2.36 (m, 1H), 0.96 (d, J=6.2 Hz, 6H).
Example 21 3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-1-cyclobutyl-azetidineMS (ESI): mass calcd. for C20H21BrFNO2, 406.3; m/z found, 407.1 [M+H]+. 1H NMR (CDCl3): 7.34-7.30 (m, 1H), 7.19-7.09 (m, 2H), 7.04-6.87 (m, 2H), 6.75 (dd, J=14.4, 5.4 Hz, 2H), 5.07 (s, 2H), 4.77-4.72 (m, 1H), 3.82-3.57 (m, 2H), 3.28-2.99 (m, 3H), 2.03-1.92 (m, 2H), 1.88-1.78 (m, 2H), 1.77-1.70 (m, 2H).
Example 22 3-[4-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C16H15BrClNO2, 368.7; m/z found, 369.1 [M+H]+. 1H NMR (CDCl3): 7.47 (s, 1H), 7.33-7.29 (m, 3H), 7.06-6.99 (m, 2H), 6.50 (d, J=8.4 Hz, 1H), 5.07 (s, 2H), 5.00-4.93 (m, 1H), 3.94-3.82 (m, 4H).
Example 23 3-[4-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-1-cyclobutyl-azetidineSynthesized from the title compound of Example 22 according to general procedure 3. MS (ESI): mass calcd. for C20H21BrClNO2, 422.7; m/z found, 423.9 [M+H]+. 1H NMR (CDCl3): 7.46-7.41 (m, 1H), 7.35-7.25 (m, 3H), 7.03-6.95 (m, 2H), 6.53 (d, J=8.6 Hz, 1H), 5.03 (s, 2H), 4.76-4.70 (m, 1H), 3.73-3.65 (m, 2H), 3.22-3.10 (m, 3H), 2.02-1.90 (m, 2H), 1.88-1.57 (m, 4H).
Example 24 3-[4-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-1-isopropyl-azetidineSynthesized from the title compound of Example 22 according to general procedure 3. MS (ESI): mass calcd. for C19H21BrClNO2, 410.7; m/z found, 412.0 [M+H]+. 1H NMR (CDCl3): 7.45 (s, 1H), 7.34-7.22 (m, 3H), 7.04-6.99 (m, 2H), 6.59-6.53 (m, 1H), 5.04 (s, 2H), 4.74-4.68 (m, 1H), 3.83-3.76 (m, 2H), 3.11-3.04 (m, 2H), 2.43-2.34 (m, 1H), 0.99-0.90 (m, 6H).
Example 25 3-[5-Chloro-2-(4-fluoro-benzyloxy)-phenoxy]-azetidine hydrochlorideMS (ESI): mass calcd. for C16H15ClFNO2, 307.1; m/z found, 308.2 [M+H]+. 1H NMR (DMSO-D6): 9.37 (s, 2H), 7.51 (dd, J=8.7, 5.6 Hz, 2H), 7.23 (t, J=8.9 Hz, 2H), 7.1 (d, J=8.7 Hz, 1H), 7.03 (dd, J=8.7, 2.4 Hz, 1H), 6.92 (d, J=2.4 Hz, 1H), 5.11 (s, 2H), 5.08-5.02 (m, 1H), 4.37 (dd, J=12.5, 6.7 Hz, 2H), 3.98 (dd, J=12.5, 5.0 Hz, 2H).
Example 26 3-[5-Chloro-2-(3-methylsulfanyl-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H18ClNO2S, 335.1; m/z found, 336.1 [M+H]+. 1H NMR (CDCl3): 7.33-7.29 (m, 2H), 7.18 (dd, J=13.3, 7.8 Hz, 2H), 6.86-6.81 (m, 2H), 6.59 (d, J=2.1 Hz, 1H), 5.07 (s, 2H), 5.01-4.95 (m, 1H), 3.94-3.84 (m, 4H), 2.49 (2, 3H).
Example 27 3-[5-Chloro-2-(3-methanesulfonyl-benzyloxy)-phenoxy]-azetidineTo the title compound of Example 26 (0.050 g, 0.10 mmol) in CH2Cl2 (1 mL) was added 77% m-CPBA (0.06 g, 0.25 mmol). After 18 h, 10% Na2S2O5 (aq.) was added and the mixture extracted with CH2Cl2 (2×). The combined organics were dried. Silica gel chromatography gave 0.038 g (80%) of the title compound as a clear oil. MS (ESI): mass calcd. for C22H26ClNO6S, 467.1; m/z found, 368.1 [M-100]+, 490.1 [M+Na]+. 1H NMR (CDCl3): 8.03 (s, 1H), 7.92 (d, J=7.8 Hz, 1H), 7.75 (d, J=7.8 Hz, 1H), 7.62 (t, J=7.8 Hz, 1H), 6.91 (dd, J=8.6, 2.3 Hz, 1H), 6.86 (d, J=8.6 Hz, 1H), 6.57 (d, J=2.3 Hz, 1H), 5.17 (s, 2H), 4.91-4.85 (m, 1H), 4.31 (dd, J=10.4, 6.4 Hz, 2H), 4.08-4.03 (m, 2H), 3.08 (s, 3H), 1.45 (s, 9H).
Step B: Preparation of 3-[5-Chloro-2-(3-methanesulfonyl-benzyloxy)-phenoxy]-azetidinePrepared from the title compound of Step A using general procedure 1. MS (ESI): mass calcd. for C17H18ClNO4S, 367.1; m/z found, 368.0 [M+H]+. 1H NMR (CDCl3): 8.10 (s, 1H), 7.91 (d, J=7.8 Hz, 1H), 7.73 (d, J=7.7 Hz, 1H), 7.60 (t, J=7.8 Hz, 1H), 6.89-6.83 (m, 2H), 6.60 (d, J=2.1 Hz, 1H), 5.17 (s, 2H), 5.03-4.97 (m, 1H), 3.97-3.85 (m, 4H), 3.07 (s, 3H).
Example 28 4-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-2-thiophen-2-yl-thiazoleMS (ESI): mass calcd. for C17H15ClN2O2S2, 378.0; m/z found, 379.1 [M+H]+. 1H NMR (CDCl3): 7.52 (dd, J=3.7, 0.9 Hz, 1H), 7.40 (dd, J=5.0, 0.9 Hz, 1H), 7.25 (m, 1H), 7.08 (dd, J=5.0, 3.7 Hz, 1H), 6.92-6.86 (m, 2H), 6.60 (d, J=2.3 Hz, 1H), 5.25 (s, 2H), 5.01-4.97 (m, 1H), 3.95-3.85 (m, 4H).
Example 29 4-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-2-methyl-thiazoleMS (ESI): mass calcd. for C17H15ClN2O2S, 310.1; m/z found, 311.2 [M+H]+. 1H NMR (CDCl3): 7.15 (d, J=10.2 Hz, 1H), 6.95-6.85 (m, 2H), 6.59 (d, J=2.1 Hz, 1H), 5.18 (d, J=0.8 Hz, 2H), 5.00-4.95 (m, 1H), 3.93-3.87 (m, 4H), 2.73 (s, 3H).
Example 30 3-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-5-methyl-isoxazoleMS (ESI): mass calcd. for C14H15ClN2O3, 294.1; m/z found, 295.2 [M+H]+. 1H NMR (CDCl3): 6.90 (d, J=8.6 Hz, 1H), 6.85 (dd, J=8.6, 2.3 Hz, 1H), 6.58 (d, J=2.3 Hz, 1H), 6.13 (s, 1H), 5.14 (s, 2H), 4.99-4.94 (m, 1H), 3.96-3.89 (m, 2H), 3.87-3.80 (m, 2H), 2.43 (s, 3H).
Example 31 3-[3-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-phenyl]-5-methyl-[1,2,4]oxadiazole hydrochlorideMS (ESI): mass calcd. for C19H18ClN3O3, 371.1; m/z found, 372.2 [M+H]+. 1H NMR (DMSO-D6): 9.22 (s, 2H), 8.10 (s, 1H), 7.95 (d, J=7.7 Hz, 1H), 7.65 (d, J=7.7 Hz, 1H), 7.59 (t, J=7.7 Hz, 1H), 7.13 (d, J=8.7 Hz, 1H), 7.03 (dd, J=8.7, 2.4 Hz, 1H), 6.93 (d, J=2.4 Hz, 1H), 5.24 (s, 2H), 5.09-5.05 (m, 1H), 4.41 (dd, J=12.5, 6.7 Hz, 2H), 4.02 (dd, J=12.3, 4.9 Hz, 2H), 2.67 (s, 3H).
Example 32 3-[5-Chloro-2-(2-trifluoromethyl-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H15ClF3NO2, 357.1; m/z found, 358.0 [M+H]+. 1H NMR (CDCl3): 7.79 (d, J=7.8 Hz, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.57 (t, J=7.6, 1H), 7.41 (t, J=7.6 Hz, 1H), 6.85 (dd, J=8.6, 2.3 Hz, 1H), 6.80 (d, J=8.6 Hz, 1H), 6.61 (d, J=2.3 Hz, 1H), 5.30 (s, 2H), 5.03-4.97 (m, 1H), 3.96-3.85 (m, 4H).
Example 33 3-[5-Chloro-2-(3-methoxy-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H18ClNO3, 319.1; m/z found, 320.2 [M+H]+. 1H NMR (CDCl3): 7.31-7.22 (m, 1H), 7.00-6.95 (m, 2H), 6.86-6.78 (m, 3H), 6.58 (d, J=2.1 Hz, 1H), 5.07 (s, 2H), 4.99-4.94 (m, 1H), 3.94-3.82 (m, 4H), 3.80 (s, 3H).
Example 34 3-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-benzonitrileMS (ESI): mass calcd. for C17H15ClN2O2, 314.1; m/z found, 315.1 [M+H]+. 1H NMR (CDCl3): 7.78 (s, 1H), 7.66 (d, J=7.8 Hz, 1H), 7.62 (d, J=7.7 Hz, 1H), 7.49 (t, J=7.8 Hz, 1H), 6.86 (dd, J=8.6, 2.3 Hz, 1H), 6.81 (d, J=8.6 Hz, 1H), 6.60 (d, J=2.3 Hz, 1H), 5.11 (s, 2H), 5.04-4.99 (m, 1H), 3.98-3.91 (m, 2H), 3.89-3.81 (m, 2H).
Example 35 3-[5-Chloro-2-(2-chloro-benzyloxy)-phenoxy]-azetidine trifluoroacetateMS (ESI): mass calcd. for C16H15O2NO2, 323.1; m/z found, 324.1 [M+H]+. 1H NMR (CDCl3): 7.46 (dd, J=5.5, 3.8 Hz, 1H), 7.43-7.39 (m, 1H), 7.32-7.27 (m, 2H), 6.98 (dd, J=8.7, 2.4 Hz, 1H), 6.87 (d, J=8.7 Hz, 1H), 6.75 (d, J=2.4 Hz, 1H), 5.14 (s, 2H), 5.07-4.99 (m, 1H), 4.34-4.19 (m, 4H).
Example 36 3-[5-Chloro-2-(4-chloro-benzyloxy)-phenoxy]-azetidine trifluoroacetateMS (ESI): mass calcd. for C16H15O2NO2, 323.1; m/z found, 324.1 [M+H]+. 1H NMR (CDCl3): 7.35 (q, J=8.6 Hz, 4H), 6.95 (dd, J=8.7, 2.4 Hz, 1H), 6.83 (d, J=8.7 Hz, 1H), 6.72 (d, J=2.4 Hz, 1H), 5.08-4.95 (m, 3H), 4.31-4.24 (m, 4H).
Example 37 3-[5-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C16H15O2NO2, 323.1; m/z found, 324.1 [M+H]+. 1H NMR (CDCl3): 7.45 (s, 1H), 7.32-7.27 (m, 3H), 6.85 (td, J=8.5, 1.9 Hz, 1H), 6.81 (dd, J=8.6, 4.6 Hz, 1H), 6.59 (d, J=2.3 Hz, 1H), 5.06 (d, J=3.9 Hz, 2H), 5.00-4.95 (m, 1H), 3.95-3.84 (m, 4H).
Example 38 3-[5-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-azetidineSynthesized from the title compound of Example 37 according to general procedure 5. MS (ESI): mass calcd. for C17H17O2NO2, 337.1; m/z found, 338.1 [M+H]+. 1H NMR (CDCl3): 7.45 (s, 1H), 7.32-7.27 (m, 3H), 6.84 (dd, J=8.6, 2.3 Hz, 1H), 6.80 (d, J=8.6 Hz, 1H), 6.63 (d, J=2.3 Hz, 1H), 5.06 (s, 2H), 4.74-4.69 (m, 1H), 3.88-3.82 (m, 2H), 3.21-3.11 (m, 2H), 2.42 (s, 3H).
Example 39 3-[5-Chloro-2-(3-trifluoromethyl-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H15ClF3NO2, 357.1; m/z found, 358.1 [M+H]+. 1H NMR (CDCl3): 7.74 (s, 1H), 7.59 (t, J=8.6 Hz, 2H), 7.50 (t, J=7.7 Hz, 1H), 6.87 (dd, J=8.6, 2.2 Hz, 1H), 6.83 (d, J=8.6 Hz, 1H), 6.60 (d, J=1.7 Hz, 1H), 5.13 (s, 2H), 5.01-4.96 (m, 1H), 3.96-3.85 (m, 4H).
Example 40 3-(2-Benzyloxy-5-chloro-phenoxy)-azetidineMS (ESI): mass calcd. for C16H16ClNO2, 289.1; m/z found, 290.1 [M+H]+. 1H NMR (CDCl3): 7.39 (d, J=4.4 Hz, 4H), 7.36-7.31 (m, 1H), 6.96 (dd, J=8.7, 2.4 Hz, 1H), 6.86 (d, J=8.7 Hz, 1H), 6.74 (d, J=2.4 Hz, 1H), 5.03 (s, 2H), 5.01-4.95 (m, 1H), 4.39-4.15 (m, 4H).
Example 41 3-[5-Chloro-2-(3-chloro-4-trifluoromethoxy-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H14Cl2F3NO3, 407.0; m/z found, 408.0 [M+H]+. 1H NMR (CD3OD/CDCl3): 7.61-7.59 (m, 1H), 7.38-7.30 (m, 2H), 6.87 (dd, J=8.6, 2.3 Hz, 1H), 6.82 (d, J=8.6 Hz, 1H), 6.59 (d, J=2.3 Hz, 1H), 5.06 (s, 2H), 5.03-4.93 (m, 1H), 4.25-3.60 (m, 4H).
Example 42 3-[5-Chloro-2-(4-trifluoromethoxy-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H15ClF3NO3, 373.1; m/z found, 374.0 [M+H]+. 1H NMR (CDCl3): 7.46 (d, J=8.7 Hz, 2H), 7.23 (d, J=8.0 Hz, 2H), 6.86 (dd, J=8.6, 2.6 Hz, 1H), 6.82 (d, J=8.6 Hz, 1H), 6.59 (d, J=2.2 Hz, 1H), 5.09 (s, 2H), 5.02-4.94 (m, 1H), 4.00-3.80 (m, 4H).
Example 43 3-[5-Chloro-2-(4-trifluoromethyl-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H15ClF3NO2, 357.1; m/z found, 358.1 [M+H]+. 1H NMR (CDCl3): 7.64 (d, J=8.1 Hz, 2H), 7.55 (d, J=8.1 Hz, 2H), 6.85 (dd, J=8.6, 2.3 Hz, 1H), 6.80 (d, J=8.6 Hz, 1H), 6.60 (d, J=2.3 Hz, 1H), 5.15 (s, 2H), 5.02-4.94 (m, 1H), 4.01-3.79 (m, 4H).
Example 44 4-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-benzonitrileMS (ESI): mass calcd. for C17H15ClN2O2, 314.1; m/z found, 315.0 [M+H]+. 1H NMR (CDCl3): 7.68 (d, J=8.3 Hz, 2H), 7.55 (d, J=8.0 Hz, 2H), 6.86 (dd, J=8.6, 2.4 Hz, 1H), 6.78 (d, J=8.6 Hz, 1H), 6.60 (d, J=2.3 Hz, 1H), 5.15, (s, 2H), 5.04-4.94 (m, 1H), 4.02-3.79 (m, 4H).
Example 45 3-[2-(2,4-Bis-trifluoromethyl-benzyloxy)-5-chloro-phenoxy]-azetidine1H NMR (CDCl3, CD3OD): 8.04-7.92 (m, 2H), 7.01 (dd, J=8.7, 2.3 Hz, 1H), 6.94 (d, J=8.7 Hz, 1H), 6.84 (d, J=2.3 Hz, 1H), 5.36, (s, 2H), 5.20-2.11 (m, 1H), 4.49 (dd, J=12.4, 6.7 Hz, 2H), 4.22 (dd, J=12.4, 5.2 Hz, 2H).
Example 46 3-[5-Chloro-2-(4-trifluoromethylsulfanyl-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H15ClF3NO2S, 389.1; m/z found, 390.1 [M+H]+. 1H NMR (CDCl3): 7.67 (d, J=8.2 Hz, 2H), 7.49 (d, J=8.4 Hz, 2H), 6.86 (dd, J=8.6, 2.3 Hz, 1H), 6.81 (d, J=8.6 Hz, 1H), 6.60 (d, J=2.3 Hz, 1H), 5.13 (s, 2H), 5.05-4.93 (m, 1H), 4.04-3.78 (m, 4H).
Example 47 3-[5-Chloro-2-(4-fluoro-3-trifluoromethyl-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H14ClF4NO2, 375.1; m/z found, 377.0 [M+H]+. 1H NMR (CDCl3): 7.77-7.70 (m, 1H), 7.64-7.57 (m, 1H), 7.25-7.18 (m, 1H), 6.88 (dd, J=8.6, 2.3 Hz, 1H), 6.83 (d, J=8.6 Hz, 1H), 6.59 (d, J=8.3 Hz, 1H), 5.08 (s, 2H), 5.02-4.94 (m, 1H), 3.98-3.90 (m, 2H), 3.87-3.80 (m, 2H).
Example 48 3-[5-Chloro-2-(2-fluoro-4-trifluoromethyl-benzyloxy)-phenoxy]-azetidine1H NMR (CDCl3): 7.70 (dd, J=7.6, 7.4 Hz, 1H), 7.45 (d, J=8.0 Hz, 1H), 7.35 (d, J=9.8 Hz, 1H), 6.88-6.84 (m, 2H), 6.61 (d, J=2.0 Hz, 1H), 5.20 (s, 2H), 5.02-4.94 (m, 1H), 3.97-3.90 (m, 2H), 3.88-3.81 (m, 2H).
Example 49 3-[5-Chloro-2-(4-chloro-3-trifluoromethyl-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H14O2F3NO2, 391.0; m/z found, 392.0 [M+H]+. 1H NMR (CDCl3): 7.73 (d, J=6.3 Hz, 1H), 7.63-7.58 (m, 1H), 7.21 (dd, J=9.4, 9.2 Hz, 1H), 6.90-6.81 (m, 2H), 6.59 (d, J=1.6 Hz, 1H), 5.10-5.05 (m, 1H), 5.08, (s, 2H), 5.05-4.95 (m, 4H).
Example 50 3-[5-Chloro-2-(3,4-dichloro-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C16H14Cl3NO2, 357.0; m/z found, 359.9 [M+H]+. 1H NMR (CDCl3): 7.56 (d, J=1.8 Hz, 1H), 7.44 (d, J=8.2 Hz, 1H), 7.24 (dd, J=8.3, 1.9 Hz, 1H), 6.85 (dd, J=8.6, 2.3 Hz, 1H), 6.80 (d, J=8.6 Hz, 1H), 6.58 (d, J=2.3 Hz, 1H), 5.04, (s, 2H), 5.05-5.00 (m, 1H), 4.52-3.00 (m, 4H).
Example 51 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-pyridineMS (ESI): mass calcd. for C15H15ClN2O2, 290.1; m/z found, 291.1 [M+H]+. 1H NMR (CDCl3): 8.62-8.57 (m, 1H), 7.75-7.69 (m, 1H), 7.55 (d, J=7.8 Hz, 1H), 7.25-7.20 (m, 1H), 6.85-6.82 (m, 2H), 6.60 (d, J=1.6 Hz, 1H), 5.24 (s, 2H), 5.09-4.94 (m, 1H), 4.18-3.64 (m, 4H).
Example 52 3-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-pyridineMS (ESI): mass calcd. for C15H15ClN2O2, 290.1; m/z found, 291.1 [M+H]+. 1H NMR (CD3OD/CDCl3): 8.68-8.61 (m, 1H), 8.53 (d, J=4.3 Hz, 1H), 7.86 (d, J=7.9 Hz, 1H), 7.45-7.37 (m, 1H), 6.93-6.87 (m, 2H), 6.63-6.60 (m, 1H), 5.13 (s, 2H), 5.04-4.94 (m, 1H), 4.12-3.70 (m, 4H).
Example 53 4-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-pyridineMS (ESI): mass calcd. for C15H15ClN2O2, 290.1; m/z found, 291.1 [M+H]+. 1H NMR (CD3OD/CDCl3): 8.56-8.53 (m, 2H), 7.50-7.44 (m, 2H), 6.92-6.86 (m, 2H), 6.66 (d, J=2.1 Hz, 1H), 5.18 (s, 2H), 5.09-5.01 (m, 1H), 4.04-3.94 (m, 2H), 3.88-3.80 (m, 2H).
Example 54 3-[5-Chloro-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C15H13ClF3NO3, 347.1; m/z found, 348.2 [M+H]+. 1H NMR (CDCl3): 6.90-6.88 (m, 2H), 6.77-6.76 (m, 1H), 6.60 (s, 1H), 6.46-6.45 (m, 1H), 5.05 (s, 2H), 4.98-4.93 (m, 1H), 3.94-3.90 (m, 2H), 3.85-3.82 (m, 2H).
Example 55 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-furan-2-carboxylic acid ethyl esterMS (ESI): mass calcd. for C17H18ClNO5, 351.1; m/z found, 352.2 [M+H]+. 1H NMR (CDCl3): 7.13 (d, J=3.4 Hz, 1H), 6.89-6.85 (m, 2H), 6.58 (d, J=1.6 Hz, 1H), 6.50 (d, J=3.4 Hz, 1H), 5.08 (s, 2H), 4.98-4.93 (m, 1H), 4.37 (q, J=7.1 Hz, 1H), 3.94-3.90 (m, 2H), 3.86-3.83 (m, 2H), 1.38 (t, J=7.1 Hz, 1H).
Example 56 3-[5-Chloro-2-(4-chloro-2-methanesulfonyl-benzyloxy)-phenoxy]-azetidine1H NMR (CD3OD/CDCl3): 7.65 (s, 1H), 7.33-7.27 (m, 2H), 6.64 (d, J=8.7 Hz, 1H), 6.58 (dd, J=8.7, 2.3 Hz, 1H), 6.37 (d, J=2.3 Hz, 1H), 5.03 (s, 2H), 4.71-4.63 (m, 1H), 3.99 (dd, J=12.6, 6.6 Hz, 2H), 3.70 (dd, J=12.5, 5.1 Hz, 2H), 2.84 (s, 3H).
Example 57 3-[5-Chloro-2-(2,4-difluoro-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C16H14ClF2NO2, 325.1; m/z found, 327.1 [M+H]+. 1H NMR (CDCl3): 7.52-7.43 (m, 1H), 6.92-6.80 (m, 4H), 6.60-6.58 (m, 1H), 5.10 (s, 2H), 5.00-4.93 (m, 1H), 4.11-3.69 (m, 4H).
Example 58 (R)-3-[5-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-pyrrolidineMS (ESI): mass calcd. for C17H17O2NO2, 337.1; m/z found, 338.1 [M+H]+. 1H NMR (CDCl3): 7.43 (s, 1H), 7.30-7.25 (m, 3H), 6.87-6.81 (m, 3H), 5.02 (s, 2H), 4.83-4.81 (m, 1H), 3.23-3.17 (m, 2H), 2.99 (dd, J=12.8, 4.7 Hz, 1H), 2.91 (ddd, J=11.3, 8.5, 5.5 Hz, 1H), 2.11-2.00 (m, 2H).
Example 59 (R)-3-[5-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-pyrrolidineSynthesized from the title compound of Example 58 according to general procedure 5. MS (ESI): mass calcd. for C18H19O2NO2, 351.1; m/z found, 352.1 [M+H]+. 1H NMR (CDCl3): 7.45 (s, 1H), 7.29-7.28 (m, 3H), 6.85-6.79 (m, 3H), 5.04 (s, 2H), 4.83-4.80 (m, 1H), 2.96 (dd, J=10.6, 6.1 Hz, 1H), 2.80-2.75 (m, 2H), 2.58-2.54 (m, 1H), 2.41 (s, 3H), 2.32-2.36 (m, 1H), 2.08-2.02 (m, 1H).
Example 60 (R)-3-[5-Chloro-2-(2-chloro-benzyloxy)-phenoxy]-pyrrolidineMS (ESI): mass calcd. for C17H17O2NO2, 337.1; m/z found, 338.1 [M+H]+. 1H NMR (CDCl3): 7.56-7.54 (m, 1H), 7.39-7.37 (m, 1H), 7.30-7.24 (m, 2H), 6.88-6.86 (m, 3H) 5.15 (s, 2H), 4.84-4.82 (m, 1H), 3.23-3.16 (m, 2H), 2.98 (dd, J=12.8, 4.6 Hz, 1H), 2.90 (ddd, J=11.3, 8.5, 5.5 Hz, 1H), 2.12-2.00 (m, 2H).
Example 61 (R)-3-[5-Chloro-2-(2-chloro-benzyloxy)-phenoxy]-1-methyl-pyrrolidineSynthesized from the title compound of Example 60 according to general procedure 5. MS (ESI): mass calcd. for C18H19O2NO2, 351.1; m/z found, 352.1 [M+H]+. 1H NMR (CDCl3): 7.60-7.58 (m, 1H), 7.38-7.37 (m, 1H), 7.29-7.23 (m, 2H), 6.85-6.82 (m, 3H) 5.17 (s, 2H), 4.85-4.81 (m, 1H), 2.95 (dd, J=10.6, 6.1 Hz, 1H), 2.78-2.73 (m, 2H), 2.57-2.53 (m, 1H), 2.39 (s, 3H), 2.32-2.36 (m, 1H), 2.08-2.02 (m, 1H).
Example 62 4-(2-Benzyloxy-5-chloro-phenoxy)-piperidineMS (ESI): mass calcd. for C18H20ClNO2, 317.1; m/z found, 318.3 [M+H]+. 1H NMR (CDCl3): 7.42-7.40 (m, 2H), 7.38-7.34 (m, 2H), 7.32-7.29 (m, 1H), 6.93-6.93 (m, 1H), 6.87-6.82 (m, 2H), 5.08 (s, 2H), 4.35-4.29 (m, 1H), 3.17-3.11 (m, 2H), 2.68 (ddd, J=12.6, 9.3, 3.1 Hz, 2H), 2.02-1.96 (m, 2H), 1.74-1.66 (m, 2H).
Example 63 4-[5-Chloro-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-piperidine hydrochlorideMS (ESI): mass calcd. for C17H17ClF3NO3, 375.1; m/z found, 378.2. 1H NMR (DMSO-D6): 9.10-9.00 (m, 2H), 7.24-7.23 (m, 2H), 7.15 (d, J=8.7 Hz, 1H), 7.01 (d, J=8.7, 2.5 Hz, 1H), 6.80 (d, J=3.2 Hz, 1H), 5.17 (s, 2H), 4.59-4.55 (m, 1H), 3.20-3.17 (m, 2H), 3.03-3.00 (m, 2H), 2.07-2.02 (m, 2H), 1.86-1.82 (m, 2H).
Example 64 4-[5-Bromo-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-piperidineMS (ESI): mass calcd. for C17H17BrF3NO3, 419.0; m/z found, 420.1 [M+H]+. 1H NMR (CDCl3): 7.09 (d, J=2.3 Hz, 1H), 7.04 (dd, J=8.5, 2.3 Hz, 1H), 6.84 (d, J=8.6 Hz, 1H), 6.79-6.75 (m, 1H), 6.45 (d, J=3.3 Hz, 1H), 5.06 (s, 2H), 4.37-4.29 (m, 1H), 3.21-3.10 (m, 2H), 2.78-2.66 (m, 2H), 2.06-1.95 (m, 2H), 1.76-1.66 (m, 2H).
Example 65 4-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-piperidineMS (ESI): mass calcd. for C18H19BrClNO2, 395.0; m/z found, 396.1 [M+H]+. 1H NMR (CDCl3): 7.45 (s, 1H), 7.29-7.27 (m, 3H), 7.07 (d, J=7.1 Hz, 1H), 7.01 (dd, J=8.6, 2.3 Hz, 1H), 6.78 (d, J=8.6 Hz, 1H), 5.04 (s, 2H), 4.36-4.30 (m, 1H), 3.18-3.12 (m, 2H), 2.73-2.67 (m, 2H), 2.02-1.97 (m, 2H), 1.75-1.67 (m, 2H).
Example 66 4-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-piperidineSynthesized from the title compound of Example 65 according to general procedure 5. MS (ESI): mass calcd. for C19H21BrClNO2, 409.0; m/z found, 410.1 [M+H]+. 1H NMR (CDCl3): 7.46 (s, 1H), 7.30-7.28 (m, 3H), 7.06 (d, J=2.3 Hz, 1H), 7.01 (dd, J=8.6, 2.3 Hz, 1H), 6.79 (d, J=8.6 Hz, 1H), 5.04 (s, 2H), 4.32-4.29 (m, 1), 2.73-2.67 (m, 2H), 2.35-2.27 (m, 4H), 2.02-1.85 (m, 4H).
Example 67 4-[5-Bromo-2-(2-fluoro-benzyloxy)-phenoxy]-piperidineMS (ESI): mass calcd. for C18H19BrFNO2, 379.1; m/z found, 380.2 [M+H]+. 1H NMR (CDCl3): 7.52-7.49 (m, 1H), 7.33-7.28 (m, 1H), 7.15 (t, J=7.5 Hz, 1H), 7.09-7.05 (m, 2H), 7.03-7.01 (m, 1H), 6.83 (dd, J=8.6, 2.4 Hz, 1H), 5.12 (s, 2H), 4.34-4.29 (m, 1H), 3.15-3.13 (m, 2H), 2.71-2.62 (m, 2H), 2.00-1.94 (m, 2H), 1.72-1.66 (m, 2H).
Example 68 4-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-piperidineMS (ESI): mass calcd. for C18H19BrFNO2, 379.1; m/z found, 380.2 [M+H]+. 1H NMR (CDCl3): 7.35-7.31 (m, 1H), 7.18-7.15 (m, 2H), 7.07 (d, J=2.3 Hz, 1H), 7.02-6.98 (m, 2H), 6.78 (d, J=8.6 Hz, 1H), 5.07 (s, 2H), 4.36-4.31 (m, 1H), 3.17-3.14 (m, 2H), 2.71 (t, J=9.6 Hz, 2H), 2.03-2.00 (m, 2H), 1.75-1.67 (m, 2H).
Example 69 (±)-3-[5-Chloro-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-piperidineMS (ESI): mass calcd. for C17H17ClF3NO3, 375.1; m/z found, 376.0 [M+H]+. 1H NMR (CDCl3): 6.96-6.95 (m, 1H), 6.88-6.87 (m, 2H), 6.76-6.75 (m, 1H), 6.45-6.44 (m, 1H), 5.04 (s, 2H), 4.22-4.17 (m, 1H), 3.12 (dd, J=2.2, 12.7 Hz, 1H), 2.88-2.82 (m, 2H), 2.78-2.72 (m, 1H), 2.02-1.96 (m, 1H), 1.85-1.74 (m, 2H), 1.53-1.45 (m, 1H).
Example 70 (±)-3-(2-Benzyloxy-5-chloro-phenoxy)-piperidineMS (ESI): mass calcd. for C18H20ClNO2, 317.12; m/z found, 318.1 [M+H]+. 1H NMR (CDCl3): 7.45-7.28 (m, 5H), 6.95 (d, J=2.1 Hz, 1H), 6.90-6.81 (m, 2H), 5.08 (s, 2H), 4.20 (dq, J=10.2, 3.3 Hz, 1H), 3.11 (dd, J=12.7, 2.3 Hz, 1H), 2.91-2.78 (m, 2H), 2.78-2.69 (m, 1H), 2.05-1.94 (m, 1H), 1.88-1.74 (m, 2H), 1.53-1.41 (m, 1H).
Example 71 (±)-3-[5-Chloro-2-(3-trifluoromethyl-benzyloxy)-phenoxy]-piperidineMS (ESI): mass calcd. for C19H19ClF3NO2, 385.11; m/z found, 386.0 [M+H]+. 1H NMR (CDCl3): 7.75 (s, 1H), 7.62-7.56 (m, 2H), 7.50 (t, J=7.7 Hz, 1H), 6.96 (d, J=2.3 Hz, 1H), 6.89 (dd, J=8.6, 2.3 Hz, 1H), 6.84 (d, J=8.6 Hz, 1H), 5.12 (s, 2H), 4.28-4.16 (m, 1H), 3.13 (dd, J=12.6, 2.3 Hz, 1H), 2.91-2.80 (m, 2H), 2.78-2.67 (m, 1H), 2.08-1.94 (m, 1H), 1.88-1.73 (m, 2H), 1.55-1.40 (m, 1H).
Example 72 3-(5-Chloro-2-cyclopentyloxy-phenoxy)-azetidine trifluoroacetateMS (ESI): mass calcd. for C14H18ClNO2, 267.1; m/z found, 268.2 [M+H]+. 1H NMR (CDCl3): 6.97 (dd, J=8.7, 2.5 Hz, 1H), 6.81 (d, J=8.8 Hz, 1H), 6.75 (d, J=2.5 Hz, 1H), 5.04-4.99 (m, 1H), 4.76-4.67 (m, 1H), 4.38-4.27 (m, 4H), 1.96-1.87 (m, 2H), 1.84-1.74 (m, 4H), 1.69-1.59 (m, 2H).
Example 73 3-(5-Chloro-2-cyclohexylmethoxy-phenoxy)-azetidine trifluoroacetateMS (ESI): mass calcd. for C18H22ClNO2, 295.1; m/z found, 296.2 [M+H]+. 1H NMR (CDCl3): 6.97 (dd, J=8.7, 2.3 Hz, 1H), 6.80 (d, J=8.7 Hz, 1H), 6.74 (d, J=2.4 Hz, 1H), 5.15-4.97 (m, 1H), 4.44-4.36 (m, 2H), 4.30 (s, 2H), 3.74 (d, J=6.3 Hz, 2H), 1.89-1.65 (m, 6H), 1.36-1.14 (m, 3H), 1.03 (m, 2H).
Example 74 3-(5-Bromo-2-cyclohexylmethoxy-phenoxy)-azetidineMS (ESI): mass calcd. for C18H22BrNO2, 339.1; m/z found, 340.1 [M+H]+. 1H NMR (CDCl3): 7.01 (dd, J=8.6, 2.3 Hz, 1H), 6.74 (d, J=8.6 Hz, 1H), 6.71 (d, J=2.3 Hz, 1H), 4.97-4.92 (m, 1H), 3.92-3.83 (m, 4H), 3.75 (d, J=6.4 Hz, 2H), 1.95-1.63 (m, 6H), 1.36-1.14 (m, 3H), 1.10-0.93 (m, 2H).
Example 75 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-2-trifluoromethyl-furan-3-carboxylic acid trifluoroacetateTo a solution of 5-methyl-2-trifluoromethyl-furan-3-carboxylic acid ethyl ester (0.95 g, 4.5 mmol) in CCl4 (12 mL) was added N-bromosuccinimide (0.84 g, 4.8 mmol) followed by AIBN (0.004 g, 0.01 mmol). After refluxing for 2 h, analytical HPLC analysis confirmed the reaction was complete. The reaction was cooled to rt, then CH2Cl2 and sat'd NaHCO3 (aq.) were added. The organic portion was separated and dried to provide the crude residue as a yellow oil. This material was purified by RP HPLC to provide the title compound (510 mg, 38%). MS (ESI): mass calcd. for C9H8BrF3O3, 300.0; m/z found, 302.9 [M+H]+. 1H NMR (CDCl3): 6.84 (s, 1H), 4.44 (s, 2H), 4.34 (q, J=7.2 Hz, 2H), 1.36 (t, J=7.1 Hz, 3H).
Step B: Preparation of 3-[2-(4-Carboxy-5-trifluoromethyl-furan-2-ylmethoxy)-5-chloro-phenoxy]-azetidine-1-carboxylic acid tert-butyl esterThe title compound was prepared as described in Example 1 Step D using 3-(5-chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (0.15 g, 0.50 mmol), the title compound of Step A (0.18 g, 0.60 mmol), Cs2CO3 (0.41 g, 1.2 mmol), KI (0.12 g, 0.70 mmol) in DMF, except upon completion of the reaction 1N NaOH and EtOAc were added. The organic layer was washed with 1N NaOH and dried. The crude material was purified by RP HPLC to provide the title compound. 1H NMR (CDCl3): 7.20-6.92 (m, 1H), 6.91-6.80 (m, 2H), 6.77-6.69 (m, 1H), 6.53 (d, J=2.1 Hz, 1H), 4.87 (s, 2H), 4.79-4.69 (m, 1H), 4.27-4.12 (m, 2H), 4.00-3.88 (m, 2H), 1.38 (s, 9H).
Step C: Preparation of 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-2-trifluoromethyl-furan-3-carboxylic acid trifluoroacetatePrepared from the title compound of Step B using general procedure 1. MS (ESI): mass calcd. for C16H13ClF3NO5 [M-TFA], 391.0; m/z found, 392.9 [M+H]+. 1H NMR (CD3OD): 7.10 (d, J=8.7 Hz, 1H), 7.03 (dd, J=8.7, 2.4 Hz, 1H), 6.99 (s, 1H), 6.88 (d, J=2.4 Hz, 1H), 5.14 (s, 2H), 5.11-5.04 (m, 1H), 4.49 (dd, J=12.4, 6.6 Hz, 2H), 4.22 (dd, J=12.4, 4.9 Hz, 2H).
Example 76 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-2-trifluoromethyl-furan-3-carboxylic acid ethyl esterThe title compound was prepared as described in Example 1 Step D using 3-(5-chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (0.3 g, 1.0 mmol), the title compound of Example 75 Step A (0.75 g, 2.5 mmol), Cs2CO3 (0.80 g, 2.4 mmol) and KI (0.23 g, 1.4 mmol) in DMF (15 mL). The crude material was purified by RP HPLC to provide the title compound (0.37 g, 71%). 1H NMR (CDCl3): 7.20-6.92 (m, 1H), 6.91-6.80 (m, 2H), 6.77-6.69 (m, 1H), 6.53 (d, J=2.1 Hz, 1H), 4.87 (s, 2H), 4.79-4.69 (m, 1H), 4.27-4.12 (m, 2H), 4.00-3.88 (m, 2H), 1.38 (s, 9H).
Step B: Preparation of 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-2-trifluoromethyl-furan-3-carboxylic acid ethyl esterPrepared from the title compound of Step A using general procedure 1. MS (ESI): mass calcd. for C18H17ClF3NO5, 419.1; m/z found, 420.0 [M+H]+. 1H NMR (CDCl3): 6.94-7.80 (m, 3H), 6.65-6.56 (m, 1H), 5.05 (s, 2H), 5.01-4.92 (m, 1H), 4.34 (q, J=7.2 Hz, 2H), 3.97-3.81 (m, 4H), 1.36 (t, J=7.1 Hz, 3H).
Example 77 5-[4-Chloro-2-(1-methyl-azetidin-3-yloxy)-phenoxymethyl]-2-trifluoromethyl-furan-3-yl]-methanolTo a solution of the title compound of Example 76 Step A (0.05 g, 0.1 mmol) at −78° C. was added DIBAL-H (1.0 M in THF, 0.24 mL). After addition was complete, the bath was replaced with a 0° C. bath and allowed to stir for 1 h. Then, an additional aliquot of DIBAL-H (1.0 M in THF, 1 mL) was added. After 3 h, the reaction was quenched with a saturated solution of sodium potassium tartrate (aq.) and allowed to stir overnight. The mixture was extracted with EtOAc (2×) and the combined organic layers were dried. The product was purified by RP HPLC to provide the title compound (0.004 g, 10%). MS (ESI): mass calcd. for C17H17ClF3NO4, 391.1; m/z found, 392.1 [M+H]+. 1H NMR (CDCl3): 6.94 (d, J=8.6 Hz, 1H), 6.89 (dd, J=8.6, 2.3 Hz, 1H), 6.65 (s, 1H), 6.54 (d, J=2.3 Hz, 1H), 5.02 (s, 2H), 4.73-4.66 (m, 1H), 4.64 (d, J=1.4 Hz, 2H), 3.76-3.69 (m, 2H), 3.27-3.21 (m, 2H), 2.41 (s, 3H).
Example 78 3-[5-Chloro-2-(5-methyl-2-trifluoromethyl-furan-3-ylmethoxy)-phenoxy]-azetidineTo a solution of 5-methyl-2-trifluoromethyl-furan-3-carboxylic acid ethyl ester (0.83 g, 3.7 mmol) in Et2O at 0° C., was added DIBAL-H (1.0 M in THF, 1.5 mL). After 10 min, the ice bath was removed and additional DIBAL-H was added (1.0 M in THF, 14.5 mL). After 2 h, the reaction was quenched with a saturated solution of sodium potassium tartrate (aq.) and allowed to stir overnight. After 18 h, EtOAc was added and the organic layer separated and dried provide the title compound (0.39 g, 58%). 1H NMR (CDCl3): 6.19 (s, 1H), 4.62 (s, 2H), 2.36-2.28 (m, 3H).
Step B: Preparation of 3-[5-chloro-2-(5-methyl-2-trifluoromethyl-furan-3-ylmethoxy)-phenoxy]-azetidine-1-carboxylic acid tert-butyl esterSynthesized from the title compound of Step A and 3-(5-chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester using general procedure 7. MS (ESI): mass calcd. for C21H23ClF3NO5, 461.1; m/z found, 485.9 [M+Na]+. 1H NMR 6.91 (dd, J=8.6, 2.3 Hz, 1H), 6.84 (d, J=8.6 Hz, 1H), 6.55 (d, J=2.3 Hz, 1H), 6.22 (s, 1H), 5.07-5.00 (m, 2H), 4.90-4.81 (m, 1H), 4.30 (ddd, J=9.7, 6.5, 0.8 Hz, 2H), 4.06 (dd, J=9.8, 4.0 Hz, 2H), 2.34 (s, 3H), 1.45 (s, 9H).
Step C: Preparation of 3-[5-Chloro-2-(5-methyl-2-trifluoromethyl-furan-3-ylmethoxy)-phenoxy]-azetidineSynthesized from the title compound of Step B using general procedure 1. MS (ESI): mass calcd. for C16H15ClF3NO3, 361.1; m/z found, 362.1 [M+H]+. 1H NMR (CDCl3): 6.86 (dd, J=8.6, 2.2 Hz, 1H), 6.81 (d, J=8.6 Hz, 1H), 6.58 (d, J=2.2 Hz, 1H), 6.23 (s, 1H), 5.03 (s, 2H), 5.01-4.93 (m, 1H), 4.01-3.77 (m, 4H), 2.33 (s, 3H).
Example 79 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-6-trifluoromethyl-pyridineTo a solution of 6-trifluoromethyl-pyridine-2-carboxylic acid (500 mg, 3 mmol) in dry THF at 0° C., was added triethylamine (0.36 mL, 2.6 mmol) followed by ethyl chloroformate (0.25 mL, 2.6 mmol). After 30 min, LiBH4 (2 M in THF, 3.3 mL, 6.5 mmol) was added. After an additional 30 min, the ice bath was removed. After 1 h, the reaction was cooled to 0° C. and quenched with MeOH followed by 1N NaOH and EtOAc. The pH of the solution was adjusted to pH=5 with 1N HCl and the mixture extracted with EtOAc (2×). The combined organic fractions were dried to provide the title compound that was used without further purification. 1H NMR (CDCl3): 7.89 (dd, J=7.8, 7.8 Hz, 1H), 7.61 (d, J=7.7 Hz, 1H), 7.51 (d, J=7.9 Hz, 1H), 4.85 (s, 2H).
Step B: Preparation of 3-[5-Chloro-2-(6-trifluoromethyl-pyridin-2-ylmethoxy)-phenoxy]-azetidine-1-carboxylic acid tert-butyl esterPrepared from the title compound of Step A and 3-(5-Chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester using general procedure 7.
Step C: Preparation of 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-6-trifluoromethyl-pyridinePrepared from the title compound of Step B according to general procedure 1. MS (ESI): mass calcd. for C16H14ClF3N2O2, 358.1; m/z found, 359.0 [M+H]+. 1H NMR (CDCl3): 7.92 (dd, J=7.8, 7.8 Hz, 1H), 7.81 (d, J=7.9 Hz, 1H), 7.63 (d, J=7.7 Hz, 1H), 6.87 (dd, J=8.6, 2.1 Hz, 1H), 6.61 (d, J=2.1, 1H), 5.29 (s, 2H), 5.21-4.99 (m, 1H), 4.21-1.15 (br m, 4H).
Examples 80-89 were prepared using the appropriate alcohol and phenol according to general procedure 7.
Example 80 3-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-2-methyl-6-trifluoromethyl-pyridineMS (ESI): mass calcd. for C17H16ClF3N2O2, 372.1; m/z found, 373.0 [M+H]+. 1H NMR (CDCl3): 7.93 (d, J=7.9 Hz, 1H), 7.55 (d, J=7.9 Hz, 1H), 6.89 (dd, J=8.6, 2.2 Hz, 1H), 6.85 (d, J=8.6 Hz, 1H), 6.60 (d, J=2.2 Hz, 1H), 5.11 (s, 2H), 5.03-4.92 (m, 1H), 4.08-3.69 (m, 4H), 2.66 (s, 3H).
Example 81 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-4-trifluoromethyl-pyridineMS (ESI): mass calcd. for C16H14ClF3N2O2, 358.1; m/z found, 358.9 [M+H]+. 1H NMR (CDCl3): 8.86 (s, 1H), 7.98 (d, J=7.9 Hz, 1H), 7.73 (d, J=8.2 Hz, 1H), 6.87 (dd, J=8.6, 2.1 Hz, 1H), 6.82 (d, J=8.6 Hz, 1H), 6.61 (d, J=1.9 Hz, 1H), 5.28 (s, 2H), 5.08-4.98 (m, 1H), 4.08-3.97 (m, 2H), 3.96-3.85 (m, 2H).
Example 82 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-2-trifluoromethyl-pyridineMS (ESI): mass calcd. for C16H14ClF3N2O2, 358.1; m/z found, 359.0 [M+H]+. 1H NMR (CDCl3): 8.81 (s, 1H), 7.98 (d, J=8.0 Hz, 1H), 7.72 (d, J=8.1 Hz, 1H), 6.90 (dd, J=8.6, 2.2 Hz, 1H), 6.86 (d, J=8.6 Hz, 1H), 6.60 (d, J=2.2 Hz, 1H), 5.18 (s, 2H), 5.03-4.95 (m, 1H), 4.02-3.95 (m, 2H), 3.89-3.82 (m, 2H).
Example 83 3-[2-(Benzofuran-5-ylmethoxy)-5-chloro-phenoxy]-azetidineMS (ESI): mass calcd. for C18H16ClNO3, 329.1; m/z found, 330.1 [M+H]+. 1H NMR (CDCl3): 7.65-7.64 (m, 2H) 7.50 (d, J=8.5 Hz, 1H), 7.35 (dd, J=8.5, 1.6 Hz, 1H), 6.87-6.82 (m, 2H), 6.76 (d, J=1.3 Hz, 1H), 6.59 (s, 1H), 5.18 (s, 2H), 5.02-4.92 (m, 1H), 4.06-3.79 (m, 4H).
Example 84 6-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-benzothiazoleMS (ESI): mass calcd. for C17H15ClN2O2S, 346.1; m/z found, 347.0 [M+H]+. 1H NMR (CDCl3): 9.01 (s, 1H), 8.14 (d, J=8.4 Hz, 1H), 8.05 (s, 1H), 7.57 (dd, J=8.4, 1.6 Hz, 1H), 6.85 (d, J=1.2 Hz, 2H), 6.60 (s, 1H), 5.35 (s, 2H), 5.00-4.98 (m, 1H), 3.93-3.87 (m, 4H).
Example 85 6-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-1-methyl-1H-benzotriazoleMS (ESI): mass calcd. for C17H17ClN4O2, 344.1; m/z found, 345.0 [M+H]+. 1H NMR (CDCl3): 8.10 (s, 1H), 7.61 (dd, J=8.6, 1.3 Hz, 1H), 7.53 (d, J=8.6 Hz, 1H), 6.88-6.80 (m, 2H), 6.59 (d, J=1.9 Hz, 1H), 5.26 (s, 2H), 5.02-4.96 (m, 1H), 4.31 (s, 3H), 3.97-3.82 (m, 4H).
Example 86 3-[5-Chloro-2-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H14ClF2NO4, 369.1; m/z found, 370.0 [M+H]+. 1H NMR (CDCl3): 7.20 (d, J=1.2 Hz, 1H), 7.11 (dd, J=8.2, 1.5 Hz, 1H), 7.04 (d, J=8.2 Hz, 1H), 6.86 (dd, J=8.6, 2.3 Hz, 1H), 6.81 (d, J=8.6 Hz, 1H), 6.59 (d, J=2.3 Hz, 1H), 5.06 (s, 2H), 5.01-4.95 (m, 1H), 3.96-3.83 (m, 4H).
Example 87 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-oxazoleMS (ESI): mass calcd. for C13H13ClN2O3, 280.1; m/z found, 281.1 [M+H]+. 1H NMR (CDCl3): 7.91 (s, 1H), 7.13 (s, 1H), 6.90-6.87 (m, 2H), 6.59 (d, J=1.9 Hz, 1H), 5.10 (s, 2H), 5.00-4.91 (m, 1H), 3.97-3.89 (m, 2H), 3.87-3.79 (m, 2H).
Example 88 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-thiazoleMS (ESI): mass calcd. for C13H13ClN2O2S, 296.0; m/z found, 297.0 [M+H]+. 1H NMR (CDCl3): 7.80 (t, J=3.1 Hz, 1H), 7.38 (t, J=3.3 Hz, 1H), 6.96-6.84 (m, 2H), 6.63 (dd, J=11.1, 2.3 Hz, 1H), 5.41-5.37 (m, 2H), 5.04-4.78 (m, 1H), 4.01-3.93 (m, 1H), 3.92-3.83 (m, 2H), 3.31-3.23 (m, 1H)
Example 89 3-[2-(Benzofuran-2-ylmethoxy)-5-chloro-phenoxy]-azetidineMS (ESI): mass calcd. for C18H16ClNO3, 329.1; m/z found, 330.0 [M+H]+. 1H NMR (CDCl3): 7.56 (d, J=7.7 Hz, 1H), 7.50 (dd, J=8.2, 0.7 Hz, 1H), 7.34-7.28 (m, 1H), 7.23 (dt, J=7.5, 1.0 Hz, 1H), 6.96 (d, J=8.6 Hz, 1H), 6.87 (dd, J=8.6, 2.4 Hz, 1H), 6.73 (d, J=0.5 Hz, 1H), 6.57 (d, J=2.4 Hz, 1H), 5.17 (s, 2H), 4.95-4.89 (m, 1H), 3.93-3.69 (m, 4H).
Example 90 (R)-3-(2-Benzyloxy-4-chloro-phenoxy)-pyrrolidineTo (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester (2.0 g, 10.9 mmol) in CH2Cl2 (50 mL) at 0° C. was added Et3N (1.4 g, 1.9 mL, 13.4 mmol) and methanesulfonyl chloride (1.38 g, 0.94 mL, 12.1 mmol). After 1 h, brine was added and the mixture extracted with CH2Cl2 (2×). The combined organics were dried to give 3-methanesulfonyloxy-pyrrolidine-1-carboxylic acid tert-butyl ester that was used without further purification.
To this compound in DMF (50 mL) was added 5-chloro-2-hydroxy-benzaldehyde (1.9 g, 12.1 mmol) and K2CO3 (1.8 g, 13.1 mmol). The reaction was heated at 90° C. for 2 h, then cooled to rt and H2O was added. The mixture was extracted with EtOAc (2×). The combined organics were washed with brine and dried. Silica gel chromatography (10-50% EtOAc in hexanes) gave 1.85 g (52%) of the title compound. 1H NMR (CDCl3): 10.36 (s, 1H), 7.81 (s, 1H), 7.50 (s, 1H), 6.90 (d, J=8.9 Hz, 1H), 5.00 (s, 1H), 3.72-3.50 (m, 4H), 2.26-2.18 (m, 2H), 1.47 (s, 9H).
Step B: Preparation of 3-(4-chloro-2-hydroxy-phenoxy)-pyrrolidine-1-carboxylic acid tert-butyl esterTo a CH2Cl2 (25 mL) solution of the title compound of Step A (1.4 g, 4.3 mmol) was added 77% m-CPBA (1.4 g, 6.2 mmol). After 18 h, additional CH2Cl2 was added and the reaction washed with saturated NaHCO3 (aq.) and 10% Na2S2O5 until KI paper negative. The combined organic layers were dried then treated with MeOH (25 mL) and 1N NaOH (25 mL). After 15 h, the reaction was acidified with 1M KHSO4 then extracted with EtOAc (2×). The combined organic layers were washed with brine and dried to give the title compound as a white solid. 1H NMR (CDCl3): 6.96 (s, 1H), 6.82-6.80 (m, 1H), 6.73 (d, J=8.6 Hz, 1H), 5.62 (s, 1H), 4.91 (s, 1H), 3.66-3.46 (m, 4H), 2.20-2.11 (m, 2H), 1.47 (s, 9H).
Step C: Preparation of 3-(2-Benzyloxy-4-chloro-phenoxy)-pyrrolidine-1-carboxylic acid tert-butyl esterPrepared according to Example 1 Step D using the title compound of Step B. MS (ESI): mass calcd. for C22H26ClNO4, 403.2; m/z found, 426.2 [M+Na]+, 348.2 [M-56]+. 1H NMR (CDCl3): 7.43-7.36 (m, 4H), 7.35-7.30 (m, 1H), 6.95 (d, J=2.4 Hz, 1H), 6.88 (dd, J=8.5, 2.4 Hz, 1H), 6.82 (d, J=8.5 Hz, 1H), 5.07 (s, 2H), 4.89-4.85 (m, 1H), 3.71-3.45 (m, 4H), 2.24-2.12 (m, 1H), 2.07-1.94 (m, 1H), 1.46 (s, 9H).
Step D: Preparation of (R)-3-(2-Benzyloxy-4-chloro-phenoxy)-pyrrolidinePrepared according to general procedure 1 using the title compound of Step C. MS (ESI): mass calcd. for C17H18ClNO2, 303.1; m/z found, 304.2 [M+H]+. 1H NMR (CDCl3): 7.45-7.36 (m, 4H), 7.35-7.30 (m, 1H), 6.94 (d, J=2.4 Hz, 1H), 6.88 (dd, J=8.6, 2.4 Hz, 1H), 6.81 (d, J=8.6 Hz, 1H), 5.06 (s, 2H), 4.86 (s, 1H), 3.25 (d, J=2.1 Hz, 2H), 2.25-1.73 (m, 4H).
Example 91 (R)-3-(2-Benzyloxy-4-chloro-phenoxy)-1-methyl-pyrrolidineSynthesized from the title compound of Example 90 according to general procedure 5. MS (ESI): mass calcd. for C18H20ClNO2, 317.1; m/z found, 318.2 [M+H]+. 1H NMR (CDCl3): 7.44-7.32 (m, 5H), 6.91 (d, J=2.3 Hz, 1H), 6.86 (dd, J=8.5, 2.4 Hz, 1H), 6.75 (d, J=8.6 Hz, 1H), 5.08 (s, 2H), 4.81 (td, J=10.4, 5.1 Hz, 1H), 2.90 (dd, J=10.1, 6.1 Hz, 1H), 2.74 (d, J=8.9 Hz, 2H), 2.53 (dd, J=13.8, 7.9 Hz, 1H), 2.38 (s, 3H), 2.28-2.21 (m, 1H), 2.08-1.98 (m, 1H).
Example 92 (R)-3-[4-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-pyrrolidineSynthesized according to Example 90 using 3-chlorobenzyl bromide. MS (ESI): mass calcd. for C17H17O2NO2, 337.1; m/z found, 338.1 [M+H]+. 1H NMR (CDCl3): 7.40 (s, 1H), 7.29-7.20 (m, 3H), 6.86 (dd, J=7.1, 2.2 Hz, 2H), 6.79-6.74 (m, 1H), 4.99 (s, 2H), 4.77 (t, J=5.1 Hz, 1H), 3.18-3.13 (m, 2H), 2.92-2.86 (m, 2H), 2.11-1.81 (m, 2H).
Example 93 (R)-3-[4-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-pyrrolidineSynthesized from the title compound of Example 92 according to general procedure 5. MS (ESI): mass calcd. for C18H19O2NO2, 351.1; m/z found, 352.2 [M+H]+. 1H NMR (CDCl3): 7.47 (s, 1H), 7.30 (s, 3H), 6.88 (dd, J=7.3, 2.2 Hz, 2H), 6.77-6.74 (m, 1H), 5.04 (s, 2H), 4.85-4.73 (m, 1H), 2.96-2.86 (m, 1H), 2.79-2.68 (m, 2H), 2.56-2.50 (m, 1H), 2.39 (s, 3H), 2.31-2.17 (m, 1H), 2.05-1.95 (m, 1H).
Example 94 (S)-3-[4-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-pyrrolidineSynthesized according to Example 90 using (R)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester and 3-chlorobenzyl bromide. MS (ESI): mass calcd. for C17H17O2NO2, 337.1; m/z found, 338.2 [M+H]+. 1H NMR (CDCl3): 7.44 (s, 1H), 7.36-7.24 (m, 3H), 6.94-6.86 (m, 2H), 6.84-6.78 (m, 1H), 5.08 (s, 2H), 4.81 (t, J=5.0 Hz, 1H), 3.26-3.08 (m, 2H), 3.00-2.84 (m, 2H), 2.12-1.91 (m, 2H).
Examples 95-100 were prepared using 1-methyl-pyrrolidin-3-ol and the appropriately substituted phenol (synthesized according to Example 90) according to general procedure 7 using resin bound PPh3.
Example 95 (±)-3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-pyrrolidineMS (ESI): mass calcd. for C18H19BrClNO2, 395.0; m/z found, 396.0 [M+H]+. 1H NMR (CDCl3): 7.46 (s, 1H), 7.33-7.24 (m, 3H), 6.98 (dd, J=8.5, 2.3 Hz, 1H), 6.94 (d, J=2.3 Hz, 1H), 6.76 (d, J=8.5 Hz, 1H), 5.04 (s, 2H), 4.82 (m, 1H), 2.95 (dd, J=10.5, 6.1 Hz, 1H), 2.82-2.73 (m, 2H), 2.55 (m, 1H), 2.41 (s, 3H), 2.31 (m, 1H), 2.10-2.00 (m, 1H).
Example 96 (±)-3-[5-Bromo-2-(3-methoxy-benzyloxy)-phenoxy]-1-methyl-pyrrolidineMS (ESI): mass calcd. for C19H22BrNO3, 391.1; m/z found, 391.1 [M+H]+. 1H NMR (CDCl3): 7.31-7.23 (m, 1H), 6.99-6.96 (m, 3H), 6.93 (d, J=2.3 Hz, 1H), 6.87-6.82 (m, 1H), 6.76 (d, J=8.5 Hz, 1H), 5.06 (s, 2H), 4.86-4.79 (m, 1H), 3.81 (s, 3H), 2.94 (dd, J=10.6, 6.1 Hz, 1H), 2.79-2.73 (m, 2H), 2.54 (m, 1H), 2.39 (s, 3H), 2.29 (m, 1H), 2.05 (m, 1H).
Example 97 (±)-3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-1-methyl-pyrrolidineMS (ESI): mass calcd. for C18H19BrFNO2, 379.1; m/z found, 380.1 [M+H]+. 1H NMR (400 MHz, DMSO-D6): 7.32 (m, 1H), 7.17 (d, J=7.3 Hz, 2H), 7.02-6.96 (m, 2H), 6.94 (d, J=2.3 Hz, 1H), 6.75 (d, J=8.5 Hz, 1H), 5.07 (s, 2H), 4.82 (m, 1H), 2.94 (m, 1H), 2.82-2.73 (m, 2H), 2.55 (m, 1H), 2.40 (s, 3H), 2.31 (m, 1H), 2.07-2.02 (m, 1H).
Example 98 (±)-3-(2-Benzyloxy-5-bromo-phenoxy)-1-methyl-pyrrolidineMS (ESI): mass calcd. for C18H20BrNO2, 361.1; m/z found, 362.1 [M+H]+. 1H NMR (CDCl3): 7.41 (m, 2H), 7.39-7.34 (m, 2H), 7.30 (m, 1H), 6.97 (dd, J=8.5, 2.3 Hz, 1H), 6.93 (d, J=2.3 Hz, 1H), 6.77 (d, J=8.5 Hz, 1H), 5.08 (s, 2H), 4.86-4.76 (m, 1H), 2.93 (m, 1H), 2.80-2.72 (m, 2H), 2.57-2.50 (m, 1H), 2.39 (s, 3H), 2.29 (m, 1H), 2.09-1.99 (m, 1H).
Example 99 (±)-Methanesulfonic acid 3-[4-bromo-2-(1-methyl-pyrrolidin-3-yloxy)-phenoxymethyl]-phenyl esterMS (ESI): mass calcd. for C19H22BrNO5S, 455.1; m/z found, 456.1 [M+H]+. 1H NMR (CDCl3): 7.46-7.35 (m, 3H), 7.23 (m, 1H), 6.98 (dd, J=8.5, 2.3 Hz, 1H), 6.93 (d, J=2.2 Hz, 1H), 6.75 (d, J=8.5 Hz, 1H), 5.08 (s, 2H), 4.81 (m, 1H), 3.13 (s, 3H), 2.89 (m, 1H), 2.82-2.74 (m, 2H), 2.55-2.46 (m, 1H), 2.39 (s, 3H), 2.31 (m, 1H), 2.03 (m, 1H).
Example 100 (±)-Methanesulfonic acid 3-[2-(1-methyl-pyrrolidin-3-yloxy)-phenoxymethyl]-phenyl esterMS (ESI): mass calcd. for C19H23NO5S, 377.1; m/z found, 378.1 [M+H]+. 1H NMR (CDCl3): 7.42 (m, 3H), 7.26-7.20 (m, 1H), 6.98-6.80 (m, 4H), 5.13 (s, 2H), 4.86 (m, 1H), 3.12 (s, 3H), 2.93 (dd, J=10.5, 6.1 Hz, 1H), 2.81-2.71 (m, 2H), 2.60-2.49 (m, 1H), 2.40 (s, 3H), 2.30 (m, 1H), 2.11-2.00 (m, 1H).
Example 101 (S)-3-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidineTo (S)-1-(3-trifluoromethyl-phenyl)-ethanol (2.30 g, 12.1 mmol), 3-(5-chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (3.80 g, 12.7 mmol) and PPh3 (3.80 g, 14.5 mmol) in THF (60 mL) at 0° C. was added DEAD (2.3 g, 2.1 mL, 13 mmol) in THF (10 mL) dropwise over 30 min. After 48 h, the reaction was concentrated and 15% EtOAc in hexanes was added. The flask was cooled to 0° C. and filtered. The filtrate was concentrated and this procedure repeated 2 more times. The resulting oil was then purified using silica gel chromatography (10-40% EtOAc in hexanes) to give 5.17 g (91%) of the title compound as a clear oil. 1H NMR (CDCl3): 7.66 (s, 1H), 7.56-7.53 (m, 2H), 7.46 (t, J=7.7 Hz, 1H), 6.79 (dd, J=8.6, 2.4 Hz, 1H), 6.71 (d, J=8.6 Hz, 1H), 6.52 (d, J=2.4 Hz, 1H), 5.29 (q, J=6.5 Hz, 1H), 4.88-4.82 (m, 1H), 4.33-4.29 (m, 2H), 4.08-4.01 (m, 2H), 1.67 (d, J=6.5 Hz, 3H), 1.46 (s, 9H).
Step B: Preparation of (S)-3-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidineTo the title compound of Step A (5.1 g, 10.8 mmol) in CH2Cl2 (50 mL) at 0° C. was added TFA (50 mL). After 1 h, PhCH3 (50 mL) was added and the mixture concentrated. The resulting oil was neutralized with saturated NaHCO3 (aq.) and extracted with CH2Cl2 (2×). The combined organics were dried and concentrated. Silica gel chromatography (1-7% 2M NH3/MeOH in CH2Cl2) gave 3.38 g (83% yield) of the title compound as a clear oil. MS (ESI): mass calcd. for C18H17ClF3NO2, 371.1; m/z found, 372.0 [M+H]+. 1H NMR (CDCl3): 7.70 (s, 1H), 7.56-7.53 (m, 2H), 7.45 (t, J=7.7 Hz, 1H), 6.77 (dd, J=8.6, 2.3 Hz, 1H), 6.70 (d, J=8.6 Hz, 1H), 6.55 (d, J=2.4 Hz, 1H), 5.30 (q, J=6.3 Hz, 1H), 5.00-4.94 (m, 1H), 3.97-3.93 (m, 2H), 3.89-3.81 (m, 2H), 1.66 (d, J=6.5 Hz, 3H).
Unless otherwise specified the compounds in Examples 102-144 were prepared similar to Example 101 using the appropriately substituted phenols and alcohols.
Example 102 (S)-3-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidine trifluoroacetatePrepared using (R)-1-(3-trifluoromethyl-phenyl)-ethanol. MS (ESI): mass calcd. for C18H17ClF3NO2, 371.1; m/z found, 372.0 [M+H]+. 1H NMR (CDCl3): 7.61 (s, 1H), 7.55-7.45 (m, 3H), 6.86 (dd, J=8.7, 2.2 Hz, 1H), 6.68-6.66 (m, 2H), 5.30 (q, J=6.3 Hz, 1H), 5.11 (s, 1H), 4.44-4.32 (m, 4H), 1.66 (d, J=6.4 Hz, 3H).
Example 103 (S)-3-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-1-methyl-azetidinePrepared according to general procedure 5 using the title compound of Example 102. MS (ESI): mass calcd. for C19H19ClF3NO2, 385.1; m/z found, 386.2 [M+H]+. 1H NMR (CDCl3): 7.69 (s, 1H), 7.54 (t, J=8.0 Hz, 2H), 7.45 (t, J=7.7 Hz, 1H), 6.76 (dd, J=8.6, 2.4 Hz, 1H), 6.70 (d, J=8.6 Hz, 1H), 6.59 (d, J=2.3 Hz, 1H), 5.29 (q, J=6.4 Hz, 1H), 4.76-4.65 (m, 1H), 3.85 (s, 2H), 3.14 (s, 2H), 2.42 (s, 3H), 1.66 (d, J=6.5 Hz, 3H).
Example 104 (S)-1-Benzyl-3-[5-chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidinePrepared according to general procedure 3 or 4 using the title compound of Example 102. MS (ESI): mass calcd. for C25H23ClF3NO2, 461.1; m/z found, 462.3 [M+H]+. 1H NMR (CDCl3): 7.69 (s, 1H), 7.54 (t, J=7.1 Hz, 2H), 7.45 (t, J=7.7 Hz, 1H), 7.37-7.23 (m, 5H), 6.75 (dd, J=8.6, 2.3 Hz, 1H), 6.69 (d, J=8.6 Hz, 1H), 6.58 (d, J=2.3 Hz, 1H), 5.28 (q, J=6.5 Hz, 1H), 4.80-4.71 (m, 1H), 3.85-3.80 (m, 2H), 3.71 (s, 2H), 3.24-3.14 (m, 2H), 1.66 (d, J=6.5 Hz, 3H).
Example 105 (±)-3-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C15H17ClF3NO2, 371.1; m/z found, 372.1 [M+H]+. 1H NMR (CDCl3): 7.61 (s, 1H), 7.54 (d, J=7.8 Hz, 2H), 7.51-7.45 (m, 1H), 6.85 (dd, J=8.7, 2.4 Hz, 1H), 6.67 (s, 1H), 6.66 (d, J=7.1 Hz, 1H), 5.31 (q, J=6.4 Hz, 1H), 5.13-5.09 (m, 1H), 4.58-4.30 (m, 4H), 1.67 (d, J=6.5 Hz, 3H).
Example 106 (±)-3-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-1-isopropyl-azetidineSynthesized from the title compound of Example 105 according to general procedure 3. MS (ESI): mass calcd. for C21H23ClF3NO2, 413.1; m/z found, 414.0 [M+H]+. 1H NMR (CDCl3): 7.68 (s, 1H), 7.54 (t, J=7.6 Hz, 2H), 7.45 (t, J=7.7 Hz, 1H), 6.76 (dd, J=8.6, 2.4 Hz, 1H), 6.69 (d, J=8.6 Hz, 1H), 6.62 (d, J=2.4 Hz, 1H), 5.28 (q, J=6.5 Hz, 1H), 4.75-4.69 (m, 1H), 3.86-3.82 (m, 2H), 3.11-3.04 (m, 2H), 2.40 (td, J=12.4, 6.2 Hz, 1H), 1.65 (d, J=6.5 Hz, 3H), 0.98 (dd, J=6.2, 0.8 Hz, 6H).
Example 107 (±)-3-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-1-cyclobutyl-azetidineSynthesized from the title compound of Example 105 according to general procedure 3. MS (ESI): mass calcd. for C22H23ClF3NO2, 425.1; m/z found, 426.0 [M+H]+. 1H NMR (CDCl3): 7.67 (s, 1H), 7.55 (t, J=8.7 Hz, 2H), 7.45 (t, J=7.7 Hz, 1H), 6.76 (dd, J=8.6, 2.3 Hz, 1H), 6.69 (d, J=8.6 Hz, 1H), 6.61 (d, J=2.3 Hz, 1H), 5.28 (q, J=6.4 Hz, 1H), 4.78-4.72 (m, 1H), 3.75 (dd, J=8.5, 6.1 Hz, 2H), 3.26-3.09 (m, 3H), 2.07-1.94 (m, 2H), 1.92-1.68 (m, 4H), 1.66 (d, J=6.5 Hz, 3H).
Example 108 (±)-1-Benzyl-3-[5-chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidineSynthesized from the title compound of Example 105 according to general procedure 3. MS (ESI): mass calcd. for C25H23ClF3NO2, 461.1; m/z found, 462.0 [M+H]+. 1H NMR (CDCl3): 7.69 (s, 1H), 7.54 (t, J=7.4 Hz, 2H), 7.44 (t, J=7.7 Hz, 1H), 7.37-7.22 (m, 5H), 6.75 (dd, J=8.6, 2.3 Hz, 1H), 6.69 (d, J=8.6 Hz, 1H), 6.58 (d, J=2.3 Hz, 1H), 5.28 (q, J=6.4 Hz, 1H), 4.79-4.73 (m, 1H), 3.86-3.79 (m, 2H), 3.70 (s, 2H), 3.24-3.13 (m, 2H), 1.66 (d, J=6.5 Hz, 3H).
Example 109 (±)-3-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-1-methyl-azetidineSynthesized from the title compound of Example 105 according to general procedure 5. MS (ESI): mass calcd. for C19H19ClF3NO2, 385.1; m/z found, 386.0 [M+H]+. 1H NMR (CDCl3): 7.69 (s, 1H), 7.54 (t, J=8.5 Hz, 2H), 7.45 (t, J=7.7 Hz, 1H), 6.76 (dd, J=8.6, 2.3 Hz, 1H), 6.70 (d, J=8.6 Hz, 1H), 6.60 (d, J=2.3 Hz, 1H), 5.29 (q, J=6.4 Hz, 1H), 4.74-4.68 (m, 1H), 3.85 (s, 2H), 3.14 (s, 2H), 2.42 (s, 3H), 1.66 (d, J=6.5 Hz, 3H).
Example 110 (±)-3-[5-Bromo-2-[1-(3-trifluoromethoxy-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C18H17BrF3NO3, 431.0; m/z found, 431.9 [M+H]+. 1H NMR (CDCl3): 7.36 (t, J=8.1 Hz, 1H), 7.27 (d, J=8.1 Hz, 2H), 7.12 (d, J=8.1 Hz, 1H), 6.91 (dd, J=8.6, 2.3 Hz, 1H), 6.70 (d, J=2.3 Hz, 1H), 6.64 (d, J=8.6 Hz, 1H), 5.25 (q, J=6.5 Hz, 1H), 5.01-4.93 (m, 1H), 4.01-3.80 (m, 4H), 1.65 (d, J=6.5 Hz, 3H).
Example 111 (±)-3-[5-Bromo-2-[1-(3-chloro-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17BrClNO2, 381.0; m/z found, 382.0 [M+H]+. 1H NMR (CDCl3): 7.42 (s, 1H), 7.29-7.19 (m, 3H), 6.90 (dd, J=8.6, 2.3 Hz, 1H), 6.69 (d, J=2.3 Hz, 1H), 6.64 (d, J=8.6 Hz, 1H), 5.20 (q, J=6.4 Hz, 1H)), 5.00-4.92 (m, 1H), 3.95-3.80 (m, 4H), 1.64 (d, J=6.5 Hz, 3H).
Example 112 (±)-3-[5-Bromo-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C18H17BrF3NO2, 415.0; m/z found, 416.0 [M+H]+. 1H NMR (CDCl3): 7.69 (s, 1H), 7.53 (t, J=7.3 Hz, 2H), 7.44 (t, J=7.7 Hz, 1H), 6.89 (dd, J=8.6, 2.3 Hz, 1H), 6.68 (d, J=2.3 Hz, 1H), 6.65 (d, J=8.6 Hz, 1H), 5.29 (q, J=6.5 Hz, 1H), 4.99-4.93 (m, 1H), 3.95-3.92 (m, 2H), 3.87-3.80 (m, 2H), 1.65 (d, J=6.5 Hz, 3H).
Example 113 (R)-3-[5-Bromo-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C18H17BrF3NO2, 415.0; m/z found, 418.0 [M+H]+. 1H NMR (CDCl3): 7.69 (s, 1H), 7.58-7.50 (m, 2H), 7.45 (t, J=7.7 Hz, 1H), 6.91 (dd, J=8.6, 2.3 Hz, 1H), 6.69 (d, J=2.3 Hz, 1H), 6.66 (d, J=8.6 Hz, 1H), 5.30 (q, J=6.5 Hz, 1H), 4.99-4.93 (m, 1H), 4.01-3.74 (m, 4H), 1.67 (d, J=6.5 Hz, 3H).
Example 114 (±)-3-[5-Chloro-2-[1-(3-chloro-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17O2NO2, 337.1; m/z found, 338.1 [M+H]+. 1H NMR (CDCl3): 7.43 (s, 1H), 7.32-7.17 (m, 3H), 6.76 (dd, J=8.6, 2.4 Hz, 1H), 6.70 (d, J=8.6 Hz, 1H), 6.56 (d, J=2.3 Hz, 1H), 5.20 (q, J=6.5 Hz, 1H), 5.02-4.92 (m, 1H), 3.94 (s, 2H), 3.92-3.78 (m, 2H), 1.65 (d, J=6.5 Hz, 3H).
Example 115 (±)-3-[5-Chloro-2-[1-(3-fluoro-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17ClFNO2, 321.1; m/z found, 322.1 [M+H]+. 1H NMR (CDCl3): 7.35-7.23 (m, 1H), 7.21-7.07 (m, 2H), 7.00-6.91 (m, 1H), 6.71-6.65 (m, 2H), 6.64-6.52 (m, 1H), 5.28-5.18 (m, 1H), 5.05-4.93 (m, 1H), 4.10-3.95 (s, 4H), 1.70-1.60 (s, 3H).
Example 116 (±)-3-[5-Chloro-2-[1-(2-chloro-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17O2NO2, 337.1; m/z found, 338.0 [M+H]+. 1H NMR (CDCl3): 7.55 (dd, J=7.6, 1.8 Hz, 1H), 7.34 (dd, J=7.8, 1.4 Hz, 1H), 7.28-7.14 (m, 2H), 6.73 (dd, J=8.6, 2.4 Hz, 1H), 6.59 (d, J=8.7 Hz, 1H), 6.56 (d, J=2.4 Hz, 1H), 5.66 (q, J=6.4 Hz, 1H), 5.00-4.94 (m, 1H), 4.02-3.81 (m, 4H), 1.64 (d, J=6.4 Hz, 3H).
Example 117 (±)-3-[5-Chloro-2-[1-(4-fluoro-3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C18H16ClF4NO2, 389.1; m/z found, 390.0 [M+H]+. 1H NMR (CDCl3): 7.68 (dd, J=6.7, 1.9 Hz, 1H), 7.58-7.51 (m, 1H), 7.19-7.14 (m, 1H), 6.78 (dd, J=8.6, 2.4 Hz, 1H), 6.71 (d, J=8.6 Hz, 1H), 6.55 (d, J=2.3 Hz, 1H), 5.27 (q, J=6.4 Hz, 1H), 4.95-4.90 (m, 1H), 3.95-3.84 (m, 4H), 1.65 (d, J=6.5 Hz, 3H).
Example 118 (±)-3-[5-Chloro-2-[1-(3-fluoro-4-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C18H16ClF4NO2, 389.1; m/z found, 390.0 [M+H]+. 1H NMR (CDCl3): 7.57 (t, J=7.6 Hz, 1H), 7.31-7.22 (m, 2H), 6.77 (dd, J=8.6, 2.4 Hz, 1H), 6.68 (d, J=8.6 Hz, 1H), 6.56 (d, J=2.4 Hz, 1H), 5.26 (q, J=6.5 Hz, 1H), 4.99-4.93 (m, 1H), 3.97-3.80 (m, 4H), 1.65 (d, J=6.5 Hz, 3H).
Example 119 (±)-3-[5-Chloro-2-[1-(3-fluoro-5-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C18H16ClF4NO2, 389.1; m/z found, 390.0 [M+H]+. 1H NMR (CDCl3): 7.33 (d, J=9.3 Hz, 1H), 7.23 (d, J=8.3 Hz, 1H), 6.79 (dd, J=8.6, 2.3 Hz, 1H), 6.73 (d, J=8.6 Hz, 1H), 6.56 (d, J=2.3 Hz, 1H), 5.28 (q, J=6.5 Hz, 1H), 4.99-4.92 (m, 1H), 7.47 (s, 1H), 4.05-3.74 (m, 4H), 1.66 (d, J=6.5 Hz, 3H).
Example 120 (±)-3-[5-Chloro-2-[1-(3-trifluoromethylsulfanyl-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C18H17ClF3NO2S, 403.1; m/z found, 404.0 [M+H]+. 1H NMR (CDCl3): 7.70 (s, 1H), 7.56 (d, J=7.6 Hz, 1H), 7.49 (d, J=7.8 Hz, 1H), 7.39 (t, J=7.7 Hz, 1H), 6.75 (dd, J=8.6, 2.3 Hz, 1H), 6.68 (d, J=8.6 Hz, 1H), 6.55 (d, J=2.2 Hz, 1H), 5.26 (q, J=6.5 Hz, 1H), 4.99-4.93 (m, 1H), 3.94-3.83 (m, 4H), 1.66 (d, J=6.5 Hz, 3H).
Example 121 (±)-3-[5-Chloro-2-[1-(2-fluoro-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17ClFNO2, 321.1; m/z found, 322.0 [M+H]+. 1H NMR (CDCl3): 7.50 (dt, J=7.6, 1.7 Hz, 1H), 7.24-7.21 (m, 1H), 7.12 (dt, J=7.6, 1.0 Hz, 1H), 7.06-6.99 (m, 1H), 6.75 (dd, J=8.6, 2.3 Hz, 1H), 6.69 (d, J=8.6 Hz, 1H), 6.56 (d, J=2.3 Hz, 1H), 5.60 (q, J=6.4 Hz, 1H), 5.00-4.94 (m, 1H), 4.00-3.79 (m, 4H), 1.67 (d, J=6.4 Hz, 3H).
Example 122 (±)-3-[5-Chloro-2-[1-(2-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C18H17ClF3NO2, 371.1; m/z found, 372.0 [M+H]+. 1H NMR (CDCl3): 7.85 (d, J=7.9 Hz, 1H), 7.61 (d, J=7.9 Hz, 1H), 7.56 (t, J=7.7 Hz, 1H), 7.36 (t, J=7.6 Hz, 1H), 6.72 (dd, J=8.6, 2.3 Hz, 1H), 6.67 (d, J=8.6 Hz, 1H), 6.54 (d, J=2.3 Hz, 1H), 5.68 (q, J=6.2 Hz, 1H), 5.00-4.94 (m, 1H), 4.01-3.79 (m, 4H), 1.66 (d, J=6.3 Hz, 3H).
Example 123 (±)-3-[5-Chloro-2-[1-(4-chloro-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17O2NO2, 337.1; m/z found, 338.0 [M+H]+. 1H NMR (CDCl3): 7.30 (s, 4H), 6.74 (dd, J=8.6, 2.4 Hz, 1H), 6.65 (d, J=8.6 Hz, 1H), 6.55 (d, J=2.4 Hz, 1H), 5.21 (q, J=6.5 Hz, 1H), 4.99-4.93 (m, 1H), 3.96-3.83 (m, 4H), 1.64 (d, J=6.5 Hz, 3H).
Example 124 (±)-3-[5-Chloro-2-[1-(4-fluoro-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17ClFNO2, 321.1; m/z found, 322.0 [M+H]+. 1H NMR (CDCl3): 7.39-7.29 (m, 2H), 7.06-6.97 (m, 2H), 6.74 (dd, J=8.6, 2.4 Hz, 1H), 6.66 (d, J=8.6 Hz, 1H), 6.55 (d, J=2.4 Hz, 1H), 5.22 (q, J=6.4 Hz, 1H), 4.99-4.93 (m, 1H), 3.99-3.78 (m, 4H), 1.64 (d, J=6.4 Hz, 3H).
Example 125 (±)-3-[1-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-ethyl]-benzonitrileMS (ESI): mass calcd. for C18H17ClN2O2, 328.1; m/z found, 329.1 [M+H]+. 1H NMR (CDCl3): 7.76 (s, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.57 (td, J=7.7, 1.3 Hz, 1H), 7.45 (t, J=7.7 Hz, 1H), 6.76 (dd, J=8.6, 2.4 Hz, 1H), 6.69 (d, J=8.6 Hz, 1H), 6.56 (d, J=2.4 Hz, 1H), 5.27 (q, J=6.6 Hz, 1H), 5.01-4.95 (m, 1H), 4.02-3.76 (m, 4H), 1.65 (d, J=6.5 Hz, 3H).
Example 126 (±)-3-[5-Chloro-2-[1-(3,4-dichloro-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C17H16Cl3NO2, 371.0; m/z found, 372.0 [M+H]+. 1H NMR (CDCl3): 7.52 (d, J=2.0 Hz, 1H), 7.40 (d, J=8.3 Hz, 1H), 7.19 (dd, J=8.3, 2.0 Hz, 1H), 6.77 (dd, J=8.6, 2.4 Hz, 1H), 6.69 (d, J=8.6 Hz, 1H), 6.55 (d, J=2.4 Hz, 1H), 5.18 (q, J=6.5 Hz, 1H), 4.99-4.93 (m, 1H), 4.00-3.76 (m, 4H), 1.63 (d, J=6.5 Hz, 3H).
Example 127 (±)-3-[5-Chloro-2-[1-(3-trifluoromethoxy-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C18H17ClF3NO3, 387.1; m/z found, 388.0 [M+H]+. 1H NMR (CDCl3): 7.36 (t, J=8.1 Hz, 1H), 7.30-7.27 (m, 2H), 7.16-7.08 (m, 1H), 6.76 (dd, J=8.6, 2.4 Hz, 1H), 6.69 (d, J=8.6 Hz, 1H), 6.55 (d, J=2.4 Hz, 1H), 5.25 (q, J=6.4 Hz, 1H), 5.00-4.93 (m, 1H), 3.98-3.77 (m, 4H), 1.65 (d, J=6.5 Hz, 3H).
Example 128 (±)-3-[5-Chloro-2-[1-(3,4-difluoro-phenyl)-ethoxy]-phenoxy]-azetidine trifluoroacetateMS (ESI): mass calcd. for C17H16ClF2NO2, 339.1; m/z found, 340.1 [M+H]+. 1H NMR (CDCl3): 7.21-7.09 (m, 2H), 7.08-7.02 (m, 1H), 6.85 (dd, J=8.7, 2.4 Hz, 1H), 6.68 (d, J=2.4 Hz, 1H), 6.65 (d, J=8.8 Hz, 1H), 5.20 (q, J=6.4 Hz, 1H), 5.13-5.05 (m, 1H), 4.44-4.32 (m, 4H), 1.62 (d, J=6.4 Hz, 3H).
Example 129 (±)-3-[5-Chloro-2-[1-(2,5-dichloro-phenyl)-ethoxy]-phenoxy]-azetidine trifluoroacetateMS (ESI): mass calcd. for C17H16Cl3NO2, 371.0; m/z found, 372.0 [M+H]+. 1H NMR (CDCl3): 7.43 (d, J=2.5 Hz, 1H), 7.30 (d, J=8.5 Hz, 1H), 7.19 (dd, J=8.5, 2.5 Hz, 1H), 6.86 (dd, J=8.7, 2.4 Hz, 1H), 6.69 (d, J=2.4 Hz, 1H), 6.57 (d, J=8.8 Hz, 1H), 5.59 (q, J=6.3 Hz 1H), 5.14 (s, 1H), 4.49-4.37 (m, 4H), 1.63 (d, J=6.4 Hz, 3H).
Example 130 (±)-3-[5-Chloro-2-[1-(2,5-difluoro-phenyl)-ethoxy]-phenoxy]-azetidine trifluoroacetateMS (ESI): mass calcd. for C17H16ClF2NO2, 339.1; m/z found, 340.0 [M+H]+. 1H NMR (CDCl3): 7.43 (d, J=2.5 Hz, 1H), 7.30 (d, J=8.5 Hz, 1H), 7.19 (dd, J=8.5, 2.5 Hz, 1H), 6.86 (dd, J=8.7, 2.4 Hz, 1H), 6.69 (d, J=2.4 Hz, 1H), 6.57 (d, J=8.8 Hz, 1H), 5.59 (q, J=6.3 Hz, 1H), 5.14 (s, 1H), 4.47-4.34 (m, 4H), 1.63 (d, J=6.4 Hz, 3H).
Example 131 2-[1-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-ethyl]-benzothiazoleMS (ESI): mass calcd. for C18H17ClN2O2S, 360.1; m/z found, 361.0 [M+H]+. 1H NMR (CDCl3): 8.01-7.99 (m, 1H), 7.92-7.86 (m, 1H), 7.48 (ddd, J=8.3, 7.3, 1.3 Hz, 1H), 7.39 (ddd, J=8.3, 7.3, 1.2 Hz, 1H), 6.93 (d, J=8.6 Hz, 1H), 6.80 (dd, J=8.6, 2.4 Hz, 1H), 6.59 (d, J=2.4 Hz, 1H), 5.66 (q, J=6.5 Hz, 1H), 5.01-4.95 (m, 1H), 3.95-3.88 (m, 2H), 3.86-3.80 (m, 2H), 1.86 (d, J=6.5 Hz, 3H).
Example 132 5-[1-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-ethyl]-thiazoleMS (ESI): mass calcd. for C14H15ClN2O2S, 310.1; m/z found, 311.0 [M+H]+. 1H NMR (CDCl3): 8.77 (s, 1H), 7.73 (s, 1H), 6.83-6.77 (m, 2H), 6.57-6.56 (m, 1H), 5.56 (q, J=6.4 Hz, 1H), 5.02-4.89 (m, 1H), 3.98-3.90 (m, 2H), 3.87-3.75 (m, 2H), 1.77 (d, J=6.4 Hz, 3H).
Example 133 2-[1-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-ethyl]-thiazoleMS (ESI): mass calcd. for C14H15ClN2O2S, 310.1; m/z found, 311.1 [M+H]+. 1H NMR (CDCl3): 7.74 (d, J=3.2 Hz, 1H), 7.33 (d, J=3.2 Hz, 1H), 6.88 (d, J=8.6 Hz, 1H), 6.81 (dd, J=8.6, 2.3 Hz, 1H), 6.59 (d, J=2.3 Hz, 1H), 5.59 (q, J=6.5 Hz, 1H), 5.02-4.92 (m, 1H), 4.04-3.72 (m, 4H), 1.79 (dd, J=6.4, 2.2 Hz, 3H).
Example 134 5-[1-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-ethyl]-2,4-dimethyl-thiazoleMS (ESI): mass calcd. for C16H19ClN2O2S, 338.1; m/z found, 339.1 [M+H]+. 1H NMR (CDCl3): 6.78 (dd, J=8.5, 2.4 Hz, 1H), 6.70 (d, J=8.6 Hz, 1H), 6.55 (d, J=2.4 Hz, 1H), 5.48 (q, J=6.4 Hz, 1H), 5.00-4.90 (m, 1H), 4.02-3.76 (m, 4H), 2.63 (s, 3H), 2.19 (s, 3H), 1.69 (d, J=6.4 Hz, 3H).
Example 135 (R)-4-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-piperidineMS (ESI): mass calcd. for C20H21ClF3NO2, 399.1; m/z found, 400.0 [M+H]+. 1H NMR (CDCl3): 7.68 (s, 1H), 7.57-7.52 (m, 2H), 7.45 (t, J=7.7 Hz, 1H), 6.90 (d, J=2.4 Hz, 1H), 6.77 (d, J=8.6, 2.4 Hz, 1H), 6.69 (d, J=8.6 Hz, 1H), 5.30 (q, J=6.4 Hz, 1H), 4.36-4.32 (m, 1H), 3.17 (br s, 2H), 2.74 (br s, 2H), 2.02 (br s, 2H), 1.72 (br s, 2H), 1.64 (d, J=6.4 Hz, 3H).
Example 136 (±)-4-[5-Chloro-2-[1-(3-chloro-phenyl)-ethoxy]-phenoxy]-piperidineMS (ESI): mass calcd. for C19H21Cl2NO2, 349.1; m/z found, 350.1 [M+H]+. 1H NMR (CDCl3): 7.40 (s, 1H), 7.29-7.19 (m, 3H), 6.89 (d, J=2.4 Hz, 1H), 6.76 (dd, J=8.6, 2.4 Hz, 1H), 6.68 (d, J=8.6 Hz, 1H), 5.21 (q, J=6.4 Hz, 1H), 4.38-4.27 (m, 1H), 3.17 (td, J=7.8, 4.6 Hz, 2H), 2.72 (ddd, J=12.5, 9.3, 3.2 Hz, 2H), 2.09-1.93 (m, 2H), 1.79-1.66 (m, 2H), 1.62 (d, J=6.5 Hz, 3H).
Example 137 (±)-4-[5-Chloro-2-[1-(3-trifluoromethoxy-phenyl)-ethoxy]-phenoxy]-piperidineMS (ESI): mass calcd. for C20H21ClF3NO3, 415.1; m/z found, 416.0 [M+H]+. 1H NMR (CDCl3): 7.36 (t, J=7.9 Hz, 1H), 7.28 (d, J=8.8 Hz, 2H), 7.12 (d, J=8.0 Hz, 1H), 6.90 (d, J=2.4 Hz, 1H), 6.76 (dd, J=8.6, 2.4 Hz, 1H), 6.68 (d, J=8.6 Hz, 1H), 5.26 (q, J=6.4 Hz, 1H), 4.43-4.24 (m, 1H), 3.22-3.09 (m, 2H), 2.73 (ddd, J=12.5, 9.2, 3.1 Hz, 2H), 2.02 (d, J=9.1 Hz, 2H), 1.72 (dt, J=12.7, 9.0, 2H), 1.63 (d, J=6.4 Hz, 3H).
Example 138 (±)-4-[5-Chloro-2-[1-(2-fluoro-phenyl)-ethoxy]-phenoxy]-piperidineMS (ESI): mass calcd. for C19H21ClFNO2, 349.1; m/z found, 350.0 [M+H]+. 1H NMR (CDCl3): 7.50 (dt, J=7.6, 1.7 Hz, 1H), 7.26-7.20 (m, 1H), 7.12 (dt, J=7.5, 1.0 Hz, 1H), 7.02 (ddd, J=10.2, 8.2, 1.1 Hz, 1H), 6.89 (d, J=2.4 Hz, 1H), 6.76 (dd, J=8.7, 2.4 Hz, 1H), 6.69 (d, J=8.7 Hz, 1H), 5.59 (q, J=6.4 Hz, 1H), 4.38-4.27 (m, 1H), 3.16 (td, J=9.8, 4.6 Hz, 2H), 2.71 (ddd, J=12.4, 9.3, 3.1 Hz, 2H), 2.01 (ddd, J=13.2, 5.0, 3.0 Hz, 2H), 1.72 (ddt, J=11.7, 8.3, 3.1 Hz, 2H), 1.64 (d, J=6.4 Hz, 3H).
Example 139 (R,S)-3-[5-Chloro-2-[1-((R)-3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-piperidineMS (ESI): mass calcd. for C20H21ClF3NO2, 399.1; m/z found, 400.0 [M+H]+. 1H NMR (CDCl3): 7.68 (s, 1H), 7.57-7.53 (m, 2H), 7.48-7.44 (m, 1H), 6.92 (dd, J=2.4, 1.1 Hz, 1H), 6.79-6.76 (m, 1H), 6.69 (dd, J=8.6, 6.1 Hz, 1H), 5.33-5.26 (m, 1H), 4.24-4.17 (m, 1H), 3.14-3.11 (m, 1H), 2.89-2.73 (m, 3H), 2.05-1.98 (m, 1H), 1.87-1.73 (m, 2H), 1.64 (d, J=6.5 Hz, 3H), 1.54-1.45 (m, 1H).
Example 140 (±)-3-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-propoxy]-phenoxy]-azetidineMS (ESI): MS (ESI): mass calcd. for C19H19ClF3NO2, 385.1; m/z found, 386.0 [M+H]+. 1H NMR (CDCl3): 7.66 (s, 1H), 7.52 (t, J=7.5 Hz, 2H), 7.44 (t, J=7.7 Hz, 1H), 6.73 (dd, J=8.6, 2.4 Hz, 1H), 6.65 (d, J=8.6 Hz, 1H), 6.54 (d, J=2.4 Hz, 1H), 5.05-5.00 (m, 1H), 4.99-4.92 (m, 1H), 4.01-3.72 (m, 4H), 2.31-1.97 (m, 1H), 1.97-1.83 (m, 1H), 1.02 (t, J=7.4 Hz, 3H).
Example 141 (±)-4-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-propoxy]-phenoxy]-piperidineMS (ESI): mass calcd. for C21H23ClF3NO2, 413.1; m/z found, 414.0 [M+H]+. 1H NMR (CDCl3): 7.61 (s, 1H), 7.51 (dd, J=7.4, 4.4 Hz, 2H), 7.47-7.40 (m, 1H), 6.88 (d, J=2.5 Hz, 1H), 6.72 (dd, J=8.6, 2.5 Hz, 1H), 6.61 (d, J=8.7 Hz, 1H), 5.05 (t, J=6.3 Hz, 1H), 4.37-4.28 (m, 1H), 3.23-3.10 (m, 2H), 2.71 (ddd, J=12.6, 9.4, 3.2 Hz, 2H), 2.13-1.97 (m, 3H), 1.96-1.84 (m, 1H), 1.76-1.65 (m, 2H), 0.98 (t, J=7.4 Hz, 3H).
Example 142 3-[5-Bromo-2-(2-fluoro-1-phenyl-ethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17BrFNO2, 365.0; m/z found, 366.0 [M+H]+. 1H NMR (CDCl3): 7.41-7.30 (m, 5H), 6.88 (dd, J=8.6, 2.3 Hz, 1H), 6.69 (dd, J=13.3, 5.4 Hz, 2H), 5.35 (ddd, J=14.3, 7.7, 3.3 Hz, 1H), 5.00-4.93 (m, 1H), 4.75 (ddd, J=48.0, 10.1, 7.7 Hz, 1H), 4.59 (ddd, J=46.7, 10.1, 3.4 Hz, 1H), 3.93-3.79 (m, 4H).
Example 143 3-[5-Chloro-2-(2-fluoro-1-phenyl-ethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17ClFNO2, 321.1; m/z found, 322.1 [M+H]+. 1H NMR (CDCl3): 7.42-7.31 (m, 5H), 6.75-6.71 (m, 2H), 6.56 (s, 1H), 5.35 (ddd, J=14.3, 7.7, 3.3 Hz, 1H), 5.00 (s, 1H), 4.75 (ddd, J=48.0, 10.0, 7.7, Hz, 1H), 4.59 (ddd, J=46.7, 10.1, 3.3 Hz, 1H), 4.26-3.53 (m, 4H).
Example 144 (±)-4-[5-Chloro-2-(2-fluoro-1-phenyl-ethoxy)-phenoxy]-piperidineMS (ESI): mass calcd. for C19H21ClFNO2, 349.1; m/z found, 350.1 [M+H]+. 1H NMR (CDCl3): δ 7.45-7.28 (m, 5H), 6.90 (d, J=2.2 Hz, 1H), 6.77-6.67 (m, 2H), 5.36 (ddd, J=14.5, 7.6, 3.3 Hz, 1H), 4.80-4.50 (m, 2H), 4.35 (dt, J=12.3, 4.0 Hz, 1H), 3.14 (dd, J=12.0, 4.9 Hz, 2H), 2.70 (dd, J=11.9, 9.7 Hz, 2H), 2.00 (dd, J=7.9, 3.9 Hz, 2H), 1.77-1.62 (m, 2H).
Example 145 (±)-3-[5-Chloro-2-(1-phenyl-ethoxy)-phenoxy]-azetidineTo 3-(5-Chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (0.80 g, 2.7 mmol) in EtOAc (2 mL) was added 4M HCl in dioxane (5 mL). After 18 h, EtOAc was added and the resulting white solid filtered to give 2-(azetidin-3-yloxy)-4-chloro-phenol hydrochloride as a white solid. To a CH2Cl2 (25 mL) solution of this compound was added Et3N (0.30 g, 0.42 mL, 3.0 mmol) and TFAA (0.58 g, 0.38 mL, 2.8 mmol). After 18 h, H2O was added and the reaction extracted with CH2Cl2 (2×). The combined organics were dried and concentrated to give 0.54 g (74% yield 2 steps) of the title compound as a brown oil that was used in the next step without further purification.
Step B: Preparation of (±)-1-[3-[5-Chloro-2-(1-phenyl-ethoxy)-phenoxy]-azetidin-1-yl]-2,2,2-trifluoro-ethanoneTo the title compound of Step A (0.17 g, 0.56 mmol) in DMF (3 mL) was added Cs2CO3 (0.25 g, 0.80 mmol), KI (0.09 g, 0.55 mmol) and (1-bromoethyl)-benzene (0.10 g, 0.08 mL, 0.56 mmol). After 15 h, H2O was added and the mixture extracted with EtOAc (2×). The combined organics were washed with brine and dried. Silica gel chromatography (5-25% EtOAc in hexanes) gave 0.14 g (64%) of the title compound. 1H NMR (CDCl3): 7.37-7.27 (m, 5H), 6.82 (dd, J=8.7, 2.4 Hz, 1H), 6.72 (d, J=2.4 Hz, 1H), 6.60 (d, J=2.4 Hz, 1H), 5.2 (q, J=6.5 Hz, 1H), 5.0-4.9 (m, 1H), 4.75-4.69 (m, 1H), 4.52-4.42 (m, 2H), 4.32-4.21 (m, 1H), 1.67 (d, J=6.4 Hz, 3H).
Step C: Preparation of (±)-3-[5-Chloro-2-(1-phenyl-ethoxy)-phenoxy]-azetidineTo the title compound of Step B in MeOH (4 mL) was added K2CO3 (0.10 g, 0.72 mmol). After 15 h, H2O was added and the mixture extracted with EtOAc (2×). The combined organics were dried and concentrated. Silica gel chromatography (1-7 2M NH3/MeOH in CH2Cl2) gave 0.75 g (68% yield) of the title compound. MS (ESI): mass calcd. for C17H18ClNO2, 303.10; m/z found, 304.1 [M+H]+. 1H NMR (CDCl3): 7.38-7.31 (m, 4H), 7.28-7.24 (m, 1H), 6.72 (dd, J=8.6, 2.4 Hz, 1H), 6.67 (d, J=8.6 Hz, 1H), 6.55 (d, J=2.4 Hz, 1H), 5.23 (q, J=6.4 Hz, 1H), 4.99-4.93 (m, 1H), 3.95-3.81 (m, 4H), 1.66 (d, J=6.5 Hz, 3H).
Example 146 (±)-3-[5-Chloro-2-[1-(5-trifluoromethyl-furan-2-yl)-ethoxy]-phenoxy]-azetidineTo 5-trifluoromethyl-furan-2-carbaldehyde (0.76 g, 4.6 mmol) in THF (20 mL) at 0° C. was added MeMgBr (3M in Et2O, 3 mL, 6 mmol) dropwise over 1 h. After an additional 1 h, ½ saturated NH4Cl (aq.) was added and the mixture extracted with EtOAc (2×). The combined organics were washed with brine and dried to give 0.81 g (97%) of the title compound. 1H NMR (CDCl3): 6.74-6.73 (m, 1H), 6.32-6.31 (m, 1H), 4.91 (q, J=6.5 Hz, 1H), 1.57 (d, J=6.6 Hz, 3H).
Step B: Preparation of 1-(3-[5-Chloro-2-[1-(5-trifluoromethyl-furan-2-yl)-ethoxy]-phenoxy]-azetidin-1-yl)-2,2,2-trifluoro-ethanonePrepared from the title compound of Step A and the title compound of Example 145 Step A using general procedure 7. 1H NMR (CDCl3): 6.94 (dd, J=8.6, 2.3 Hz, 1H), 6.88 (dd, J=8.7, 1.4 Hz, 1H), 6.73 (m, 1H), 6.62 (d, J=2.3 Hz, 1H), 6.33 (d, J=3.3 Hz, 1H), 5.27-5.22 (m, 1H), 5.01-4.94 (m, 1H), 4.76-4.69 (m, 1H), 4.52-4.44 (m, 2H), 4.27-4.21 (m, 1H), 1.74 (d, J=6.6 Hz, 3H).
Step C: Preparation of (±)-3-[5-Chloro-2-[1-(5-trifluoromethyl-furan-2-yl)-ethoxy]-phenoxy]-azetidinePrepared from the title compound of Step B according to Example 145 Step C. MS (ESI): mass calcd. for C16H15ClF3NO3, 361.1; m/z found, 362.0 [M+H]+. 1H NMR (CDCl3): 6.84-6.79 (m, 2H), 6.72-6.71 (m, 1H), 6.57 (d, J=1.9 Hz, 1H), 6.32 (d, J=3.4 Hz, 1H), 5.24 (q, J=6.6 Hz, 1H), 4.98-4.92 (m, 1H), 3.93-3.82 (m, 4H), 1.72 (d, J=6.6 Hz, 3H).
Example 147 3-[5-Chloro-2-(1-phenyl-propoxy)-phenoxy]-azetidineSynthesized according to Example 146 using 1-phenyl-propan-1-ol. MS (ESI): mass calcd. for C18H20ClNO2, 317.1; m/z found, 318.1 [M+H]+. 1H NMR (CDCl3): 7.33-7.23 (m, 5H), 6.70 (dd, J=8.6, 2.4 Hz, 1H), 6.62 (d, J=8.6 Hz, 1H), 6.54 (d, J=2.3 Hz, 1H), 4.97-4.92 (m, 2H), 4.03-3.78 (m, 4H), 2.11-2.02 (m, 1H), 1.95-1.85 (m, 1H), 1.01 (t, J=7.4 Hz, 3H).
Example 148 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-2-phenyl-ethanolTo 3-(5-Chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (1.1 g, 3.7 mmol) in DMF (18 mL) was added Cs2CO3 (1.5 g, 4.4 mmol) and bromophenylacetic acid methyl ester (0.92 g, 0.63 mL, 4.0 mmol). After 15 h, H2O was added and the mixture extracted with EtOAc (2×). The combined organics were washed with brine and dried. Silica gel chromatography (5-25% EtOAc in hexanes) gave 1.6 g (96%) of the title compound. 1H NMR (CDCl3): 7.55-7.33 (m, 2H), 7.43-7.36 (m, 3H), 6.85 (d, J=1.2, 2H), 6.51 (t, J=1.2 Hz, 1H), 5.58 (s, 1H), 4.91-4.85 (m, 1H), 4.31-4.26 (m, 2H), 3.98-3.93 (m, 2H), 3.89-3.74 (m, 3H), 1.46 (s, 9H).
Step B: Preparation of 3-[5-Chloro-2-(methoxycarbonyl-phenyl-methoxy)-phenoxy]-azetidine-1-carboxylic acid tert-butyl esterTo the title compound of Step A (0.22 g, 0.50 mmol) in THF at 0° C. was added LiBH4 (2M in THF, 0.4 mL, 0.8 mmol). After 2 h, 1N KHSO4 (aq.) was added and the mixture extracted with EtOAc (2×). The combined organic layers were washed with brine and dried. Silica gel chromatography (5-25% EtOAc in hexanes) gave 0.17 g (82%) of the title compound. 1H NMR (CDCl3): 7.36-7.30 (m, 5H), 6.75 (dd, J=8.6, 2.3 Hz, 1H), 6.68 (d, J=8.7 Hz, 1H), 6.51 (d, J=2.3 Hz, 1H), 5.09 (dd, J=8.7, 3.4 Hz, 1H), 4.90-4.85 (m, 1H), 4.35-4.30 (m, 2H), 4.15-3.94 (m, 4H), 3.80-3.77 (m, 1H), 1.47 (s, 9H).
Step C: Preparation of 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-2-phenyl-ethanolPrepared from the title compound of Step B according to general procedure 1. MS (ESI): mass calcd. for C17H18ClNO3, 319.1; m/z found, 320.1 [M+H]+. 1H NMR (DMSO-D6): 7.40 (m, 5H), 6.94-6.69 (m, 3H), 5.32-5.28 (m, 1H), 5.11-4.79 (m, 2H), 3.80-3.75 (m, 3H), 3.61 (dd, J=11.4, 4.1 Hz, 1H), 3.54-3.20 (m, 2H).
Example 149 [2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-phenyl-acetic acid hydrochlorideTo the title compound of Example 148 Step A (0.16 g, 0.36 mmol) in MeOH (3 mL) was added 1N NaOH (3 mL). After 18 h, the solution was acidified with 1N KHSO4 and extracted with EtOAc (2×). The combined organics were washed with brine and dried to give 0.16 g (>98%) of the title compound. 1H NMR (CDCl3): 8.56-8.19 (broad s, 1H), 7.55-7.51 (m, 2H), 7.41-7.36 (m, 3H), 6.85-6.84 (m, 2H), 6.54 (s, 1H), 5.55 (s, 1H), 4.88-4.83 (m, 1H), 4.29-4.24 (m, 2H), 4.06-3.97 (m, 2H), 1.44 (s, 9H).
Step B: Preparation of [2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-phenyl-acetic acid hydrochloridePrepared from the title compound of Step A according to general procedure 1. MS (ESI): mass calcd. for C17H16ClNO4, 333.1; m/z found, 334.1 [M+H]+. 1H NMR (DMSO-D6): 13.3 (s, 1H), 9.27 (s, 2H), 7.58-7.56 (m, 2H), 7.46-7.37 (m, 3H), 7.05-6.99 (m, 2H), 6.96 (d, J=2.2 Hz, 1H), 5.86 (s, 1H), 5.11-5.06 (m, 1H), 4.45-4.37 (m, 2H), 4.05-3.98 (m, 2H).
Example 150 (±)-3-[5-Chloro-2-(6-fluoro-indan-1-yloxy)-phenoxy]-azetidineTo a solution of 6-fluoro-indan-1-one (0.50 g, 3.3 mmol) in DCE (10 mL) and MeOH (10 mL) was added NaBH4 (0.25 g, 6.6 mmol). After 30 min the reaction was quenched with H2O (10 mL) and extracted with CH2Cl2 (3×20 mL). The organic layers were combined and dried to give the title compound (0.49 g, 97%). MS (ESI): mass calcd. for C9H7FO, 150.1; m/z found, 151.4 [M+H]+. 1H NMR (CDCl3): 7.23-7.13 (m, 1H), 7.09 (dd, J=8.6, 2.5 Hz, 1H), 6.99-6.90 (m, 1H), 5.21 (t, J=6.3 Hz, 1H), 3.13-2.91 (m, 1H), 2.85-2.68 (m, 1H), 2.63-2.44 (m, 1H), 2.09-1.74 (m, 2H).
Step B: Preparation of 1-[3-[5-Chloro-2-(6-fluoro-indan-1-yloxy)-phenoxy]-azetidin-1-yl]-2,2,2-trifluoro-ethanonePrepared from the title compound of Step A and the title compound of Example 145 Step A according to the general procedure 7.
Step C: Preparation of 3-[5-Chloro-2-(6-fluoro-indan-1-yloxy)-phenoxy]-azetidinePrepared from the title compound of Step B using general procedure 2. MS (ESI): mass calcd. for C18H17ClFNO2, 333.1; m/z found, 334.1 [M+H]+. 1H NMR (CDCl3): 7.23 (dd, J=8.2, 5.0 Hz, 1H), 7.10-6.87 (m, 4H), 6.65 (s, 1H), 5.68-5.53 (m, 1H), 4.94 (s, 1H), 4.15-4.06 (m, 4H), 3.19-2.99 (m, 1H), 2.97-2.66 (m, 1H), 2.67-2.43 (m, 1H), 2.40-2.17 (m, 1H).
Unless otherwise specified the compounds in Examples 151-161 were prepared according to Example 150 using the appropriately substituted phenol and alcohol.
Example 151 (±)-3-[5-Bromo-2-(indan-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C18H18BrNO2, 359.1; m/z found, 360.0 [M+H]+. 1H NMR (CDCl3): 7.40-7.16 (m, 4H), 7.11 (d, J=8.5 Hz, 1H), 7.05-6.90 (m, 2H), 5.67 (d, J=3.4 Hz, 1H), 4.05-3.84 (m, 2H), 3.82-3.52 (m, 2H), 3.24-3.10 (m, 1H), 2.93 (d, J=4.5 Hz, 1H), 2.65-2.43 (m, 1H), 2.34-2.17 (m, 2H).
Example 152 (±)-3-[5-Bromo-2-(5-chloro-indan-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C18H17BrClNO2, 393.0; m/z found, 394.0 [M+H]+. 1H NMR (CDCl3): 7.36-7.12 (m, 4H), 7.00-6.87 (m, 1H), 6.79 (s, 1H), 5.65 (s, 1H), 4.98-4.74 (m, 1H), 4.46-4.29 (m, 1H), 4.29-4.04 (m, 2H), 3.25-3.10 (m, 1H), 3.03-2.83 (m, 1H), 2.60-2.46 (m, 1H), 2.36-2.20 (m, 2H).
Example 153 (±)-3-[5-Bromo-2-(6-chloro-indan-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C18H17BrClNO2, 393.0; m/z found, 394.0 [M+H]+. 1H NMR (CDCl3): 7.42-7.09 (m, 5H), 7.02-6.83 (m, 1H), 5.62 (s, 1H), 4.38 (s, 1H), 4.27-3.90 (m, 2H), 3.73-3.54 (m, 1H), 3.12 (s, 1H), 2.90 (s, 1H), 2.53 (s, 1H), 2.35-2.14 (m, 2H).
Example 154 (±)-3-[5-Bromo-2-(5-fluoro-indan-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C18H17BrFNO, 377.0; m/z found, 378.0 [M+H]+. 1H NMR (CDCl3): 7.23 (d, J=5.2, 1H), 7.13-7.03 (m, 1H), 6.98-6.79 (m, 4H), 4.95-4.68 (m, 1H), 4.37-3.96 (m, 4H), 3.08 (s, 1H), 2.86 (s, 1H), 2.53-2.38 (m, 1H), 2.31-2.11 (m, 2H).
Example 155 (±)-3-[5-Bromo-2-(5-methyl-indan-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H20BrNO2, 373.1; m/z found, 374.0 [M+H]+. 1H NMR (CDCl3): 7.25-7.10 (m, 4H), 7.04-6.78 (m, 2H), 5.65 (s, 2H), 4.31 (s, 1H), 4.12 (s, 2H), 3.10 (s, 1H), 2.89 (s, 1H), 2.46 (s, 2H), 2.35 (d, J=6.6 Hz, 4H).
Example 156 (±)-3-[5-Bromo-2-(6-methyl-indan-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H20BrNO2, 373.1; m/z found, 374.0 [M+H]+. 1H NMR (CDCl3): 7.36-7.18 (m, 3H), 7.08 (d, J=8.2, 1H), 7.02-6.92 (m, 2H), 5.67 (d, J=3.4 Hz, 1H), 4.02-3.84 (m, 2H), 3.80-3.53 (m, 2H), 3.24-3.10 (m, 1H), 2.93 (d, J=4.5 Hz, 1H), 2.65-2.46 (m, 1H), 2.37-2.18 (m, 5H).
Example 157 (±)-3-[5-Bromo-2-(6-trifluoromethyl-indan-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H17BrF3NO2, 427.1; m/z found, 429.0 [M+H]+. 1H NMR (CDCl3): 7.69-7.35 (m, 3H), 7.07 (dd, J=8.5, 2.3 Hz, 1H), 6.91 (d, J=8.5 Hz, 1H), 6.76 (d, J=2.3 Hz, 1H), 5.72-5.56 (m, 1H), 4.95 (s, 1H), 3.91 (s, 4H), 3.21 (d, J=9.4 Hz, 1H), 3.07-2.85 (m, 1H), 2.61-2.46 (m, 1H), 2.42-2.22 (m, 1H).
Example 158 (±)-3-[5-Chloro-2-(6-methyl-indan-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H20ClNO2, 329.1; m/z found, 330.4 [M+H]+. 1H NMR (CDCl3): 7.22-7.08 (m, 3H), 7.02-6.89 (m, 2H), 6.67-6.60 (m, 1H), 5.63 (dd, J=6.5, 4.1 Hz, 1H), 4.96-4.86 (m, 1H), 4.04-3.72 (m, 4H), 3.21-3.02 (m, 1H), 2.94-2.77 (m, 1H), 2.57-2.40 (m, 1H), 2.33 (d, J=8.2 Hz, 3H), 2.29-2.17 (m, 1H).
Example 159 (±)-3-[5-Chloro-2-(6-chloro-indan-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C18H17O2NO2, 349.1; m/z found, 350.0 [M+H]+. 1H NMR (CDCl3): 7.38-7.19 (m, 3H), 7.06-6.93 (m, 2H), 6.76-6.59 (m, 1H), 5.74-5.54 (m, 1H), 5.05-4.78 (m, 1H), 4.30-3.89 (m, 3H), 3.13 (d, J=8.2 Hz, 1H), 2.91 (d, J=5.1 Hz, 1H), 2.63-2.45 (m, 1H), 2.27 (s, 1H), 2.19 (s, 1H).
Example 160 3-[5-Chloro-2-(6-trifluoromethyl-indan-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H17ClF3NO2, 383.1; m/z found, 384.1 [M+H]+. 1H NMR (CDCl3): 7.74-7.40 (m, 3H), 7.03-6.88 (m, 2H), 6.65 (d, J=2.2 Hz, 1H), 5.73-5.59 (m, 1H), 4.99 (s, 1H), 4.33-3.65 (m, 2H), 3.23 (s, 1H), 3.01 (s, 2H), 2.68-2.48 (m, 2H), 2.44-2.31 (m, 1H).
Example 161 3-[5-Chloro-2-(1,2,3,4-tetrahydro-naphthalen-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H20ClNO2, 329.1; m/z found, 330.2 [M+H]+. 1H NMR (CDCl3): 7.29-7.13 (m, 4H), 7.01 (d, J=8.7 Hz, 3H), 5.27 (s, 1H), 4.96-4.71 (m, 1H), 4.08 (s, 3H), 2.91 (s, 1H), 2.79 (s, 1H), 2.19-2.04 (m, 4H), 1.86 (s, 1H).
Example 162 3-[5-Bromo-2-(5-tert-butyl-indan-1-yloxy)-phenoxy]-azetidineTo a solution of tert-butyl benzene (1.0 g, 7.5 mmol) and 3-chloropropionyl chloride (0.7 mL, 7.5 mmol.) in CH2Cl2 (20 mL) was added dropwise to a suspension of AlCl3 (1.1 g, 8.2 mmol) in CH2Cl2 (10 mL) at 0° C. The reaction was allowed to warm to rt. After 15 h, the reaction was quenched with H2O (10 mL) and extracted with CH2Cl2 (2×20 mL). The organic layers were combined and dried to give the title compound that was used without further purification (1.3 g).
Step B.: Preparation of 5-tert-butyl-indan-1-oneThe title compound of Step A (1.3 g, 5.8 mmol) was dissolved in conc. H2SO4 (10 mL) and heated at 95° C. for 3 h. The reaction mixture was cooled to rt, poured onto ice, and extracted with Et2O (3×25 mL). The combined organic extracts were washed with sat'd NaHCO3 (aq.) and dried to provide the title compound (0.74 g, 68%). MS (ESI): mass calcd. for C13H16O, 188.1; m/z found, 189.2 [M+H]+. 1H NMR (CDCl3): 7.67-7.58 (m, 1H), 7.44-7.32 (m, 2H), 3.09-3.02 (m, 2H), 2.65-2.68 (m, 2H), 1.27 (d, J=8.5 Hz, 9H).
Step B.: Preparation of 3-[5-Bromo-2-(5-tert-butyl-indan-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C22H26BrNO2, 415.1; m/z found, 418.1 [M+H]+. 1H NMR (CDCl3): 7.38-7.13 (m, 4H), 7.08-6.84 (m, 2H), 5.71 (s, 1H), 4.32 (s, 2H), 3.71-3.50 (m, 2H), 3.14 (s, 1H), 2.94 (s, 1H), 2.53 (s, 1H), 2.24 (s, 2H), 1.43-1.20 (m, 9H).
Example 163 3-[5-Chloro-2-(tetrahydro-furan-3-ylmethoxy)-phenoxy]-azetidineA mixture of 3-(5-chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (0.5 mmol), tetrahydro-furan-3-yl-methanol (0.5 mmol), and cyanomethylenetri-n-butylphosphorane (0.5 mmol) in toluene (3 mL) was heated at 120° C. in a microwave reactor for 1 h. The mixture was cooled to rt and purified via PTLC providing 3-[5-chloro-2-(tetrahydro-furan-3-ylmethoxy)-phenoxy]azetidine-1-carboxylic acid tert-butyl ester (120 mg). To this compound was added CH2Cl2 (20 mL) and TFA (3 mL). After 4 h at rt the mixture was concentrated to give the title compound (161 mg). MS (ESI): mass calcd. for C14H18ClNO3, 283.1; m/z found, 284.0 [M+H]+. 1H NMR (MeOD): 7.05-6.96 (m, 2H), 6.88 (d, J=1.9 Hz, 1H), 5.15-5.05 (m, 1H), 4.57-4.48 (m, 2H), 4.28-4.19 (m, 2H), 4.04-3.88 (m 4H), 3.82-3.70 (m 2H), 2.82-2.70 (m, 1H), 2.20-2.09 (m, 1H), 1.84-1.73 (m, 1H).
The compounds in Examples 164-174 were prepared according to Example 163 with the appropriate alcohols.
Example 164 3-[5-Chloro-2-(1,2,3,4-tetrahydro-naphthalen-2-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H20ClNO2, 329.1; m/z found, 330.0 [M+H]+. 1H NMR (MeOD): 7.18-6.90 (m, 7H), 4.98-4.89 (m, 1H), 4.87-4.78 (m, 1H), 4.35-4.25 (m, 2H), 4.12-3.95 (m, 2H), 3.30-2.80 (m, 4H), 2.18-2.02 (m, 2H).
Example 165 3-[5-Chloro-2-(chroman-2-ylmethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H20ClNO3, 345.1; m/z found, 346.1[M+H]+. 1H NMR (400 MHz, CDCl3): 7.13-6.75 (m, 7H), 5.15-4.98 (m, 1H), 4.55-4.09 (m, 7H), 3.00-2.75 (m, 2H), 2.18-1.85 (m, 2H).
Example 166 3-[5-Chloro-2-(tetrahydro-furan-2-ylmethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C14H18ClNO3, 283.1; m/z found, 284.0 [M+H]+. 1H NMR (MeOD): 7.05-6.86 (m, 3H), 5.12-5.02 (m, 1H), 4.60-4.46 (m, 2H), 4.32-4.20 (m, 3H), 4.09-4.00 (m, 1H), 3.95-3.87 (m, 2H), 3.86-3.70 (m, 1H), 2.20-1.90 (m, 3H), 1.80-1.68 (m, 1H).
Example 167 3-[5-Chloro-2-(chroman-3-ylmethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H20ClNO3, 345.1; m/z found, 346.1 [M+H]+. 1H NMR (MeOD): 7.15-6.63 (m, 7H), 5.15-4.98 (m, 1H), 4.60-3.90 (m, 8H), 3.10-2.93 (m, 1H), 2.78-2.50 (m, 2H).
Example 168 3-[5-Chloro-2-(2-methoxy-2-phenyl-ethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C18H20ClNO3, 333.1; m/z found, 334.1 [M+H]+. 1H NMR (CDCl3): 7.45-7.25 (m, 5H), 7.04-6.88 (m, 3H), 5.05-4.96 (m, 1H), 4.63-4.57 (m, 1H), 4.53-4.42 (m, 2H), 4.26-4.05 (m, 4H), 4.33 (s, 3H).
Example 169 3-[5-Chloro-2-(2,3-dihydro-benzofuran-2-ylmethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C18H18ClNO3, 331.1; m/z found, 332.1 [M+H]+. 1H NMR (CDCl3): 7.20-6.66 (m, 7H), 5.20-5.05 (m, 1H), 4.98-4.88 (m, 1H), 4.35-4.03 (m, 6H), 3.42-3.32 (m, 1H), 3.12-3.03 (m, 1H).
Example 170 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-1,3-dimethyl-1H-pyrazoleMS (ESI): mass calcd. for C15H18ClN3O2, 307.1; m/z found, 308.1 [M+H]+. 1H NMR (MeOD): 7.12 (d, J=8.7 Hz, 1H), 7.00 (dd, J=8.7, 2.1 Hz, 1H), 6.87 (d, J=2.1 Hz, 1H), 6.17 (s, 1H), 5.13-5.05 (m, 3H), 4.48-4.39 (m, 2H), 4.18-4.12 (m, 2H), 3.85 (s, 3H), 2.20 (s, 3H).
Example 171 3-[5-Chloro-2-(2-phenoxy-ethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H18ClNO3, 319.1; m/z found, 320.0 [M+H]+. 1H NMR (MeOD): 7.34-7.26 (m, 2H), 7.12-6.92 (m, 6H), 5.14-4.95 (m, 2H), 4.83-4.74 (m, 1H), 4.48-4.42 (m, 1H), 4.39-4.30 (m, 4H), 4.24-4.16 (m, 1H).
Example 172 3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-1-phenyl-azetidinePrepared by the procedure of Example 163 using 5-bromo-2-(3-fluoro-benzyloxy)-phenol and 1-phenyl-azetidin-3-ol. MS (ESI): mass calcd. for C22H19BrFNO2, 427.1; m/z found, 428.2 [M+H]+. 1H NMR (CDCl3): 7.34-6.47 (m, 12H), 5.11-5.03 (m, 3H), 4.36-4.28 (m, 2H), 3.98-3.91 (m, 2H).
Example 173 3-[5-Chloro-2-(indan-2-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C18H18ClNO2, 315.1; m/z found, 316.1 [M+H]+. 1H NMR (MeOD): 7.35-7.06 (m, 6H), 6.93-6.90 (m, 1H), 5.28-5.21 (m, 1H), 4.86-4.78 (m, 1H), 4.28-4.18 (m, 2H), 4.08-3.98 (m, 2H), 3.42-3.35 (m, 2H), 3.18-3.08 (m, 2H).
Example 174 3-[5-Bromo-2-(indan-2-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C18H18BrNO2, 359.1; m/z found, 359.9 [M+H]+. 1H NMR (MeOD): 7.33-7.02 (m, 7H), 5.28-5.21 (m, 1H), 4.86-4.78 (m, 1H), 4.28-4.16 (m, 2H), 4.08-3.98 (m, 2H), 3.42-3.35 (m, 2H), 3.18-3.08 (m, 2H).
Example 175 3-[5-Chloro-2-(5-fluoro-indan-2-yloxy)-phenoxy]-azetidineTo the solution of 5-fluoro-indan-1-one (10 mmol) in MeOH/CH2Cl2 (40 mL/120 mL) was added Bu4NBr3 (11 mmol). The mixture was stirred at 25° C. for 16 h, concentrated and partitioned between CH2Cl2/H2O (150 mL/80 mL). The organic layer was concentrated and purified providing the title compound (2 g).
Step B: Preparation of 3-[5-Chloro-2-(5-fluoro-indan-2-yloxy)-phenoxy]-azetidineThe mixture of 3-(5-chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (0.5 mmol), the title compound of Step A (0.5 mmol), and K2CO3 (1 mmol) in acetonitrile (3 mL) was heated at 100° C. in a microwave reactor for 1 h. The mixture was cooled to rt and purified via PTLC providing the title compound (150 mg). To this product was added DCE (5 mL), Et3SiH (1 mL) and TFA (3 mL). The mixture was stirred at 80° C. for 16 h. After concentration, the title compound was obtained (91 mg). MS (ESI): mass calcd. for C18H17ClFNO2, 333.1; m/z found, 334.1 [M+H]+. 1H NMR (CDCl3): 7.20-7.13 (m, 1H), 6.96-6.60 (m, 5H), 5.18-5.08 (m, 1H), 4.93-4.83 (m, 1H), 3.98-3.70 (m, 4H), 3.38-3.05 (m, 4H).
The compounds in Examples 176-178 were prepared according to Example 175 using the appropriately substituted indanone.
Example 176 3-[5-Chloro-2-(5-chloro-indan-2-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C18H17O2NO2, 349.1; m/z found, 350.0 [M+H]+. 1H NMR (CDCl3): 7.26-6.63 (m, 6H), 5.20-5.05 (m, 1H), 4.93-4.83 (m, 1H), 4.10-3.85 (M, 4H), 3.45-3.05 (m, 4H).
Example 177 3-[5-Chloro-2-(5-methoxy-indan-2-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H20ClNO3, 345.1; m/z found, 346.0 [M+H]+. 1H NMR (MeOD): 7.15 (d, J=8.2 Hz, 1H), 7.08-7.03 (m, 2H), 6.94-6.73 (m, 3H), 5.25-5.17 (m, 1H), 4.90-4.81 (m, 1H), 4.80-4.70 (m, 2H), 4.12-4.02 (m, 2H), 3.77 (s, 3H), 3.37-3.24 (m, 2H), 3.12-2.98 (m, 2H).
Example 178 3-[5-Chloro-2-(4-methoxy-indan-2-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H20ClNO3, 345.1; m/z found, 346.1 [M+H]+. 1H NMR (MeOD): 7.22-6.76 (m, 6H), 5.26-5.18 (m, 1H), 4.94-4.83 (m, 1H), 4.18-4.10 (m, 2H), 3.98-3.88 (m, 2H), 3.83 (s, 3H), 3.40-3.20 (m, 2H), 3.15-3.02 (m, 2H).
Example 179 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-indan-1-one oximeThe mixture of 3-(5-chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (0.5 mmol), 1-bromo-indan-2-one (0.5 mmol), and K2CO3 (1 mmol) in actetonitrile (3 mL) was heated at 100° C. in a microwave reactor for 1 h. The mixture was cooled down and separated through PTLC providing the title compound (150 mg).
Step B: Preparation of 3-[5-Chloro-2-(1-hydroxyimino-indan-2-yloxy)-phenoxy]-azetidine-1-carboxylic acid tert-butyl esterThe title compound of Step A was dissolved into MeOH (2 mL), then NH2OH HCl (1 mmol) and K2CO3 (2 mmol) were added. The mixture was heated at 100° C. using a microwave reactor for 1 h. The mixture was cooled to rt and purified by PTLC providing the title compound (120 mg).
Step C: Preparation of 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-indan-1-one oximeThe title compound from Step B was dissolved in CH2Cl2 (20 mL), and CF3COOH (3 mL) was added. The mixture was stirred at 25° C. for 4 h. After concentration and purification via PTLC, the title compound was obtained (91 mg). MS (ESI): mass calcd. for C18H17ON2O3, 344.1; m/z found, 345.0 [M+H]+. 1H NMR (MeOD): 8.40 (d, J=8.0 Hz, 1H), 7.50-6.80 (m, 6H), 5.48-5.46 (m, 1H), 5.18-5.10 (m, 1H), 4.45-4.32 (m, 2H), 4.18-4.08 (m, 2H), 3.62-3.52 (m, 1H), 3.16-3.08 (m, 1H).
Example 180-183 were prepared by the procedure of example 179 using the appropriate α-bromo-ketone and NH2OH or NH2OCH3.
Example 180 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-indan-1-one O-methyl-oximeMS (ESI): mass calcd. for C19H19ClN2O3, 358.1; m/z found, 359.0 [M+H]+. 1H NMR (MeOD): 8.70 (d, J=8.0 Hz, 1H), 7.60-6.90 (m, 6H), 6.03-5.98 (m, 1H), 5.15-5.05 (m, 1H), 4.56-4.43 (m, 2H), 4.22-1.18 (m, 2H), 3.93 (s, 3H), 3.76-3.64 (m, 1H), 3.24-3.16 (m, 1H).
Example 181 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-1-phenyl-ethanone oximeMS (ESI): mass calcd. for C17H17ClN2O3, 332.1; m/z found, 333.0 [M+H]+. 1H NMR (MeOD): 8.12-6.80 (m, 8H), 5.56-5.30 (m, 2H), 5.25-4.80 (m, 1H), 4.60-3.98 (m, 4H).
Example 182 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-1-phenyl-ethanone O-methyl-oximeMS (ESI): mass calcd. for C18H19ClN2O3, 346.1; m/z found, 347.0 [M+H]+. 1H NMR (MeOD): 8.18-6.80 (m, 8H), 5.56-5.33 (m, 2H), 5.32-4.80 (m, 1H), 4.60-3.98 (m, 7H).
Example 183 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-1-(4-chloro-phenyl)-ethanone1H NMR (CDCl3): 7.97 (d, J=8.6 Hz, 2H), 7.48 (d, J=8.6 Hz, 2H), 6.85 (dd, J=8.6, 2.3 Hz, 1H), 6.78 (d, J=8.6 Hz, 1H), 6.59 (d, J=8.6 Hz, 1H), 5.25 (s, 2H), 5.00-4.97 (m, 1H), 3.98-3.80 (m, 4H).
Example 184 3-[5-Chloro-2-(2,2-difluoro-2-phenyl-ethoxy)-phenoxy]-azetidineThe mixture of 3-(5-chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (0.5 mmol), (2-bromo-1,1-difluoro-ethyl)benzene (1 mmol), and K2CO3 (1 mmol) in acetonitrile (3 mL) was heated at 180° C. in a microwave reactor for 1 h. The mixture was cooled to rt and purified via PTLC providing 3-[5-chloro-2-(2,2-difluoro-2-phenyl-ethoxy)-phenoxy]-azetidine-1-carboxylic acid tert-butyl ester (90 mg). To this compound was added CH2Cl2 (20 mL) and CF3COOH (3 mL). The mixture was stirred at rt for 4 h and concentrated to give the title compound (50 mg). MS (ESI): mass calcd. for C17H16ClF2NO2, 339.1; m/z found, 340.0 [M+H]+. 1H NMR (MeOD): 7.66-7.46 (m, 5H), 7.02-6.83 (m, 3H), 5.05-4.95 (m, 1H), 4.50 (t, J=12.7 Hz, 2H), 4.30-4.20 (m, 2H), 4.10-3.98 (m, 2H).
Example 185 3-[5-Chloro-2-[2-(3-chloro-phenyl)-ethoxy]-phenoxy]-azetidineTo a solution of 2-(3-chloro-phenyl)-ethanol (566 mg, 3.6 mmol) in CH2Cl2 (10 mL) was added methanesulfonyl chloride (310 μL, 4.0 mmol). After 5 min, Et3N (756 μL, 5.4 mmol) was added and the reaction was allowed to stir for 18 h. The reaction was then diluted with H2O. The organic layer was separated and washed with H2O, brine, then dried and concentrated to give a yellow oil (770 mg, 91%). 1H NMR (CDCl3): 7.27-7.23 (m, 3H), 7.14-7.11 (m, 1H), 4.41 (t, J=6.8 Hz, 2H), 3.04 (t, J=6.8 Hz, 2H), 2.90 (s, 3H).
Step B. Preparation of 3-[5-Chloro-2-[2-(3-chloro-phenyl)-ethoxy]-phenoxy]-azetidine-1-carboxylic acid tert-butyl esterTo a solution of 3-(5-chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (60 mg, 0.20 mmol) in DMF (2 mL) was added NaH (10 mg, 0.24 mmol). After 5 min, the title compound of Step A (56 mg, 0.24 mmol) was added and the resulting mixture was heated at 65° C. for 18 h. The reaction was diluted with H2O and extracted EtOAc (3×). The organics were dried and purified by RP HPLC (Agilent) to give the title compound as an oil (47 mg, 54%). MS (ESI): mass calcd. for C22H25Cl2NO4, 438.3; m/z found, 382.0 [M-56+H]+. 1H NMR (CDCl3): 7.34-7.32 (m, 1H), 7.25-7.22 (m, 2H), 7.19-7.16 (m, 1H), 6.90 (dd, J=8.8, 2.0 Hz, 1H), 6.78 (d, J=8.8 Hz, 1H), 6.54 (d, J=2.4 Hz, 1H), 4.85-4.79 (m, 1H), 4.30-4.25 (m, 2H), 4.16 (t, J=6.7 Hz, 2H), 4.07-4.03 (m, 2H), 3.10 (t, J=6.7 Hz, 2H), 1.46 (s, 9H).
Step C: Preparation of 3-[5-Chloro-2-[2-(3-chloro-phenyl)-ethoxy]-phenoxy]-azetidinePrepared from title compound of Step B using general procedure 1. MS (ESI): mass calcd. for C17H17O2NO2, 338.2; m/z found, 338.1 [M+H]+. 1H NMR (CDCl3): 7.35-7.34 (m, 1H), 7.25-7.21 (m, 3H), 7.18-7.16 (m, 1H), 6.88-6.85 (m, 1H), 6.77 (d, J=8.8 Hz, 1H), 6.57 (d, J=2.4 Hz, 1H), 4.98-4.91 (m, 1H), 4.17 (t, J=6.8 Hz, 2H), 3.96-3.85 (m, 4H), 3.10 (t, J=6.7 Hz, 2H).
The compounds in Examples 186-195 were synthesized according to Example 185 using the appropriately substituted mesylates as prepared in Example 185 Step A.
Example 186 3-[5-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H18ClNO2, 303.8; m/z found, 304.1 [M+H]+. 1H NMR (CDCl3): 7.39-7.19 (m, 7H), 6.93-6.73 (m, 2H), 6.58 (d, J=2.4 Hz, 1H), 4.94 (s, 1H), 4.18 (t, J=7.3 Hz, 2H), 3.91 (s, 3H), 3.14 (t, J=7.3 Hz, 2H).
Example 187 3-[5-Chloro-2-(2-fluoro-2-phenyl-ethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17ClFNO2, 321.8; m/z found, 322.1 [M+H]+. 1H NMR (CDCl3): 7.42 (s, 5H), 6.87-6.61 (m, 2H), 6.62 (d, J=2.2 Hz, 1H), 5.85 (dd, J=48.0, 8.0 Hz, 1H), 5.02 (bs, 1H), 4.40-4.08 (m, 7H).
Example 188 3-[5-Chloro-2-[1-(4-chloro-phenyl)-cyclobutylmethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C20H21Cl2NO2, 378.3; m/z found, 378.0 [M+H]+. 1H NMR (CDCl3): 7.34-7.27 (m, 5H), 7.21-7.20 (m, 1H), 7.19-7.18 (m 1H), 6.81 (s, 1H), 6.70 (d, J=8.6, 1H), 6.54 (d, J=2.4 Hz, 1H), 4.97-4.87 (m, 1H), 4.01 (s, 2H), 3.94-3.90 (m, 2H), 3.82-3.78 (m, 2H), 2.42 (t, J=7.7 Hz, 4H).
Example 189 3-[5-Chloro-2-[1-(3-chloro-phenyl)-cyclobutylmethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C20H21Cl2NO2, 378.3; m/z found, 378.0. 1H NMR (CDCl3): 7.28-7.22 (m, 5H), 7.19-7.16 (m, 1H), 7.13-7.10 (m, 1H), 6.82 (dd, J=8.6, 2.4 Hz, 1H), 6.70 (d, J=8.6 Hz, 1H), 6.54 (d, J=2.4, 1H), 4.92 (m, 1H), 4.03 (s, 2H), 3.94-3.76 (m, 3H), 2.42 (d, J=8.8 Hz, 3H), 2.17 (s, 2H).
Example 190 3-[5-Chloro-2-[2-(3-methoxy-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C18H20ClNO3, 333.8; m/z found, 334.1 [M+H]+. 1H NMR (CDCl3): 7.24-7.22 (m, 2H), 6.90-6.86 (m, 3H), 6.81-6.77 (m, 2H), 6.60 (d, J=2.4, 1H), 5.00-4.87 (m, 1H), 4.18 (t, J=7.2, 2H), 4.03-3.94 (m, 2H), 3.90-3.86 (m, 2H), 3.80 (s, 3H), 3.11 (t, J=7.1 Hz, 2H).
Example 191 3-[5-Chloro-2-[2-(3-fluoro-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17ClFNO2, 321.8; m/z found, 322.0 [M+H]+. 1H NMR (CDCl3): 7.30-7.24 (m, 2H), 7.09-7.05 (m, 2H), 6.96-6.91 (m, 1H), 6.88-6.85 (m, 1H), 6.77 (d, J=8.8 Hz, 1H), 6.57 (d, J=2.4, 1H), 4.95 (s, 1H), 4.18 (t, J=6.8 Hz, 2H), 3.95-3.84 (m, 4H), 3.12 (t, J=6.8 Hz, 2H).
Example 192 3-[5-Chloro-2-[2-(4-chloro-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17O2NO2, 338.2; m/z found, 338.0. 1H NMR (CDCl3): 7.34-7.17 (m, 5H), 6.89 (dd, J=8.6, 2.4 Hz, 1H), 6.77 (d, J=8.7 Hz, 1H), 6.60 (d, J=2.4 Hz, 1H), 4.95 (t, J=6.2 Hz, 1H), 4.16-4.13 (m, 2H), 4.04-3.99 (m, 2H), 3.93-3.89 (m, 2H), 3.09 (t, J=6.9 Hz, 2H).
Example 193 3-[5-Chloro-2-[2-(4-fluoro-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C17H17ClFNO2, 321.8; m/z found, 322.1 [M+H]+. 1H NMR (CDCl3): 7.32-7.20 (m, 4H), 7.00 (t, J=8.7 Hz, 1H), 6.87-6.85 (m, 1H), 6.77 (d, J=8.8 Hz, 1H), 6.57 (d, J=2.4 Hz, 1H), 5.00-4.87 (m, 1H), 4.15 (t, J=7.0 Hz, 2H), 3.94-3.90 (m, 2H), 3.85-3.81 (m, 2H), 3.10 (t, J=7.0 Hz, 2H).
Example 194 3-[5-Chloro-2-[2-(4-methoxy-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C18H20ClNO3, 333.8; m/z found, 334.1 [M+H]+. 1H NMR (CDCl3): 7.22-7.20 (m, 2H), 6.93-6.85 (m, 3H), 6.77 (d, J=8.4 Hz, 1H), 6.58 (d, J=2.4 Hz, 1H), 4.98-4.91 (m, 1H), 4.13 (t, J=7.3 Hz, 2H), 3.96-3.92 (m, 2H), 3.89-3.85 (m, 2H), 3.79 (s, 3H), 3.07 (t, J=7.3 Hz, 2H).
Example 195 3-(5-Bromo-2-phenethyloxy-phenoxy)-azetidinePrepared according to Example 185 using 3-(5-Bromo-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester. MS (ESI): mass calcd. for C17H18BrNO2, 348.2; m/z found, 348.0. 1H NMR (CDCl3): 7.39-7.20 (m, 6H), 7.05 (dd, J=8.6, 2.3 Hz, 1H), 6.76 (dd, J=6.8, 5.5 Hz, 2H), 4.99-4.87 (m, 1H), 4.18 (t, J=7.2 Hz, 2H), 4.03-3.98 (m, 2H), 3.95-3.91 (m, 2H), 3.13 (t, J=7.2 Hz, 2H).
Example 196 3-(Azetidin-3-yloxy)-2-benzyloxy-5-chloro-pyridineTo 60% NaH in mineral oil (1.0 g, 25.0 mmol) in THF (25 mL) was added benzyl alcohol (2.7 g, 2.6 mL, 25.0 mmol) dropwise. After 1 h, 5-chloro-2,3-difluoro-pyridine (3.73 g, 25.0 mmol) was added in THF (5 mL). After an additional 18 h, H2O was added and the mixture extracted with EtOAc (2×). The combined organics were washed with brine and dried. Silica gel chromatography (1-15% EtOAc in hexanes) gave 4.02 g (67% yield) of the title compound as a clear oil. 1H NMR (CDCl3): 7.91 (d, J=2.2 Hz, 1H), 7.48-7.46 (m, 2H), 7.39-7.32 (m, 4H), 5.44 (s, 2H).
Step B: Preparation of 3-(2-Benzyloxy-5-chloro-pyridin-3-yloxy)-azetidine-1-carboxylic acid tert-butyl esterTo 3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester (0.35 g, 2.0 mmol) in NMP (3 mL) was added 60% NaH in mineral oil (0.08 g, 2.0 mmol). After 20 min at rt, the reaction was heated to 50° C. for 20 min, cooled to rt and the title compound from step A (0.40 g, 1.7 mmol) in NMP (1 mL) was added. The reaction was then heated in a microwave reactor at 145° C. for 1 h, cooled to rt, poured into H2O and extracted with EtOAc (2×). The combined organics were washed with brine and dried. Silica gel chromatography (2-15% EtOAc in hexanes) gave 0.34 g (51% yield) of the title compound as a white solid. 1H NMR (CDCl3): 7.74 (d, J=2.1 Hz, 1H), 7.46 (d, J=7.0 Hz, 2H), 7.39-7.30 (m, 3H), 6.77 (d, J=2.1 Hz, 1H), 5.42 (s, 2H), 4.87-4.82 (m, 1H), 4.26 (dd, J=10.5, 6.4 Hz, 2H), 4.05 (dd, J=10.3, 4.2 Hz, 2H), 1.44 (s, 9H).
Step C: Preparation of 3-(Azetidin-3-yloxy)-2-benzyloxy-5-chloro-pyridinePrepared from the title compound of Step B using general procedure 1. MS (ESI): mass calcd. for C15H15ClN2O2, 290.1; m/z found, 291.1 [M+H]+. 1H NMR (CDCl3): 7.70 (d, J=2.2 Hz, 1H), 7.46 (d, J=7.3 Hz, 2H), 7.37 (t, J=7.2 Hz, 2H), 7.33-7.29 (m, 1H), 6.77 (d, J=2.2 Hz, 1H), 5.43 (s, 2H), 4.99-4.93 (m, 1H), 3.96-3.81 (m, 4H).
Example 197 3-(2-Benzyloxy-5-chloro-3-fluoro-phenoxy)-azetidineTo a −78° C. solution of 1-chloro-3,5-difluoro-benzene (5.0 g, 34 mmol) in THF (70 mL) at was added n-butyl lithium (1.6 M in hexane, 19 mL). After 50 min, DMF (5.2 mL, 67 mmol) was added and the reaction was allowed to warm to rt over 18 h. After the addition of 0.5 M HCl (150 mL) and ether (150 mL), the aqueous layer was extracted with Et2O (3×). The combined organic extracts were dried and concentrated to provide a yellow solid. The crude material was dissolved in warm hexanes and a small amount of white solid formed upon cooling. This white solid was filtered off and discarded. The filtrate was concentrated to provide the title compound as a light yellow solid (2.5 g, 41%). 1H NMR (CDCl3): 10.3 (s, 1H), 7.06 (d, J=8.1 Hz, 2H).
Step B: Preparation of 3-(5-Chloro-3-fluoro-2-formyl-phenoxy)-azetidine-1-carboxylic acid tert-butyl esterTo a solution of the title compound of Step A (270 mg, 1.5 mmol) and 3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester (270 mg, 1.5 mmol) in dry DMF (10 mL) at 0° C. was added NaH (60% in mineral oil, 22 mg, 1.5 mmol). After 18 h, H2O and EtOAc were added and the aqueous layer was extracted with EtOAc. The combined organic extracts were dried and concentrated. The crude residue was purified by RP HPLC to provide the title compound (75 mg, 15%). MS (ESI): mass calcd. for C15H17ClFNO4, 329.1; m/z found, 274.0 [M+H-56]+. 1H NMR (CDCl3): 10.4 (s, 1H), 6.84 (dd, J=10.0, 1.6 Hz, 1H), 6.39 (dd, J=1.4, 1.3 Hz, 1H), 5.00-4.92 (m, 1H), 4.38 (dd, J=9.9, 6.3 Hz, 2H), 4.08 (dd, J=10.7, 4.0 Hz, 2H), 1.46 (s, 9H).
Step C: Preparation of 3-(5-Chloro-3-fluoro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl esterTo a solution of the title compound of Step B (650 mg, 2.0 mmol) in CH2Cl2 (100 mL) was added 77% m-CPBA (510 mg, 3.0 mmol). After stirring for 72 h, the starting aldehyde remained as determined by analytical HPLC analysis. Thus an additional portion of m-CPBA (790 mg, 4.6 mmol) was added. After 18 h, analytical HPLC analysis indicated that the reaction was complete. A solution of 10% aqueous sodium bisulfite (100 mL) was added to the reaction mixture. After an additional 18 h, CH2Cl2 was added and the aqueous portion extracted three times with CH2Cl2. The combined organic extracts were washed with saturated NaHCO3 (2×) and concentrated. The residue was then treated with MeOH (500 mL) and 1 N NaOH (250 mL). The solution immediately turned dark brown. After 2 h, the MeOH was removed by rotary evaporation and 1 M KHSO4 was added to the residue until the pH of the solution reached pH=4. The reaction mixture was then extracted with EtOAc (3×). The combined organic layers were washed with brine and dried. The residue was purified by RP HPLC to provide the desired phenol (290 mg, 46%). 1H NMR (CDCl3): 6.74 (dd, J=10.1, 2.3 Hz, 1H), 6.30 (dd, J=2.0, 2.1 Hz, 1H), 4.87-4.80 (m, 1H), 4.26 (dd, J=9.9, 6.4 Hz, 2H), 4.00 (dd, J=9.9, 3.8 Hz, 2H), 3.29-3.13 (m, 1H), 1.40 (s, 9H).
Step D: Preparation of 3-(2-Benzyloxy-5-chloro-3-fluoro-phenoxy)-azetidine-1-carboxylic acid tert-butyl esterPrepared from the title compound of Step C using according to Example 1 Step D. MS (ESI): mass calcd. for C21H23ClFNO4, 407.1; m/z found, 430.0 [M+Na]+. 1H NMR (CDCl3): 7.46-7.29 (m, 5H), 6.79 (dd, J=9.9, 2.4 Hz, 1H), 6.29 (dd, J=2.1, 2.1 Hz, 1H), 5.06 (s, 2H), 4.82-4.72 (m, 1H), 4.25 (ddd, J=9.7, 6.4, 1.0 Hz, 2H), 3.92 (dd, J=9.8, 3.9 Hz, 2H), 1.46 (s, 9H).
Step E: Preparation of 3-(2-Benzyloxy-5-chloro-3-fluoro-phenoxy)-azetidinePrepared from the title compound of Step D using general procedure 1. MS (ESI): mass calcd. for C16H15ClFNO2, 307.1; m/z found, 308.0 [M+H]+. 1H NMR (CDCl3): 7.47-7.41 (m, 2H), 7.37-7.30 (m, 3H), 6.76 (dd, J=9.9, 2.4 Hz, 1H), 6.34 (dd, J=2.1, 2.1 Hz, 1H), 5.06 (s, 2H), 4.97-4.86 (m, 1H), 4.05-3.63 (m, 4H), 2.27-2.00 (m, 1H).
Example 198 3-[5-Chloro-3-fluoro-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-azetidinePrepared according to Example 199 using 2-bromomethyl-5-trifluoromethyl-furan. MS (ESI): mass calcd. for C15H12ClF4NO3, 365.0; m/z found, 367.0 [M+H]+. 1H NMR (CDCl3): 6.78-6.72 (m, 2H), 6.42 (d, J=3.3 Hz, 1H), 6.36 (dd, J=2.1, 2.1 Hz, 1H), 5.04 (s, 2H), 4.98-4.85 (m, 1H), 4.05-3.69 (m, 4H), 2.20-1.99 (m, 1H).
Example 199 3-[5-Trifluoromethyl-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-azetidinePrepared according to Example 1 using 3-(2-hydroxy-5-trifluoromethyl-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester and 2-bromomethyl-5-trifluoromethyl-furan. MS (ESI): mass calcd. for C16H13F6N3O3, 381.1; m/z found, 382.0 [M+H]+. 1H NMR (CDCl3): 7.21 (dd, J=8.4, 1.2 Hz, 1H), 7.03 (d, J=8.4 Hz, 1H), 6.83 (d, J=2.0 Hz, 1H), 6.79-6.78 (m, 1H), 6.51 (d, J=3.1 Hz, 1H), 5.13 (s, 2H), 5.05-4.99 (m, 1H), 3.94-3.87 (m, 4H).
Example 200 3-[5-Trifluoromethyl-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidinePrepared according to Example 101 using 3-(2-hydroxy-5-trifluoromethyl-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester. MS (ESI): mass calcd. for C16H17F6NO2, 405.1; m/z found, 406.0 [M+H]+. 1H NMR (CDCl3): 7.70 (s, 1H), 7.56 (t, J=7.6 Hz, 2H), 7.47 (t, J=7.7 Hz, 1H), 7.08 (d, J=8.4 Hz, 1H), 6.83-6.80 (m, 2H), 5.41 (q, J=6.4 Hz, 1H), 5.07 (br s, 1H), 4.33-3.64 (m, 4H), 1.70 (d, J=6.5 Hz, 3H).
Example 201 3-[2-(1-Phenyl-ethoxy)-5-trifluoromethyl-phenoxy]-azetidine hydrochloridePrepared according to Example 1 using 3-(2-hydroxy-5-trifluoromethyl-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester and benzyl bromide. MS (ESI): mass calcd. for C17H16F3NO2, 323.1; m/z found, 324.1 [M+H]+. 1H NMR (DMSO-D6): 9.39 (s, 2H), 7.49-7.48 (m, 2H), 7.44-7.34 (m, 2H), 7.30 (d, J=8.5 Hz, 1H), 7.13 (d, J=1.9 Hz, 1H), 5.23 (s, 2H), 5.14-5.10 (m, 1H), 4.39-4.34 (m, 2H), 4.01-3.98 (m, 2H).
Example 202 3-[2-(3-Chloro-benzyloxy)-5-fluoro-phenoxy]-azetidine hydrochlorideA mixture of 5-fluorosalicyladehyde (5.0 g, 36 mmol), 3-chloro-benzyl bromide (7.34 g, 35.7 mmol), K2CO3 (6.0 g, 43 mmol) in DMF (50 mL) was heated at 65° C. for 18 h. The reaction mixture was cooled to rt and diluted with a mixture of EtOAc (500 mL) and H2O (300 mL). The organic phase was separated, washed with H2O (3×250 mL), and dried to give the title compound (9.4 g, 99%) that was used without further purification.
Step B: Preparation of 2-(3-Chloro-benzyloxy)-5-fluoro-phenolTo the title compound from Step A (9.4 g, 36 mmol) in CH2Cl2 (200 mL) was added 77% m-CPBA (12.0 g, 54.0 mmol). The mixture was allowed to stir for 36 h at rt and 10 wt % NaHSO3 (aq.) solution was added. After 48 h, the reaction mixture was washed with H2O (2×250 mL). The organic layer was dried and treated with 1N NaOH (100 mL) and MeOH (100 mL). After 48 h, the MeOH was removed and 1N H2SO4 was added slowly to adjust the pH to 1.5. The resulting solution was extracted with CH2Cl2 (3×150 mL). The combined extracts were washed with H2O and dried to give a red oil (8.4 g). Chromatography (SiO2. 0-20% EtOAc/hexane) gave the title compound (5.0 g, 56%). 1H NMR (CDCl3) 7.50-7.16 (m, 4H), 6.87-6.57 (m, 2H), 6.50 (t, J=8.6, 3.0 Hz, 1H), 5.80 (s, 1H), 5.05-4.89 (m, 2H).
Step C: Preparation of 3-[2-(3-Chloro-benzyloxy)-5-fluoro-phenoxy]-azetidine-1-carboxylic acid tert-butyl esterTo the title compound of Step B (200 mg, 0.79 mmol) in DMF (5.0 mL) was added 60 wt % NaH (34.3 mg, 0.86 mmol). The mixture was heated to 50° C. for 1 h then cooled to rt and 3-methanesulfonyloxy-azetidine-1-carboxylic acid tert-butyl ester (Example 90 Step A, 229 mg, 0.91 mmol) in DMF was added. This mixture was heated to 80° C. for 18 h, cooled to rt and treated with EtOAc (50 mL) and H2O (100 mL). The organic layer was separated, washed with H2O (2×50 mL) and dried to give a solid (400 mg). This solid was purified on RP HPLC to yield the title compound (90 mg, 28%). 1H NMR (CDCl3) 7.44 (s, 1H), 7.36-7.23 (m, 3H), 6.86 (dd, J=8.9, 5.4 Hz, 1H), 6.60 (dd, J=8.0, 2.9 Hz, 1H), 6.33 (dd, J=9.6, 2.9 Hz, 1H), 5.03 (s, 2H), 4.90-4.80 (m, 1H), 4.33-4.22 (m, 2H), 4.07-4.02 (m, 2H), 1.54-1.28 (m, 9H).
Step D: Preparation of 3-[2-(3-Chloro-benzyloxy)-5-fluoro-phenoxy]-azetidine hydrochlorideThe title compound from step C (85 mg) was dissolved in MeOH (5 mL) and 4M HCl in dioxane (3 mL) was added. The mixture was stirred at rt for 18 h. The reaction was concentrated and dried under vacuum to yield the title compound (75 mg). MS (ESI): mass calcd. for C16H15ClFNO2, 307.8; m/z found, 310.2 [M+H]+. 1H NMR (MeOD): 7.46 (s, 1H), 7.37-7.28 (m, 3H), 7.04 (dd, J=9.0 Hz, 5.3, 1H), 6.75-6.61 (m, 2H), 5.09-5.00 (m, 3H), 4.42 (dd, J=12.7, 6.6 Hz, 2H), 4.14 (dd, J=12.7, 4.9 Hz, 2H).
Example 203 3-[2-(3-Chloro-benzyloxy)-5-fluoro-phenoxy]-1-methyl-azetidinePrepared according to general procedure 5 using the title compound from Example 202. MS (ESI): mass calcd. for C17H17ClFNO2, 321.8; m/z found, 322.2 [M+H]+. 1H NMR (CDCl3): 7.47-7.39 (m, 1H), 7.31-7.25 (m, 3H), 6.81 (dd, J=8.9, 5.5 Hz, 1H), 6.56-6.52 (m, 1H), 6.38 (dd, J=9.9, 2.9 Hz, 1H), 5.02 (s, 2H), 4.72-4.67 (m, 1H), 3.87-3.78 (m, 2H), 3.17-3.08 (m, 2H), 2.40 (s, 3H).
Example 204 3-[2-(3-Chloro-benzyloxy)-5-fluoro-phenoxy]-1-isopropyl-azetidinePrepared according to general procedure 3 or 4 using the title compound from Example 202. MS (ESI): mass calcd. for C19H21ClFNO2, 349.8; m/z found, 350.2 [M+H]+. 1H NMR (CDCl3): 7.44 (s, 1H), 7.29-7.26 (m, 3H), 6.81 (dd, J=8.9, 5.5 Hz, 1H), 6.54-6.52 (m, 1H), 6.41 (dd, J=9.9, 2.9, 1H), 5.01 (s, 2H), 4.73-4.68 (m, 1H), 3.85-3.77 (m, 2H), 3.11-3.04 (m, 2H), 2.43-2.36 (m, 1H), 0.95 (d, J=6.2 Hz, 6H).
Example 205 3-[2-(3-Chloro-benzyloxy)-5-fluoro-phenoxy]-1-cyclobutyl-azetidinePrepared according to general procedure 3 or 4 using the title compound from Example 202. MS (ESI): mass calcd. for C20H21ClFNO2, 361.8; m/z found, 362.2 [M+H]+. 1H NMR (CDCl3): 7.44 (s, 1H), 7.32-7.22 (m, 3H), 6.82 (dd, J=8.9, 5.5 Hz, 1H), 6.57-6.53 (m, 1H), 6.41 (dd, J=9.8, 2.9 Hz, 1H), 5.02 (s, 2H), 4.77-4.72 (m, 1H), 3.77-3.69 (m, 2H), 3.23-3.12 (m, 3H), 2.01-1.95 (m, 2H), 1.87-1.62 (m, 4H).
Example 206 3-[2-(3-Chloro-benzyloxy)-5-fluoro-phenoxy]-1-propyl-azetidinePrepared according to general procedure 3 or 4 using the title compound from Example 202. MS (ESI): mass calcd. for C19H21ClFNO2, 349.8; m/z found, 350.2 [M+H]+. 1H NMR (CDCl3): 7.46 (s, 1H), 7.30 (m, 3H), 6.83 (dd, J=8.9, 5.5 Hz, 1H), 6.59-6.51 (m, 1H), 6.42 (dd, J=9.9, 2.9 Hz, 1H), 5.04 (s, 2H), 4.78-4.73 (m, 1H), 3.8-3.80 (m, 2H), 3.13-3.05 (m, 2H), 2.52-2.44 (m, 2H), 1.45-1.34 (m, 2H), 0.91 (t, J=7.4 Hz, 3H).
Example 207 3-[2-(3-Chloro-benzyloxy)-5-fluoro-phenoxy]-1-ethyl-azetidinePrepared according to general procedure 3 or 4 using the title compound from Example 202. MS (ESI) mass calcd. for C18H19ClFNO2, 335.8; m/z found, 338.2 [M+H]+. 1H NMR (CDCl3) 7.47 (s, 1H), 7.32-7.28 (m, 3H), 6.84 (dd, J=8.9, 5.5 Hz, 1H), 6.59-6.55 (m, 1H), 6.43 (dd, J=9.8, 2.9 Hz, 1H), 5.04 (s, 2H), 4.79-4.74 (m, 1H), 3.87-3.80 (m, 2H), 3.15-3.06 (m, 2H), 2.59-2.54 (m, 2H), 1.01 (dd, J=8.8, 5.6 Hz, 3H).
Example 208 3-[5-Fluoro-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-azetidinePrepared according top Example 202 using 2-bromomethyl-5-trifluoromethyl-furan. MS (ESI): mass calcd. for C15H13F4NO3, 331.26; m/z found, 332.2 [M+H]+. 1H NMR (CDCl3): 6.91 (dd, J=8.9, 5.5 Hz, 1H), 6.77 (d, J=2.3, 1H), 6.66-6.53 (m, 1H), 6.49-6.29 (m, 2H), 5.04 (s, 2H), 5.00-4.92 (m, 1H), 3.98-3.94 (m, 4H), 2.44 (s br, 1H).
Example 209 3-[5-Fluoro-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-1-isopropyl-azetidinePrepared according to general procedure 3 or 4 using the title compound from Example 208. MS (ESI): mass calcd. for C18H19F4NO3, 373.3; m/z found, 374.1 [M+H]+. 1H NMR (CDCl3): 6.89 (dd, J=8.9, 5.5 Hz, 1H), 6.77-6.75 (m, 1H), 6.63-6.51 (m, 1H), 6.44-6.41 (m, 2H), 5.01 (s, 2H), 4.78-4.58 (m, 1H), 3.83 (dd, J=8.8, 6.0 Hz, 2H), 3.09 (dd, J=8.8, 6.0 Hz, 2H), 2.47-2.31 (m, 1H), 0.97 (d, J=6.2 Hz, 6H).
Example 210 3-[2-(3-Chloro-benzyloxy)-5-thiophen-3-yl-phenoxy]-azetidine3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-azetidine-1-carboxylic acid tert-butyl ester (188 mg, 0.4 mmol), 3-thiophene boronic acid (53 mg, 0.41 mmol), Q-Phos (23 mg, 0.032 mmol), Pd(dba)2 (9.2 mg, 0.016 mmol) and K3PO4 (255 mg, 1.2 mmol) were taken into toluene (3 mL) and heated at 80° C. After the reaction was complete it was cooled to rt, diluted with CH2Cl2 (20 mL), filtered, washed with H2O (2×25 mL) and concentrated to give 3-[2-(3-chloro-benzyloxy)-5-thiophen-3-yl-phenoxy]-azetidine-1-carboxylic acid tert-butyl ester. To this compound was added MeOH (10 mL) followed by 4M HCl in dioxane (4 mL). After 4 h the reaction was concentrated and purified on RP HPLC (basic) to yield the title compound (12 mg). MS (ESI): mass calcd. for C20H18ClNO2S, 371.9; m/z found, 372.2 [M+H]+. 1H NMR (CDCl3): 10.30-9.57 (m, 1H), 7.43 (s, 1H), 7.40-7.28 (m, 6H), 7.24 (dd, J=8.4, 2.1 Hz, 1H), 7.01 (d, J=2.1 Hz, 1H), 6.96 (d, J=8.5 Hz, 1H), 5.24-4.99 (m, 3H), 4.40-4.11 (m, 4H).
Example 211 3-(Azetidin-3-yloxy)-4-(3-chloro-benzyloxy)-N,N-dimethyl-benzamideA suspension of 3-[5-bromo-2-(3-chloro-benzyloxy)-phenoxy]-azetidine-1-carboxylic acid tert-butyl ester (94 mg, 0.2 mmol), Na2CO3 (53 mg, 0.5 mmol), 40% Me2NH in H2O (0.17 mmol), Hermann's catalyst (8 mg, 0.008 mmol) and Mo(CO)6 (22 mg, 0.083 mmol) in H2O (2 mL) was heated to 170° C. in a microwave reactor for 10 min. The reaction was cooled rt, and saturated NaHCO3 (aq.) was added. This solution was extracted with CH2Cl2 (3×). The combined organic layers were concentrated to give a solid (30 mg) that was dissolved in MeOH (2 mL) and treated with 4M HCl in dioxane (1 mL). After 3 h, the mixture was concentrated to give a residue that was purified on RP HPLC providing the title compound (5 mg). MS (ESI): mass calcd. for C16H21ClN2O3, 360.8; m/z found, 361.5 [M+H]+. 1H NMR (CDCl3): 7.45 (s, 1H), 7.29-7.27 (m, 3H), 6.96 (dd, J=8.2, 1.9 Hz, 1H), 6.87 (d, J=8.3 Hz, 1H), 6.72 (d, J=1.9 Hz, 1H), 5.11 (s, 2H), 5.05-4.95 (m, 1H), 3.92-3.85 (m, 4H), 3.00 (s br, 6H).
Example 212 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-3-methyl-azetidineTo 1-benzhydryl-azetidin-3-one (1.0 g, 4.2 mmol) in ether (100 mL) at 0° C. was added CH3MgBr (1.5 mL, 3M in ether). The mixture was warmed to rt over 1 h and 1N NaOH (3 mL) was added. The organic layer was concentrated providing the title compound (1.1 g). MS (ESI): mass calcd. for C17H16N0, 253.2; m/z found, 254.2 [M+H]+. 1H NMR (CDCl3): 7.42-7.11 (m, 10H), 4.32 (s, 1H), 3.14 (d, J=8.5 Hz, 2H), 2.96 (d, J=8.5 Hz, 2H), 1.43 (s, 3H).
Step B: Preparation of 1-benzhydryl-3-[5-bromo-2-(3-chloro-benzyloxy)-phenoxy]-3-methyl-azetidineThe mixture of the title compound from Step A (0.5 mmol), 5-bromo-2-(3-chloro-benzyloxy)-phenol (0.5 mmol), and cyanomethylenetri-n-butylphosphorane (0.5 mmol) in toluene (3 mL) was heated at 150° C. in a microwave reactor for 1 h. The mixture was cooled to rt and purified via PTLC providing the title compound (120 mg). MS (ESI): mass calcd. for C30H27BrClNO2, 547.1; m/z found, 548.0 [M+H]+.
Step C: Preparation of 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-3-methyl-azetidineThe title compound from Step B (60 mg) was dissolved in DCE (10 mL) and chloroethylformate (0.2 mmol) was added. The mixture was heated at 80-100° C. for 1 h and concentrated. The residue was dissolved in MeOH (3 mL) and heated at 150° C. in a microwave reactor for another 1 h. The mixture was cooled to rt and purified via PTLC providing the title compound (30 mg). MS (ESI): mass calcd. for C17H17BrClNO2, 381.0; m/z found, 382.0 [M+H]+. 1H NMR (CDCl3): 7.43-7.23 (m, 4H), 7.12-7.06 (m, 1H), 6.86-6.78 (m, 2H), 5.12 (s, 2H), 4.24-4.16 (m, 2H), 3.78-3.67 (m, 2H), 1.67 (s, 3H).
Example 213 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-3-ethyl-azetidinePrepared according to Example 212 using the ethylmagnesium bromide in Step A. MS (ESI): mass calcd. for C18H19BrClNO2, 395.0; m/z found, 396.1 [M+H]+. 1H NMR (CDCl3): 7.41-7.25 (m, 4H), 7.15-7.05 (m, 1H), 6.84-6.73 (m, 2H), 5.13 (s, 2H), 4.26-4.19 (m, 2H), 3.85-3.74 (m, 2H), 2.19-2.00 (m, 2H), 1.00-0.90 (m, 3H).
Example 214 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-3-isopropyl-azetidinePrepared according to Example 212 using the isopropylmagnesium bromide in Step A. MS (ESI): mass calcd. for C19H21BrClNO2, 409.0; m/z found, 409.9 [M+H]+. 1H NMR (CDCl3): 7.43-7.23 (m, 4H), 7.14-6.78 (m, 3H), 5.13 (s, 2H), 3.98-3.85 (m, 2H), 3.48-3.33 (m, 2H), 1.45-1.36 (m, 1H), 0.63-0.50 (m, 6H).
Example 215 3-(5-Bromo-2-phenethyloxy-phenoxy)-3-methyl-azetidineA mixture of 4-bromo-2-fluorobenzaldehyde (10 g, 47 mmol), tert-butyl amine (6.1 mL, 57 mmol) and 4 Å powder molecular sieves (8.0 g) in 160 mL CH2Cl2 (160 mL) was stirred at rt for 18 h. The reaction mixture was filtered through a pad of celite and concentrated to give the title compound (9.9 g, 78%). MS (ESI): mass calcd. for C11H13BrFNO, 258.1; m/z found, 260.0 [M+H]+. 1H NMR (CDCl3): 10.32 (s, 1H), 8.48 (s, 1H), 7.89 (t, J=8.1 Hz, 1H), 7.50-7.20 (m, 1H), 1.49-1.08 (m, 9H).
Step B: Preparation of 3-hydroxy-3-methyl-azetidine-1-carboxylic acid tert-butyl esterA solution of 1-Boc-azetidin-3-one (3.5 g, 20 mmol) in 50 mL anh Et2O was cooled to 0° C. and 3M MeMgBr in Et2O (10 mL, 30 mmol) was added dropwise over 1 h. After 45 min, the reaction was allowed to warm to rt and stir an additional for 18 h. Then ½ sat'd NH4Cl (aq.) was added and the mixture extracted with EtOAc (2×). The combined organic layers were dried and the resulting semisolid was purified by RP HPLC (Agilent) to give the title compound as a white solid (3.2 g, 84%). 1H NMR (CDCl3): 3.84 (q, J=9.2 Hz, 4H), 1.97 (bs, 1H), 1.52 (s, 3H), 1.44 (m, 9H).
Step C: Preparation of 3-(5-Bromo-2-formyl-phenoxy)-3-methyl-azetidine-1-carboxylic acid tert-butyl esterTo a solution of the title compound from Step B (400 mg, 2.2 mmol) in DMSO (8 mL) was added 60% NaH (120 mg, 3.0 mmol). After 30 min, the title compound from Step A was added and the resulting mixture was heated at 125° C. for 1 h in a microwave reactor. An additional quantity of the title compound from Step B (100 mg) and 60% NaH (32 mg) were added to the reaction. Heating was then resumed at 125° C. for another 1 h in a microwave reactor. The reaction was diluted with H2O and extracted with EtOAc (3×) followed by methanolic EtOAc (2×). The organics were dried, then THF (5 mL), H2O (5 mL) and AcOH (3 mL) were added. After 18 h at rt, the reaction was diluted with H2O and extracted with CH2Cl2. The organics were dried and purified by PTLC to give the title compound as an off white solid (247 mg, 31%). 1H NMR (CDCl3): 10.36 (s, 1H), 7.74 (d, J=8.3 Hz, 1H), 7.22-7.20 (m, 1H), 6.68 (d, J=1.6 Hz, 1H), 4.25 (d, J=9.2 Hz, 2H), 4.03 (d, J=9.8 Hz, 2H), 1.55 (s, 3H), 1.46 (m, 9H).
Step D: Preparation of 3-(5-Bromo-2-hydroxy-phenoxy)-3-methyl-azetidine-1-carboxylic acid tert-butyl esterPrepared according to Example 1 Step C using the title compound from Step C. Purification was accomplished by PTLC to give the title compound as a peach solid (152 mg, 64%). 1H NMR (CDCl3): 7.02 (dd, J=8.5, 2.2 Hz, 1H), 6.84 (d, J=8.5 Hz, 1H), 6.63 (d, J=2.2 Hz, 1H), 4.22 (d, J=9.2 Hz, 2H), 3.98 (d, J=9.5 Hz, 2H), 3.49 (s, 1H), 1.69 (s, 3H), 1.46 (s, 9H).
Step E. Preparation of 3-(5-Bromo-2-phenethyloxy-phenoxy)-3-methyl-azetidine-1-carboxylic acid tert-butyl esterA mixture of 3-(5-bromo-2-hydroxy-phenoxy)-3-methyl-azetidine-1-carboxylic acid tert-butyl ester (30 mg. 0.08 mmol), (2-bromoethyl)benzene (29 μL, 0.21 mmol), KI (42 mg, 0.25 mmol) and Cs2CO3 (82 mg, 0.25 mmol) in 3 mL DMF was stirred at rt for 18 h. The reaction mixture was diluted with H2O and extracted with EtOAc (3×). The organic layers were dried and purified by RP HPLC (Agilent) to give the title compound as an oil (22 mg, 58%). MS (ESI): mass calcd. for C23H28BrNO4, 462.4; m/z found, 408.0 [M-56+H]+. 1H NMR (CDCl3): 7.38-7.18 (m, 5H), 7.07 (dd, J=8.6, 2.3 Hz, 1H), 6.76-6.74 (m, 2H), 4.24-4.08 (m, 4H), 3.84 (d, J=9.7 Hz, 2H), 3.11 (t, J=7.1 Hz, 2H), 1.58 (s, 3H), 1.45 (s, 9H).
Step F: Preparation of 3-(5-Bromo-2-phenethyloxy-phenoxy)-3-methyl-azetidineA mixture of 3-(5-bromo-2-phenethyloxy-phenoxy)-3-methyl-azetidine-1-carboxylic acid tert-butyl ester (20 mg) and TFA (1 mL) in CH2Cl2(2 mL) was stirred at rt for 2 h. The reaction was concentrated in vacuo and purified by PTLC followed by additional purification using RP HPLC (Agilent) to give the title compound as an oil (12 mg, 77%). MS (ESI): mass calcd. for C18H20BrNO2, 362.3; m/z found, 362.0 [M+H]+. 1H NMR (CDCl3): 7.38-7.18 (m, 5H), 7.04 (dd, J=8.6, 2.3 Hz, 1H), 6.74 (dd, J=5.5, 3.1, 2H), 4.15 (t, J=7.2 Hz, 2H), 3.97 (d, J=8.9 Hz, 2H), 3.45 (d, J=9.2 Hz, 2H), 3.11 (t, J=7.1 Hz, 2H), 1.98 (s, 1H), 1.65 (s, 3H).
The compounds in Examples 216-217 were prepared according to Example 215 using the appropriate alkyl halide in Step E.
Example 216 3-[5-Bromo-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C16H15BrF3NO3, 406.2; m/z found, 407.9 [M+H]+. 1H NMR (CDCl3): 7.05 (dd, J=8.6, 2.3 Hz, 1H), 6.83 (d, J=8.8 Hz, 1H), 6.76-6.75 (m, 2H), 6.45-6.44 (m, 1H), 5.02 (s, 2H), 4.00 (d, J=9.0 Hz, 2H), 3.59-3.43 (m, 2H), 2.35 (br s, 1H), 1.67 (s, 3H).
Example 217 3-[5-Bromo-2-(3-trifluoromethyl-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C18H17BrF3NO2, 416.2; m/z found, 416.0 [M+H]+. 1H NMR (CDCl3): 7.72 (bs, 1H), 7.59-7.57 (m, 2H), 7.51-7.46 (m, 2H), 7.03 (dd, J=8.6, 2.3 Hz, 1H), 6.79 (d, J=8.4 Hz, 1H), 6.74 (d, J=2.4 Hz, 1H), 5.11 (s, 2H), 4.03 (br s, 2H), 3.54 (bs, 2H), 1.71 (s, 3H).
Example 218 3-(5-Bromo-2-phenoxy-phenoxy)-3-methyl-azetidinePrepared according to general procedure 6 using the title compound of Example 215 Step D. MS (ESI): mass calcd. for C16H16BrNO2, 334.2; m/z found, 334.0 [M+H]+. 1H NMR (CDCl3): 7.34-7.24 (m, 2H), 7.08-7.04 (m, 2H), 6.94-6.86 (m, 3H), 6.80 (d, J=2.3, 1H), 3.88 (d, J=8.3 Hz, 2H), 3.46 (d, J=8.7 Hz, 2H), 1.85 (br s, 1H), 1.65 (s, 3H).
Example 219 (±)-trans-3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-2-methyl-azetidineSee Shimizu et al., Organic Process & Research Development, 2005, Vol 9(3), pp. 278-287. To a stirred solution of crotyl bromide (10 g, 63 mmol) in CH2Cl2 (200 mL) was slowly added 77% m-CPBA (19.8 g, 88 mmol) portionwise over 45 min. After stirring at rt for 18 h, the solids were removed by filtration. The filtrate was treated with aqueous 10% aq. NaHSO3 (150 mL) and stirred at rt for 5 h. The organic layer was separated, washed with sat'd NaHCO3 (3×), brine (2×) and dried to give the title compound as a colorless oil (6.6 g, 70%). 1H NMR (CDCl3): 3.43-3.39 (m, 1H), 3.35-3.18 (m, 1H), 3.04-2.89 (m, 2H), 1.35 (d, J=5.2 Hz, 3H).
Step B. Preparation of cis and trans 1-benzhydryl-2-methyl-azetidin-3-olSee PCT pat appl. WO 01/01988. A mixture of 2-bromomethyl-3-methyl-oxirane (3.6 g, 23.8 mmol) and aminodiphenylmethane (4.1 mL, 23.8 mmol) in 12 mL MeOH was stirred at rt for 72 h. Next, the reaction was heated at reflux for 72 h. After cooling to rt, the reaction was purified by reverse phase basic HPLC (Agilent) to give the cis and trans isomers of the title compound. Trans isomer as an oil (424 mg), 1H NMR (CDCl3): 7.44-7.35 (m, 4H), 7.28-7.12 (m, 7H), 4.34 (s, 1H), 3.93-3.90 (m, 1H), 3.67-3.64 (m, 1H), 3.03-2.99 (m, 1H), 2.57-2.55 (m, 1H), 0.75 (d, J=6.1, 3H). Cis isomer as an off white solid (914 mg), 1H NMR (CDCl3): 7.42-7.36 (m, 4H), 7.28-7.22 (m, 4H), 7.18-7.16 (m, 2H), 4.37 (s, 1H), 4.30-4.27 (m, 1H), 3.46-3.42 (m, 1H), 3.26-3.24 (m, 1H), 3.06-3.04 (m, 1H), 0.74 (d, J=6.5 Hz, 3H).
Step C. Preparation of (±)-trans-1-3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-2-methyl-azetidinePrepared according to Example 212 Steps B-C using the trans-isomer from Step B. MS (ESI): mass calcd. for C17H17BrFNO2, 365.0; m/z found, 366.1 [M+H]+. 1H NMR (MeOD): 7.43-6.95 (m, 7H), 5.12 (s, 2H), 4.68-4.62 (m, 1H), 4.32-4.25 (m, 1H), 3.98-3.92 (m, 1H), 3.75-3.68 (m, 1H), 1.44 (d, J=6.7 Hz, 3H).
Example 220: cis-1-Benzyl-3-[5-bromo-2-(3-fluoro-benzyloxy)-phenoxy]-2-methyl-azetidine
Prepared from cis-(±)-1-benzyl-2-methyl-azetidin-3-ol according to Example 219. MS (ESI): mass calcd. for C24H23BrFNO2, 455.1; m/z found, 456.0 [M+H]+. 1H NMR (CDCl3): 7.39-6.94 (m, 11H), 6.78-6.69 (m, 2H), 5.08 (s, 2H), 4.78-4.72 (m, 1H), 3.76-3.62 (m, 3H), 3.54-3.48 (m, 1H), 3.34-3.26 (m, 1H), 1.20 (d, J=6.4 Hz. 3H).
Example 221 trans-1-Benzyl-3-[5-bromo-2-(3-fluoro-benzyloxy)-phenoxy]-2-methyl-azetidinePrepared from trans-(±)-1-benzyl-2-methyl-azetidin-3-ol according to Example 219. MS (ESI): mass calcd. for C24H23BrFNO2, 455.1; m/z found, 456.0 [M+H]+. 1H NMR (CDCl3): 7.38-7.22 (m, 5H), 7.17-7.16 (m, 2H), 7.05-6.96 (m, 2H), 6.84 (d, J=2.2 Hz, 1H), 6.74 (d, J=8.6 Hz, 1H), 5.07 (s, 2H), 4.33 (q, J=6.0 Hz, 1H), 3.82-3.80 (m, 2H), 3.57 (d, J=6.9 Hz, 1H), 3.41-3.39 (m, 1H), 2.87 (t, J=7.0 Hz, 1H), 1.21 (d, J=6.2 Hz, 3H).
Example 222 3-[5-Chloro-2-(1-phenyl-azetidin-3-ol)-phenoxy]-azetidineThe mixture of azetidin-3-ol (2 mmol), bromobenzene (2 mmol), Pd(OAc)2 (0.1 mmol), 2-(di-tert-butylphosphino)biphenyl (0.2 mmol) and NaOtBu (3 mmol) in toluene (3 mL) was heated at 100° C. for 1 h. The mixture was cooled to rt and purified via PTLC providing the title compound (15 mg).
Step B: Preparation of 3-[5-Chloro-2-(1-phenyl-azetidin-3-ol)-phenoxy]-azetidineThe mixture of the title compound of Step A (15 mg), 3-(5-chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (0.2 mmol) and cyanomethylenetri-n-butylphosphorane (0.2 mmol) in toluene (2 mL) was heated at 120° C. in a microwave reactor for 1 h. The mixture was cooled to rt and purified via PTLC providing the title compound (20 mg). This compound was dissolved in CH2Cl2 (5 mL) and TFA (1 mL) was added. The mixture was stirred at rt for 4 h and concentrated to provide the title compound (25 mg). MS (ESI): mass calcd. for C18H19ClN2O2, 330.1; m/z found, 331.1 [M+H]+. 1H NMR (MeOD): 7.26-6.58 (m, 8H), 5.20-5.05 (m, 2H), 4.55-4.45 (m, 2H), 4.37-4.28 (m, 2H), 4.25-4.16 (m, 2H), 3.88-3.85 (m, 2H).
Examples 223-225 were prepared similar to Example 222 using the appropriately substituted hydroxyazetidine.
Example 223 (±)-3-[5-Chloro-2-(trans-1-benzyl-2-methyl-azetidin-3-ol)-phenoxy]-azetidinePrepared from trans-(±)-1-benzyl-2-methyl-azetidin-3-ol. MS (ESI): mass calcd. for C20H23ClN2O2, 358.1; m/z found, 359.1 [M+H]+. 1H NMR (MeOD): 7.61-7.43 (m, 5H), 7.03-6.87 (m, 3H), 5.23-5.16 (m, 1H), 4.88-4.78 (m, 1H), 4.76-4.65 (m, 1H), 4.63-4.45 (m, 5H), 4.29-4.19 (m, 2H), 4.18-4.09 (m, 1H), 1.40 (d, J=6.7 Hz, 3H).
Example 224 3-[5-Chloro-2-(1-Isopropyl-azetidin-3-ol)-phenoxy]-azetidinePrepared from 1-isopropyl-azetidin-3-ol. MS (ESI): mass calcd. for C15H21ClN2O2, 296.1; m/z found, 297.0 [M+H]+. 1H NMR (MeOD): 7.70 (dd, J=8.7, 2.5 Hz, 1H), 6.78-6.67 (m, 2H), 5.04-4.97 (m, 1H), 4.76-4.67 (m, 1H), 3.98-3.92 (m, 2H), 3.80-3.67 (m, 4H), 3.34-3.26 (m, 2H), 2.53-2.46 (m, 1H), 0.98 (d, J=6.3 Hz, 6H).
Example 225 3-[5-Chloro-2(1-benzhydryl-azetidin-3-ol)-phenoxy]-azetidinePrepared from 1-benzhydryl-azetidin-3-ol. MS (ESI): mass calcd. for C25H25ClN2O2, 420.2; m/z found, 421.0 [M+H]+. 1H NMR (MeOD): 7.58-7.39 (m, 10H), 7.02-6.81 (m, 3H), 5.81 (s, 1H), 5.19-5.10 (m, 2H), 4.67-4.50 (m, 4H), 4.39-4.31 (m, 2H), 4.23-4.16 (m, 2H).
Example 226 3-[5-Chloro-2-(1-azetidin-3-ol)-phenoxy]-azetidinePrepared according to the procedure of Example 222 Step B using 3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester. MS (ESI): mass calcd. for C12H15ClN2O2, 254.1; m/z found, 255.1 [M+H]+. 1H NMR (MeOD): 7.00 (dd, J=8.6, 2.4 Hz, 1H). 6.91 (d, J=2.4 Hz, 1H), 6.83 (d, J=8.6 Hz, 1H), 5.22-5.11 (m, 2H), 4.62-4.53 (m, 4H), 4.31-4.22 (m, 4H).
Example 227 3-[5-Chloro-2-(1-Isopropyl-azetidin-3-ol)-phenoxy]-1-isopropyl-azetidineTo the title compound of Step 226 (100 mg) in CH2Cl2 (50 mL) was added acetone (100 μL) and NaBH3CN (1 mL, 1M in CH2Cl2). The mixture was stirred at rt for 16 h. Then, NaOH solution (2 mL, 1M in H2O) was added. After 1 h, the organic layer was separated and concentrated. PTLC provided the title compound (20 mg). MS (ESI): mass calcd. for C18H27ClN2O2, 338.2; m/z found, 339.3 [M+H]+. 1H NMR (CDCl3): 6.85 (dd, J=8.6, 2.4 Hz, 1H). 6.63 (d, J=2.4 Hz, 1H), 6.58 (d, J=8.6 Hz, 1H), 4.83-4.67 (m, 2H), 3.96-3.76 (m, 4H), 3.26-3.05 (m, 4H), 2.47-2.38 (m, 2H), 1.00 (d, J=6.1 Hz, 12H).
Example 228 3-[5-Chloro-2-(3-phenyl-cyclobutoxy)-phenoxy]-azetidineTo the solution of 3-phenyl-cyclobutanone (100 mg) in THF (10 mL) was added LiAlH4 (0.2 mL, 2M in THF). The mixture was stirred at rt for 2 h, then 2M NaOH (1 mL) was added. The organic layer was concentrated and purified by PTLC providing the title compound (80 mg).
Step B: Preparation of 3-[5-Chloro-2-(3-phenyl-cyclobutoxy)-phenoxy]-azetidineThe mixture of the title compound of Step A (80 mg), 3-(5-chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (200 mg) and cyanomethylenetri-n-butylphosphorane (1.0 mmol) in toluene (2 mL) was heated at 120° C. in a microwave reactor for 1 h. The mixture was cooled to rt and purified via PTLC providing 3-[5-chloro-2-(3-phenyl-cyclobutoxy)-phenoxy]-azetidine-1-carboxylic acid tert-butyl ester (120 mg). The ester was re-dissolved into CH2Cl2 (10 mL), and TFA (2 mL) was added. The mixture was stirred at rt for 4 h then concentrated to give the title compound (168 mg). MS (ESI): mass calcd. for C19H20ClNO2, 329.1; m/z found, 330.1 [M+H]+. 1H NMR (MeOD): 7.26-6.64 (m, 8H), 5.30-5.15 (m, 2H), 4.95-4.83 (m, 2H), 4.60-4.52 (m, 1H), 3.78-3.65 (m, 1H), 2.68-2.58 (m, 4H).
Example 229 3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-1-tert-butyl-azetidineTo a solution of tert-butylamine (10 mmol) in isopropylalcohol (20 mL) was added dropwise epichlorohydrine (10 mmol). The mixture was stirred at 25° C. for 16 h. After concentration, the residue was re-dissolved in acetonitrile (20 mL) and triethylamine (20 mmol) was added. The mixture was heated at 100° C. for 24 h, cooled to rt and filtered. The filtrate was concentrated providing 1-tert-butyl-azetidin-3-ol (1.1 g). MS (ESI): mass calcd. for C7H15N0, 129.1; m/z found, 130.1 [M+H]+. 1H NMR (CDCl3): 6.15-5.70 (br s, 1H), 4.84-4.72 (m, 1H), 4.24-4.12 (m, 2H), 4.03-3.87 (m, 2H), 1.37 (s, 9H).
Step B: Preparation of 3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-1-tert-butyl-azetidineTo a solution of the title compound of Step A (3 mmol), and triethylamine (6 mmol) in CH2Cl2 (50 mL), was added MeSO3C1 (4 mmol). The mixture was stirred at 25° C. for 16 h. After concentration, ⅓ of the residue was dissolved in MeCN (20 mL). Next, 5-bromo-2-(3-fluoro-benzyloxy)-phenol (0.5 mmol) and K2CO3 (2 mmol) were added. The mixture was stirred at 100° C. for 16 h, concentrated and purified via PTLC providing the title compound (189 mg). MS (ESI): mass calcd. for C20H23BrFNO2, 407.1; m/z found, 408.0 [M+H]+. 1H NMR (CDCl3): 7.37-7.28 (m, 1H), 7.19-7.12 (m, 2H), 7.04-6.95 (m, 2H), 6.84-6.63 (m, 2H), 5.08 (s, 2H), 4.78-4.48 (m, 1H), 3.68-3.62 (m, 2H), 3.35-3.26 (m, 2H), 1.00 (s, 9H).
Example 230-231 was prepared by the procedure of Example 229 using the appropriately substituted phenols.
Example 230 1-tert-Butyl-3-[5-chloro-2-(3-trifluoromethyl-benzyloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C21H23ClF3NO2, 413.1; m/z found, 413.9 [M+H]+. 1H NMR (CDCl3): 7.75-7.46 (m, 4H), 6.90-6.65 (m, 3H), 5.12 (s, 2H), 4.80-4.71 (m, 1H), 3.71-3.62 (m, 2H), 3.35-3.26 (m, 2H), 0.99 (s, 9H).
Example 231 1-tert-Butyl-3-[5-chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-azetidineMS (ESI): mass calcd. for C22H25ClF3NO2, 427.2; m/z found, 428.3 [M+H]+. 1H NMR (CDCl3): 7.68-7.42 (m, 4H), 6.78-6.62 (m, 3H), 5.32-5.23 (m, 1H), 4.78-4.68 (m, 1H), 3.70-3.62 (m, 2H), 3.33-3.25 (m, 2H), 1.65 (d, J=6.4 Hz, 3H), 0.99 (s, 9H).
Example 232 3-[5-Bromo-2-(5-trifluoromethyl-furan-2-ylmethoxy)-benzyl]-azetidineTo a solution of azetidine-1,3-dicarboxylic acid mono-tert-butyl ester (3.5 g, 17 mmol) in DMF (50 mL) was added O,N-dimethyl-hydroxylamine hydrochloride (3.4 g, 34 mmol), triethylamine (9.6 mL, 69 mmol), HATU (13.4 g, 34.6 mmol) and DCM (125 mL). After stirring for 16 h, saturated NaHCO3 solution and ethyl acetate were added. The aqueous portion was extracted three times with ethyl acetate. The combined organic fractions were dried (Na2SO4) and concentrated and the crude product was purified using RP HPLC (basic conditions) to provide the title compound (3.5 g, 83%) MS (ESI): mass calcd. for C11H20N2O4, 244.1; m/z found, 189.1 [M-t-Bu]+. 1H NMR (CDCl3): 4.14-4.03 (m, 2H), 4.05 (t, J=8.7 Hz, 2H), 3.66 (s, 3H), 3.63-3.59 (m, 1H), 3.21 (s, 1H), 1.43 (s, 9H).
Step B: Preparation of 3-(2-Methoxy-benzoyl)-azetidine-1-carboxylic acid tert-butyl esterTo a solution of 3-(methoxy-methyl-carbamoyl)-azetidine-1-carboxylic acid tert-butyl ester (3.48 g, 14.2 mmol) in dry ether (150 mL) at 0° C. was added 2-methoxylphenylmagnesium bromide (1.0 M in THF, 17 mL, 17 mmol). The reaction was allowed to slowly warm to rt and stirred for 36 h. Then a solution of 1M KHSO4 and EtOAc were added and the aqueous portion was extracted once with EtOAc. The combined organic fractions were dried (Na2SO4) and concentrated to provide the title compound. This material was used in subsequent reactions without additional purifications. MS (ESI): mass calcd. for C16H21NO4, 291.1; m/z found, 236.1 [M-t-Bu]+. 1H NMR (CDCl3): 7.83 (dd, J=7.8, 1.8 Hz, 1H), 7.51 (ddd, J=8.5, 7.3, 1.8 Hz, 1H), 7.06-6.95 (m, 2H), 4.13-4.03 (m, 5H), 3.90 (s, 3H), 1.44 (s, 9H).
Step C: Preparation of 3-(2-Methoxy-benzyl)-azetidine-1-carboxylic acid tert-butyl esterTo a solution of 3-(2-methoxy-benzoyl)-azetidine-1-carboxylic acid tert-butyl ester (2.1 g, 7.2 mmol) in methanol (50 mL) was added sodium borohydride (1.08 g, 28.8 mmol). After stirring for 36 h, saturated sodium bicarbonate solution and EtOAc were added. The aqueous portion was extracted three times with EtOAc and the combined organic were dried (Na2SO4) and concentrated. To a solution of this material in ethanol (50 mL) was added 10% Pd/C. This reaction was then placed on a Parr hydrogenation apparatus with 60 psi of hydrogen gas. After 72 h, the reaction mixture was filtered through a pad of Celite and the filtrate concentrated. The crude product was purified by RP HPLC (basic conditions) to provide the title compound (370 mg, 19%). MS (ESI): mass calcd. for C16H23NO3, 277.2; m/z found, 222.2 [M-t-Bu]+. 1H NMR (CDCl3): 7.23-7.10 (m, 1H), 7.06 (d, J=7.3 Hz, 1H), 6.92-6.77 (m, 2H), 3.96 (t, J=8.0 Hz, 2H), 3.81 (s, 3H), 3.65-3.63 (m, 2H), 2.94-2.78 (m, 5H), 1.44 (s, 9H).
Step D: Preparation of 2,2,2-Trifluoro-1-[3-(2-methoxy-benzyl)-azetidin-1-yl]-ethanoneTo a solution of 3-(2-methoxy-benzyl)-azetidine-1-carboxylic acid tert-butyl ester (370 mg, 1.3 mmol) in DCM (10 mL) was added TFA (3 mL). After stirring for 16 h, TLC analysis indicated complete consumption of the starting material. To quench the reaction, saturated NaHCO3 solution and EtOAc were added. The aqueous portion was extracted twice with EtOAc and the combined organic extracts were dried (Na2SO4) and concentrated. To a solution of this material in DCM (20 mL) was added triethylamine (370 μL, 2.60 mmol) followed by trifluoroacetic anhydride (204 μL, 1.50 mmol). After 1 h, saturated NaHCO3 solution and EtOAc were added. The aqueous portion was extracted twice with EtOAc and the combined organic extracts were dried (Na2SO4) and concentrated to provide the title compound (274 mg, 75%). MS (ESI): mass calcd. for C13H14F3NO2, 273.1; m/z found, 274.2 [M+H]+. 1H NMR (CDCl3): 7.26-7.20 (m, 1H), 7.07 (dd, J=7.4, 1.6 Hz, 1H), 6.94-6.82 (m, 2H), 4.41 (dd, J=9.6, 8.4 Hz, 1H), 4.23-4.14 (m, 1H), 4.12-4.08 (m, 1H), 3.93-3.84 (m, 1H), 3.82 (s, 3H), 3.18-3.00 (m, 1H), 2.95-2.91 (m, 2H).
Step E: Preparation of 1-[3-(5-Bromo-2-methoxy-benzyl)-azetidin-1-yl]-2,2,2-trifluoro-ethanoneTo a solution of 2,2,2-trifluoro-1-[3-(2-methoxy-benzyl)-azetidin-1-yl]-ethanone (95 mg, 0.35 mmol) in acetone (2 mL) and water (2 mL) was added NaBr (143 mg, 1.40 mmol) followed by Oxone (210 mg, 0.35 mmol). After 5 h, 10% sodium metabisulfite solution was added. After 1 h, EtOAc was added and the aqueous portion extracted twice with EtOAc. The combined organics were dried (Na2SO4) and concentrated. The crude product was purified by RP HPLC (basic conditions) to provide the title compound (66 mg, 53%). MS (ESI): mass calcd. for C13H13BrF3NO2, 352.1; m/z found, 354.1 [M+H]+. 1H NMR (CDCl3): 7.32 (dd, J=8.7, 2.5 Hz, 1H), 7.17 (d, J=2.5 Hz, 1H), 6.75 (t, J=10.2 Hz, 1H), 4.43 (dd, J=9.6, 8.4 Hz, 1H), 4.26-4.14 (m, 1H), 4.09 (dd, J=9.6, 5.7 Hz, 1H), 3.89 (dd, J=10.7, 5.7 Hz, 1H), 3.81 (s, 3H), 3.14-2.96 (m, 1H), 2.90 (d, J=7.8 Hz, 2H).
Step F: Preparation of 1-[3-(5-Bromo-2-hydroxy-benzyl)-azetidin-1-yl]-2,2,2-trifluoro-ethanoneTo a solution of 1-[3-(5-bromo-2-methoxy-benzyl)-azetidin-1-yl]-2,2,2-trifluoro-ethanone (66 mg, 0.19 mmol) in dry DCM (10 mL) at 0° C. was added BBr3 (1.0 M in DCM, 370 mL, 0.37 mmol). After warming to rt overnight, saturated NaHCO3 solution and EtOAc were added. The aqueous portion was extracted twice with EtOAc and the combined organic extracts were dried (Na2SO4) and concentrated to provide the title compound (59 mg, 92%). MS (ESI): mass calcd. for C12H11BrF3NO2, 337.0; m/z found, 338.0 [M+H]+. 1H NMR (CDCl3): 7.23-7.10 (m, 2H), 6.70 (t, J=8.7 Hz, 1H), 4.53-4.40 (m, 1H), 4.27-4.11 (m, 2H), 3.97 (dd, J=10.7, 6.0 Hz, 1H), 3.17-3.01 (m, 1H), 3.01-2.78 (m, 2H).
Step G: Preparation of 1-{3-[5-Bromo-2-(5-trifluoromethyl-furan-2-ylmethoxy)-benzyl]-azetidin-1-yl}-2,2,2-trifluoro-ethanoneTo a solution of 1-[3-(5-bromo-2-hydroxy-benzyl)-azetidin-1-yl]-2,2,2-trifluoro-ethanone (59 mg, 0.17 mmol) in DMF (10 mL) was added KI (40 mg, 0.24 mmol), Cs2CO3 (170 mg, 0.51 mmol) and 2-bromomethyl-5-trifluoromethyl-furan (56 mg, 0.24 mmol). After 16 h, saturated sodium bicarbonate solution and EtOAc were added. The aqueous portion was extracted three times with EtOAc and the combined organic were dried (Na2SO4) and concentrated. The crude product was purified by RP HPLC (basic conditions) to provide the title compound (76 mg, 91%). MS (ESI): mass calcd. for C18H14BrF6NO3, 486.2; m/z found, 488.1 [M+H]+. 1H NMR (CDCl3): 7.34 (dd, J=8.7, 2.5 Hz, 1H), 7.21 (d, J=2.5 Hz, 1H), 6.89-6.76 (m, 2H), 6.48 (d, J=3.4 Hz, 1H), 5.02 (s, 2H), 4.40 (dd, J=9.6, 8.4 Hz, 1H), 4.22-4.11 (m, 1H), 4.08-4.02 (m, 1H), 3.84 (dd, J=10.7, 5.7 Hz, 1H), 3.11-2.97 (m, 1H), 2.97-2.82 (m, 2H).
Step H: Preparation of 3-[5-Bromo-2-(5-trifluoromethyl-furan-2-ylmethoxy)-benzyl]-azetidineTo a solution of 1-{3-[5-bromo-2-(5-trifluoromethyl-furan-2-ylmethoxy)-benzyl]-azetidin-1-yl}-2,2,2-trifluoro-ethanone (76 mg, 0.16 mmol) in methanol (10 mL) was added K2CO3 (94 mg, 0.70 mmol). After 1 h, TLC analysis indicated complete consumption of the starting material. Brine and EtOAc were added to the reaction mixture and the aqueous portion was extracted with EtOAc (3×). The combined organic layers were dried. The crude product was purified by RP HPLC (basic conditions) to provide the title compound (50 mg, 76%). MS (ESI): mass calcd. for C16H15BrF3NO2, 390.2; m/z found, 393.2 [M+H]+. 1H NMR (CDCl3): 7.50-7.41 (m, 1H), 7.35-7.26 (m, 1H), 6.89-6.79 (m, 2H), 6.53 (s, 1H), 5.05 (s, 2H), 4.43-4.20 (m, 1H), 3.63 (t, J=8.2 Hz, 2H), 3.44 (t, J=7.7 Hz, 2H), 2.85 (d, J=7.6 Hz, 2H).
Example 233 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxymethyl]-azetidinePrepared similar to Example 1 using 3-hydroxymethyl-azetidine-1-carboxylic acid tert-butyl ester. MS (ESI): mass calcd. for C17H17BrClNO2, 381.0: m/z found, 382.1 [M+H]+. 1H NMR (CDCl3): 7.45 (s, 1H), 7.35-7.21 (m, 3H), 7.15-6.96 (m, 2H), 6.77 (d, J=8.5, 1H), 5.04 (s, 2H), 4.16 (d, J=6.4, 2H), 3.81 (m, 2H), 3.63 (m, 1H), 3.62-3.52 (m, 1H), 3.21 (m, 1H), 2.17 (m, 1H).
Example 234 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxymethyl]-1-methyl-azetidinePrepared from Example 233 using general procedure 5. MS (ESI): mass calcd. for C18H19BrClNO2, 395.0; m/z found, 396.1 [M+H]+. 1H NMR (CDCl3): 7.52 (d, J=2.5, 1H), 7.40 (s, 1H), 7.36-7.22 (m, 4H), 6.74 (d, J=8.7, 1H), 5.04 (s, 2H), 4.45 (s, 2H), 4.23-4.15 (m, 1H), 3.64 (s, 2H), 2.93 (s, 2H), 2.35 (s, 3H).
Example 235 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxymethyl]-azetidin-3-olThe mixture of the title compound of Example 215 Step B (2.3 mmol), 5-bromo-2-(3-chloro-benzyloxy)-phenol (1.3 mmol), and cyanomethylenetri-n-butylphosphorane (2 mmol) in toluene (5 mL) was heated at 150° C. in a microwave reactor for 1 h. The mixture was cooled to rt and purified by PTLC providing the title compound (580 mg). MS (ESI): mass calcd. for C22H25BrClNO5, 497.1; m/z found, 504.2 [M−OH+Na]+. 1H NMR (CDCl3): 7.52-7.23 (m, 4H), 6.99-6.68 (m, 3H), 5.70-5.10 (br S, 1H), 5.04 (s, 2H), 4.99-4.97 (m, 2H), 4.50-4.46 (m, 4H), 1.45 (s, 9H).
Step B: 3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxymethyl]-azetidin-3-olThe title compound of Step A (160 mg) was dissolved in CH2Cl2 (20 mL), and TFA (3 mL) was added. The mixture was stirred at rt for 4 h and concentrated. The resulting residue was dissolved into MeOH (20 mL), and Dowex 66 ion-exchange resin (Dowex hydroxide, weakly basic anion, Macroporous) was added to adjust the pH to 7. The resin was filtered and the filtrate concentrated providing the title compound (120 mg). MS (ESI): mass calcd. for C17H17BrClNO3, 397.0; m/z found, 382.2 [M—OH+H]+. 1H NMR (MeOD): 7.52-7.28 (m, 4H), 6.97-6.81 (m, 3H), 5.18-5.15 (m, 2H), 5.12 (s, 2H), 4.73-4.68 (m, 4H).
Example 236 3-[1-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-ethyl]-azetidin-3-olPrepared according to Example 235 using 3-ethyl-3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester. MS (ESI): mass calcd. for C18H19BrClNO3, 411.0; m/z found, 396.0 [M−OH+H]+. 1H NMR (MeOD): 7.52-7.27 (m, 4H), 6.98-6.80 (m, 3H), 5.57-5.48 (m, 1H), 5.12 (s, 2H), 4.73-4.61 (br s, 4H), 1.63-1.57 (m, 3H).
Example 237 3-[5-Bromo-2-(3-chloro-benzyloxy)-benzyloxy]-azetidineTo a solution of 5-bromo-2-(3-chloro-benzyloxy)-benzaldehyde (6.0 g, 18.4 mmol) in MeOH (90 mL) at rt was added NaBH4 (1.07 g, 27.7 mmol) over 1 h. After 18 h at rt, H2O was added (5 mL) and the reaction concentrated to a residual mass, which was dissolved into EtOAc (150 mL). This EtOAc solution was washed with H2O (2×100 mL) and dried to yield the title compound as a light yellow (6.0 g, 100%). MS (ESI): mass calcd. for C14H12BrClO, 327.6; m/z found, 328.3 [M+H]+. 1H NMR (CDCl3) 7.48 (d, J=2.5 Hz, 1H), 7.42-7.20 (m, 5H), 6.76 (d, J=8.7 Hz, 1H), 5.07 (d, J=19.2 Hz, 2H), 4.69 (d, J=17.5 Hz, 2H), 2.15 (t, J=10.0 Hz, 1H).
Step B. 5-Bromo-2-(3-chloro-benzyloxy)-benzyl chlorideThe title compound of Step A was dissolved into CH2Cl2 (8 mL) and thionyl chloride (114 mg, 0.95 mmol) was added at rt. The reaction mixture was stirred for 2 h and concentrated to yield the title compound (300 mg). 1H NMR (CDCl3): 7.51 (d, J=2.5 Hz, 1H), 7.48-7.22 (m, 6H), 6.76 (t, J=11.1 Hz, 1H), 5.14-4.99 (m, 2H), 4.65 (d, J=14.7 Hz, 2H).
Step C. 3-[5-Bromo-2-(3-chloro-benzyloxy)-benzyloxy]-azetidineTo a DMF (5 mL) solution of 3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester (150 mg, 0.87 mmol) at rt was added 60% NaH (36 mg, 0.91 mmol). The reaction mixture was stirred at rt for 0.5 h. Then a DMF solution of the title compound of Step B (300 mg, 0.87 mmol) was added. After 18 h, the reaction mixture was partitioned between EtOAc and H2O. The organic phase was dried and concentrated to yield the title compound (380 mg). This material was purified by chromatography (SiO2) using 0-25% EtOAc in hexanes to give 3-[5-bromo-2-(3-chloro-benzyloxy)-benzyloxy]-azetidine-1-carboxylic acid tert-butyl ester (70 mg, 37%). This compound was treated with 4M HCl in dioxane and stirred 6 h at rt and concentrated. Purification by RP HPLC (basic system) gave the title compound (26 mg, 7%) MS (ESI): mass calcd. for C17H17BrClNO2, 381.7; m/z found, 383.0 [M+H]+. 1H NMR (CDCl3): 7.52 (d, J=2.5 Hz, 1H), 7.41 (s, 1H), 7.36-7.21 (m, 4H), 6.74 (d, J=8.7 Hz, 1H), 5.03 (s, 2H), 4.49-4.39 (m, 3H), 3.68 (m, 4H), 1.75 (s, 1H).
Example 238 3-[5-Chloro-2-(3-chloro-benzyloxy)-benzyloxy]-azetidinePrepared according to Example 237 using 5-chloro-2-(3-chloro-benzyloxy)-benzaldehyde. MS (ESI): mass calcd. for C17H17O2NO2, 337.06; m/z found, 338.2 [M+H]+. 1H NMR (CDCl3): 7.43-7.15 (m, 6H), 6.79 (d, J=8.7 Hz, 1H), 5.04 (s, 2H), 4.49-4.39 (m, 3H), 3.71-3.67 (m, 3H), 1.92 (m, 1H), 1.90-1.83 (m, 1H).
Example 239 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-3-methyl-[1,2,4]oxadiazoleTo 3-(5-Chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (1.5 g, 5.0 mmol) in DMF (20 mL) was added Cs2CO3 (2.1 g, 6.4 mmol), KI (0.84 g, 5.0 mmol) and bromoethyl acetate (0.84 g, 0.55 mL, 5.0 mmol). After 18 h, H2O was added and the mixture extracted with EtOAc (2×). The combined organics were washed with brine and dried. Silica gel chromatography (5-30% EtOAc in hexanes) gave 1.95 g (99%) of the title compound as a clear oil. 1H NMR (CDCl3): 6.91 (dd, J=8.7, 2.4 Hz, 1H), 6.79 (d, J=8.7 Hz, 1H), 6.58 (d, J=2.4 Hz, 1H), 4.91-4.87 (m, 1H), 4.65 (s, 2H), 4.32-4.25 (m, 4H), 4.01 (dd, J=10.5, 4.2 Hz, 2H), 1.44 (s, 9H), 1.30 (t, J=7.1 Hz, 3H).
Step B: Preparation of 3-(2-Carboxymethoxy-5-chloro-phenoxy)-azetidine-1-carboxylic acid tert-butyl esterTo the title compound from Step A (1.70 g, 4.40 mmol) in MeOH (10 mL) was added 4N NaOH (10 mL). After 2 h, CH2Cl2 was added and the mixture acidified with 1N KHSO4 (50 mL) then extracted with CH2Cl2 (2×). The combined organics were dried to give a 0.90 g (57%) of the title compound as a white solid that was used without further purification. MS (ESI): mass calcd. for C16H20ClNO6, 357.1; m/z found, 380.1 [M+Na]+. 1H NMR (400 MHz): 6.92 (dd, J=8.6, 2.3 Hz, 1H), 6.85 (d, J=8.7 Hz, 1H), 6.59 (d, J=2.3 Hz, 1H), 4.92-4.86 (m, 1H), 4.67 (s, 2H), 4.31 (dd, J=9.9, 6.5 Hz, 2H), 4.07 (dd, J=10.0, 4.1 Hz, 2H), 1.45 (s, 9H).
Step C: Preparation of 3-[5-Chloro-2-(3-methyl-[1,2,4]oxadiazol-5-ylmethoxy)-phenoxy]-azetidine-1-carboxylic acid tert-butyl esterTo the title compound of Step B (0.15 g, 0.42 mmol) in CH2Cl2 (4 mL) was added DMF (catalytic) and 2M COCl2 in CH2Cl2 (0.3 mL, 0.6 mmol). After 2 h, the reaction was concentrated and THF (2 mL) was added. This solution was added to N-hydroxy-acetamidine (0.035 g, 0.46 mmol) and N,N-diisopropylethylamine (0.065 g, 0.088 mL, 0.50 mmol) in THF (2 mL). The mixture was then heated for 20 min at 155° C. in a microwave reactor, cooled to rt and concentrated. Silica gel chromatography (5-30% EtOAc in hexanes) gave 0.155 g (93%) of the title compound as a clear oil. MS (ESI): mass calcd. for C18H22ClN3O5, 395.1; m/z found, 295.3 [M-100]+. 1H NMR (400 MHz): 6.94 (d, J=8.6 Hz, 1H), 6.91 (dd, J=8.6, 2.2 Hz, 1H), 6.57 (d, J=2.1 Hz, 1H), 5.27 (s, 2H), 4.89-4.85 (m, 1H), 4.32-4.29 (m, 2H), 4.04 (dd, J=10.4, 4.2 Hz, 2H), 2.43 (s, 3H), 1.45 (s, 9H).
Step D: Preparation of 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-3-methyl-[1,2,4]oxadiazole hydrochloridePrepared from the title compound of Step B using general procedure 1. MS (ESI): mass calcd. for C13H14ClN3O3, 295.1; m/z found, 296.2 [M+H]+. 1H NMR (DMSO-D6): 9.30 (s, 2H), 7.14 (d, J=8.7 Hz, 1H), 7.05 (dd, J=8.7, 2.4 Hz, 1H), 6.96 (d, J=2.4 Hz, 1H), 5.52 (s, 2H), 5.10-5.05 (m, 1H), 4.42 (dd, J=12.5, 6.7 Hz, 2H), 4.01 (dd, J=12.5, 4.8 Hz, 2H) 2.36 (s, 3H).
The compounds in Examples 240-243 were synthesized according to Example 239 using the appropriately substituted N-hydroxyamidine.
Example 240 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-3-cyclobutyl-[1,2,4]oxadiazoleMS (ESI): mass calcd. for C16H18ClN3O3, 335.1; m/z found, 336.2 [M+H]+. 1H NMR (CDCl3): 6.95 (d, J=8.6 Hz, 1H), 6.87 (dd, J=8.6, 2.3 Hz, 1H), 6.62 (s, 1H), 5.28 (s, 2H), 4.99-4.89 (m, 1H), 3.98-3.66 (m, 5H), 2.41-2.36 (m, 4H), 2.17-1.98 (m, 2H).
Example 241 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-3-cyclopropyl-[1,2,4]oxadiazole hydrochlorideMS (ESI): mass calcd. for C15H16ClN3O3, 321.1; m/z found, 322.2 [M+H]+. 1H NMR (DMSO-D6): 9.31 (s, 2H), 7.12 (d, J=8.8 Hz, 1H), 7.05 (dd, J=8.7, 2.4 Hz, 1H), 6.96 (d, J=2.4 Hz, 1H), 5.49 (s, 2H), 5.09-5.04 (m, 1H), 4.42 (dd, J=12.2, 6.6 Hz, 2H), 4.03-3.99 (m, 2H), 2.17-2.13 (m, 1H), 1.11-1.07 (m, 2H), 0.90-0.87 (m, 2H).
Example 242 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-3-isopropyl-[1,2,4]oxadiazole hydrochlorideMS (ESI): mass calcd. for C15H18ClN3O3, 323.1; m/z found, 324.2 [M+H]+. 1H NMR (DMSO-D6): 9.28 (s, 2H), 7.14 (d, J=8.7 Hz, 1H), 7.06 (dd, J=8.7, 2.4 Hz, 1H), 6.97 (d, J=2.4 Hz, 1H), 5.51 (s, 2H), 5.10-5.05 (m, 1H), 4.43 (dd, J=12.3, 6.6 Hz, 2H), 4.02 (dd, J=12.3, 4.7 Hz, 2H), 3.12-3.07 (m, 1H), 1.28 (d, J=6.9 Hz, 6H).
Example 243 5-[2-(Azetidin-3-yloxy)-4-chloro-phenoxymethyl]-3-ethyl-[1,2,4]oxadiazole hydrochlorideMS (ESI): mass calcd. for C14H16ClN3O3, 309.1; m/z found, 310.2 [M+H]+. 1H NMR (DMSO-D6): 9.34 (s, 2H), 7.14 (d, J=8.7 Hz, 1H), 7.06 (dd, J=8.7, 2.4 Hz, 1H), 6.97 (d, J=2.4 Hz, 1H), 5.51 (s, 2H), 5.10-5.05 (m, 1H), 4.42 (dd, J=12.6, 6.7 Hz, 2H), 4.02 (dd, J=12.5, 4.9 Hz, 2H), 2.75 (q, J=7.6 Hz, 2H), 1.26 (t, J=7.6 Hz, 2H).
Compounds in Examples 244-278 were synthesized according to general procedure 6.
Example 244 3-(5-Bromo-2-phenoxy-phenoxy)-azetidineMS (ESI): mass calcd. for C15H14BrNO2, 320.2; m/z found, 322.1 [M+H]+. 1H NMR (CDCl3): 7.32-7.28 (m, 2H), 7.07-7.05 (m, 2H), 6.94-6.92 (m, 2H), 6.88-6.84 (m, 2H), 4.97-4.91 (m, 1H), 3.85-3.81 (m, 2H), 3.71-3.67 (m, 2H).
Example 245 3-[5-Bromo-2-(3-bromo-phenoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C15H13Br2NO2, 399.1; m/z found, 401.0 [M+H]+. 1H NMR (CDCl3): 7.21-7.12 (m, 2H), 7.09 (dd, J=8.5, 2.2 Hz, 1H), 7.04-6.98 (m, 1H), 6.91 (d, J=8.5, 1H), 6.88-6.77 (m, 2H), 4.96-4.92 (m, 1H), 3.90-3.78 (m, 2H), 3.72-3.60 (m, 2H).
Example 246 3-[5-Bromo-2-(3-fluoro-phenoxy)-phenoxy]-azetidineMS (ESI) mass calcd. for C15H13BrFNO2, 337.01; m/z found, 338.3 [M+H]+. 1H NMR (CD3OD) 7.37-7.21 (m, 2H), 7.18 (d, J=2.2 Hz, 1H), 7.03 (d, J=8.6 Hz, 1H), 6.83 (t, J=8.4, 2.4 Hz, 1H), 6.75-6.63 (m, 2H), 5.15 (m, 1H), 4.47 (dd, J=12.4, 6.6 Hz, 2H), 4.05 (dd, J=12.4, 4.7 Hz, 2H).
Example 247 3-(5-Bromo-2-m-tolyloxy-phenoxy)-azetidineMS (ESI) mass calcd. for C16H16BrFNO2, 333.04; m/z found, 334.1 [M+H]+. 1H NMR (CD3OD) 7.25-7.10 (m, 3H), 6.92 (dd, J=12.9, 8.1 Hz, 2H), 6.80-6.64 (m, 2H), 5.19-5.03 (m, 1H), 4.45 (dd, J=12.7, 6.7 Hz, 2H), 4.09 (dd, J=12.6, 4.9 Hz, 2H).
Example 248 3-[5-Bromo-2-(3-methoxy-phenoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C16H16BrNO3, 350.2; m/z found, 351.1 [M+H]+. 1H NMR (CDCl3): 7.18 (t, J=8.1 Hz, 1H), 7.06 (dd, J=8.5, 2.2 Hz, 1H), 6.88 (d, J=8.5 Hz, 1H), 6.83 (d, J=2.2 Hz, 1H), 6.62 (dd, J=8.2, 1.7 Hz, 1H), 6.53-6.45 (m, 2H), 5.00-4.90 (m, 1H), 3.95-3.62 (m, 7H).
Example 249 3-[5-Bromo-2-(4-fluoro-phenoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C15H13BrFNO2, 338.2; m/z found, 339.1 [M+H]+. 1H NMR (CDCl3): 7.05 (dd, J=8.5, 2.2 Hz, 1H), 7.01-6.97 (m, 2H), 6.90-6.88 (m, 2H), 6.82 (dd, J=5.4, 3.1 Hz, 2H), 4.99-4.90 (m, 1H), 3.92-3.64 (m, 4H).
Example 250 3-[5-Bromo-2-(4-bromo-phenoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C15H13Br2NO2, 399.1; m/z found, 401.0 [M+H]+. 1H NMR (CDCl3): 7.43-7.33 (m, 2H), 7.08 (dd, J=8.5, 2.3 Hz, 1H), 6.88 (d, J=8.5 Hz, 1H), 6.83-6.78 (m, 3H), 4.99-4.90 (m, 1H), 3.95-3.55 (m, 4H).
Example 251 3-[5-Bromo-2-(4-chloro-phenoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C15H13BrClNO2, 354.6; m/z found, 355.0 [M+H]+. 1H NMR (MeOD): 7.34-7.22 (m, 2H), 7.18 (d, J=2.2 Hz, 1H), 7.10 (dd, J=8.0, 1.9 Hz, 1H), 7.02 (d, J=8.6 Hz, 1H), 6.94 (t, J=2.2 Hz, 1H), 6.85 (dd, J=8.3, 2.4 Hz, 1H), 5.18-5.10 (m, 1H), 4.50-4.41 (m, 2H), 4.07-4.04 (m, 2H).
Example 252 3-[5-Bromo-2-(3-chloro-phenoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C15H13BrClNO2, 354.6; m/z found, 355.0 [M+H]+. 1H NMR (MeOD): 7.34-7.22 (m, 2H), 7.18 (d, J=2.2 Hz, 1H), 7.10 (dd, J=8.0, 1.9 Hz, 1H), 7.02 (d, J=8.6 Hz, 1H), 6.94 (t, J=2.2 Hz, 1H), 6.85 (dd, J=8.3, 2.4 Hz, 1H), 5.18-5.10 (m, 1H), 4.50-4.41 (m, 2H), 4.07-4.04 (m, 2H).
Example 253 3-[5-Bromo-2-(3-trifluoromethoxy-phenoxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C16H13BrF3NO3, 403.0; m/z found, 404.1 [M+H]+. 1H NMR (MeOD): 7.41 (t, J=8.3 Hz, 1H), 7.31-7.13 (m, 2H), 7.06-7.02 (m, 1H), 7.02-6.97 (m, 1H), 6.93-6.78 (m, 2H), 5.21-5.09 (m, 1H), 4.50-4.47 (m, 2H), 4.06-4.03 (m, 2H), 3.34-3.24 (m, 1H).
Example 254 3-[5-Bromo-2-(naphthalen-2-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H16BrNO2, 369.0; m/z found, 370.1 [M+H]+. 1H NMR (MeOD): 7.92-7.77 (m, 2H), 7.70 (d, J=8.1 Hz, 1H), 7.49-6.97 (m, 7H), 5.20-5.12 (m, 1H), 4.44 (dd, J=12.5, 6.6 Hz, 2H), 4.05 (dd, J=12.5, 5.0 Hz, 2H).
Example 255 3-[5-Bromo-2-(naphthalen-1-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H16BrNO2, 369.0; m/z found, 370.1 [M+H]+. 1H NMR (MeOD): 8.25-8.16 (m, 1H), 7.95-7.85 (m, 1H), 7.65-7.16 (m, 6H), 6.95-6.72 (m, 2H), 5.21-5.12 (m, 1H), 4.42 (m, 2H), 4.05 (dd, J=12.5, 5.0 Hz, 2H).
Example 256 3-(5-Chloro-2-phenoxy-phenoxy)-azetidineMS (ESI): mass calcd. for C15H14ClNO2, 275.1; m/z found, 276.1 [M+H]+. 1H NMR (CDCl3): 7.33-7.26 (m, 2H), 7.11-6.99 (m, 1H), 6.99-6.84 (m, 4H), 6.70 (d, J=1.3 Hz, 1H), 4.97-4.91 (m, 1H), 3.88-3.79 (m, 2H), 3.75-3.64 (m, 2H).
Example 257 3-[5-Chloro-2-(3-chloro-phenoxy)-phenoxy]-azetidine maleateMS (ESI): mass calcd. for C15H13O2NO2, 309.0; m/z found, 310.1 [M+H]+. 1H NMR (CDCl3): 7.22 (t, J=8.2 Hz, 1H), 7.04 (d, J=8.1 Hz, 1H), 7.01 (dd, J=8.6 Hz, 2.3 Hz, 1H), 6.93 (d, J=8.6 Hz, 1H), 6.89 (t, J=2.1 Hz, 1H), 6.80 (dt, J=5.2, 2.5 Hz, 2H), 6.29 (s, 2H), 5.18-5.08 (m, 1H), 4.44 (d, J=6.7 Hz, 2H), 4.21 (s, 2H).
Example 258 3-[5-Chloro-2-(4-chloro-phenoxy)-phenoxy]-azetidine trifluoroacetateMS (ESI): mass calcd. for C15H13O2NO2, 309.0; m/z found, 310.8 [M+H]+. 1H NMR (CDCl3): 7.31-7.27 (m, 2H), 7.02 (dd, J=8.7, 2.4 Hz, 1H), 6.91 (d, J=8.6 Hz, 1H), 6.88-6.83 (m, 2H), 6.79 (d, J=2.3 Hz, 1H), 5.11-5.06 (m, 1H), 4.34 (dd, J=11.8, 6.8 Hz, 2H), 4.14 (dd, J=11.7, 5.5 Hz, 2H).
Example 259 3-(5-Chloro-2-o-tolyloxy-phenoxy)-azetidine trifluoroacetateMS (ESI): mass calcd. for C16H16ClNO2, 289.1; m/z found, 290.2 [M+H]+. 1H NMR (CDCl3): 7.25 (d, J=7.5 Hz, 1H), 7.15 (t, J=7.0 Hz, 1H), 7.07 (t, J=7.4 Hz, 1H), 6.95 (dd, J=8.7, 2.4 Hz, 1H), 6.81 (d, J=2.4 Hz, 1H), 6.75 (d, J=8.0 Hz, 1H), 6.68 (d, J=8.7 Hz, 1H), 5.10 (s, 1H), 4.34 (s, 2H), 4.19 (s, 2H), 2.24 (s, 3H).
Example 260 3-[5-Chloro-2-(naphthalen-2-yloxy)-phenoxy]-azetidineMS (ESI): mass calcd. for C19H16ClNO2, 325.1; m/z found, 326.2 [M+H]+. 1H NMR (MeOD): 7.90-7.79 (m, 2H), 7.70 (d, J=8.0 Hz, 1H), 7.48-7.03 (m, 7H), 5.20-5.12 (m, 1H), 4.44 (dd, J=12.6, 6.6 Hz, 2H), 4.05 (dd, J=12.6, 5.0 Hz, 2H).
Example 261 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-benzothiazoleA mixture of 3-(5-chloro-2-hydroxy-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (0.5 mmol), 2-chloro-benzothiazole (0.5 mmol), and K2CO3 (1 mmol) in CH3CN (3 mL) was heated at 120-150° C. via Microwave for 1 h. The mixture was cooled down and separated through PTLC providing 3-[2-(benzothiazol-2-yloxy)-5-chloro-phenoxy]-azetidine-1-carboxylic acid tert-butyl ester (180 mg). The ester was re-dissolved into CH2Cl2 (20 mL), and CF3COOH (3 mL) was added. The mixture was stirred at 25° C. for 4 h. After concentration, the title compound was obtained (192 mg). MS (ESI): mass calcd. for C16H13ClN2O2S, 332.0; m/z found, 333.1 [M+H]+. 1H NMR (MeOD): 7.23-7.07 (m, 4H), 6.92-6.81 (m, 3H), 5.14-5.08 (m, 1H), 4.51 (dd, J=12.5, 6.6 Hz, 2H), 4.23 (dd, J=12.5, 5.0 Hz, 2H).
Example 262 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-benzooxazoleMS (ESI): mass calcd. for C16H13ClN2O3, 316.1; m/z found, 317.1 [M+H]+. 1H NMR (MeOD): 7.83-7.78 (m, 1H), 7.67-7.62 (m, 1H), 7.46-7.41 (m, 2H), 7.26-7.21 (m, 1H), 7.20 (dd, J=8.6, 2.3 Hz, 1H), 7.11 (d, J=2.3 Hz, 1H), 5.26-5.21 (m, 1H), 4.50 (dd, J=12.7, 6.6 Hz, 2H), 4.07 (dd, J=12.7, 4.8 Hz, 2H).
Example 263 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-[1,8]naphthyridineMS (ESI): mass calcd. for C17H14ClN3O2, 327.1; m/z found, 328.1 [M+H]+. 1H NMR (MeOD): 9.06-9.04 (m, 1H), 8.97 (d, J=4.7 Hz, 1H), 8.74 (d, J=8.9 Hz, 1H), 7.92 (dd, J=8.1, 5.4 Hz, 1H), 7.70 (d, J=8.9 Hz, 1H), 7.25 (d, J=8.6 Hz, 1H), 7.20 (dd, J=8.6, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 5.27-5.18 (m, 1H), 4.46 (dd, J=12.7, 6.6 Hz, 2H), 3.97 (dd, J=12.7, 4.8 Hz, 2H).
Example 264 2-[2-(Azetidin-3-yloxy)-4-chloro-phenoxy]-quinolineMS (ESI): mass calcd. for C18H15ClN2O2, 327.1; m/z found, 328.1 [M+H]+. 1H NMR (CDCl3): 8.75 (s, 1H), 8.12-8.06 (m, 1H), 7.65-7.58 (m, 3H), 7.20 (d, J=8.6 Hz, 1H), 7.04 (dd, J=8.6, 2.3 Hz, 1H), 6.73 (d, J=2.3 Hz, 1H), 4.99-4.88 (m, 1H), 3.86-3.72 (m, 2H), 3.61-3.47 (m, 2H).
Example 265 4-(5-Chloro-2-phenoxy-phenoxy)-piperidineMS (ESI): mass calcd. for C17H18ClNO2, 303.8; m/z found, 304.2 [M+H]+. 1H NMR (CDCl3): 7.29-7.26 (m, 2H), 7.04-7.01 (m, 1H), 6.99-6.97 (m, 2H), 6.93-6.89 (m, 3H), 4.35-4.30 (m, 2H), 2.95-2.91 (m, 2H), 2.62 (ddd, J=12.3, 8.6, 3.3 Hz, 2H), 1.88-1.82 (m, 2H), 1.57-1.45 (m, 2H).
Example 266 (S)-3-(4-Chloro-2-p-tolyloxy-phenoxy)-pyrrolidineMS (ESI): mass calcd. for C17H18ClNO2, 303.1; m/z found, 304.2 [M+H]+. 1H NMR (CDCl3): 7.09 (t, J=7.7 Hz, 2H), 7.04 (dd, J=8.7, 2.5 Hz, 1H), 6.99 (d, J=2.5 Hz, 1H), 6.87 (d, J=8.7 Hz, 1H), 6.84-6.78 (m, 2H), 4.79 (dd, J=5.7, 4.4 Hz, 1H), 3.06 (d, J=12.8 Hz, 1H), 2.98-2.89 (m, 1H), 2.82-2.71 (m, 2H), 2.32 (s, 3H), 1.99-1.89 (m, 1H), 1.87-1.78 (m, 1H).
Example 267 (R)-3-(4-Chloro-2-p-tolyloxy-phenoxy)-pyrrolidineMS (ESI): mass calcd. for C17H18ClNO2, 303.1; m/z found, 304.2 [M+H]+. 1H NMR (CDCl3): 7.09 (d, J=8.3 Hz, 2H), 7.04 (dd, J=8.7, 2.5 Hz, 1H), 6.98 (d, J=2.5 Hz, 1H), 6.86 (d, J=8.7 Hz, 1H), 6.83-6.79 (m, 2H), 4.79 (t, J=4.8 Hz, 1H), 3.05 (d, J=12.8 Hz, 1H), 2.97-2.89 (m, 1H), 2.78 (d, J=9.3 Hz, 2H), 2.31 (s, 3H), 1.99-1.89 (m, 1H), 1.86-1.77 (m, 1H).
Example 268 (R)-3-(4-Chloro-2-p-tolyloxy-phenoxy)-1-methyl-pyrrolidinePrepared from Example 261 using general procedure 5. MS (ESI): mass calcd. for C18H20ClNO2, 317.1; m/z found, 318.2 [M+H]+. 1H NMR (CDCl3): 7.10 (d, J=8.4 Hz, 2H), 7.00 (dd, J=8.7, 2.5 Hz, 1H), 6.90 (d, J=2.5 Hz, 1H), 6.87-6.79 (m, 3H), 4.84-4.74 (m, 1H), 2.91 (dd, J=10.6, 6.1 Hz, 1H), 2.58 (dd, J=6.9, 6.3 Hz, 2H), 2.54-2.48 (m, 1H), 2.32 (d, J=4.5 Hz, 6H), 2.23-2.16 (m, 1H), 1.98-1.86 (m, 1H).
Example 269 (S)-3-[4-Chloro-2-(4-fluoro-phenoxy)-phenoxy]-pyrrolidineMS (ESI): mass calcd. for C16H15ClFNO2, 307.1; m/z found, 308.2 [M+H]+. 1H NMR (CDCl3): 7.07 (dd, J=8.7, 2.5 Hz, 1H), 7.03-6.96 (m, 3H), 6.92-6.84 (m, 3H), 4.78 (dd, J=5.9, 4.5 Hz, 1H), 3.04 (d, J=12.8 Hz, 1H), 2.95 (dt, J=11.3, 7.4 Hz, 1H), 2.89-2.75 (m, 2H), 2.02-1.92 (m, 1H), 1.85-1.77 (m, 1H).
Example 270 (R)-3-[4-Chloro-2-(4-fluoro-phenoxy)-phenoxy]-pyrrolidineMS (ESI): mass calcd. for C16H15ClFNO2, 307.1; m/z found, 308.2 [M+H]+. 1H NMR (CDCl3): 7.06 (dd, J=8.7, 2.5 Hz, 1H), 7.02-6.96 (m, 3H), 6.91-6.84 (m, 3H), 4.78 (dd, J=5.8, 4.5 Hz, 1H), 3.05 (d, J=12.8 Hz, 1H), 2.96 (dt, J=11.3, 7.4 Hz, 1H), 2.90-2.74 (m, 2H), 2.03-1.92 (m, 1H), 1.85-1.77 (m, 1H).
Example 271 (R)-3-[4-Chloro-2-(4-fluoro-phenoxy)-phenoxy]-1-methyl-pyrrolidinePrepared from Example 264 using general procedure 5. MS (ESI): mass calcd. for C17H17ClFNO2, 321.1; m/z found, 322.2 [M+H]+. 1H NMR (CDCl3): 7.05-6.96 (m, 3H), 6.94-6.86 (m, 3H), 6.81 (d, J=8.7 Hz, 1H), 4.93-4.53 (m, 1H), 2.91 (dd, J=10.6, 6.1 Hz, 1H), 2.63-2.41 (m, 3H), 2.32 (s, 3H), 2.23-2.16 (m, 1H), 1.90-1.81 (m, 1H).
Example 272 (S)-3-(4-Chloro-2-o-tolyloxy-phenoxy)-pyrrolidineMS (ESI): mass calcd. for C17H18ClNO2, 303.1; m/z found, 304.2 [M+H]+. 1H NMR (CDCl3): 7.23 (d, J=6.8 Hz, 1H), 7.11-7.06 (m, 1H), 7.04-6.98 (m, 2H), 6.91 (d, J=2.5 Hz, 1H), 6.86 (d, J=8.7 Hz, 1H), 6.69 (d, J=8.0 Hz, 1H), 4.79 (dd, J=5.6, 4.4 Hz, 1H), 3.04 (d, J=12.9 Hz, 1H), 2.89 (dt, J=11.4, 7.4 Hz, 1H), 2.81-2.71 (m, 2H), 2.29 (s, 3H), 1.98-1.89 (m, 1H), 1.85-1.75 (m, 1H).
Example 273 (S)-3-(4-Chloro-2-m-tolyloxy-phenoxy)-pyrrolidineMS (ESI): mass calcd. for C17H18ClNO2, 303.1; m/z found, 304.2 [M+H]+. 1H NMR (CDCl3): 7.17 (t, J=7.8 Hz, 1H), 7.08-7.02 (m, 2H), 7.04-7.00 (m, 1H), 6.91-6.85 (m, 2H), 6.76-6.66 (m, 2H), 4.81-4.75 (m, 1H), 3.03 (d, J=12.8 Hz, 1H), 2.89 (dt, J=11.3, 7.5 Hz, 1H), 2.80-2.70 (m, 2H), 2.31 (s, 3H), 1.96-1.88 (m, 1H), 1.85-1.74 (m, 1H).
Example 274 (S)-3-[4-Chloro-2-(4-fluoro-3-methyl-phenoxy)-phenoxy]-pyrrolidineMS (ESI): mass calcd. for C17H17ClFNO2, 321.1; m/z found, 322.2 [M+H]+. 1H NMR (CDCl3): 7.05 (dd, J=8.7, 2.5 Hz, 1H), 6.95 (d, J=2.5 Hz, 1H), 6.92 (d, J=8.9 Hz, 1H), 6.88 (d, J=8.7 Hz, 1H), 6.75 (dd, J=6.2, 3.0 Hz, 1H), 6.72-6.65 (m, 1H), 4.79 (dd, J=5.8, 4.5 Hz, 1H), 3.07 (d, J=12.8 Hz, 1H), 2.98 (dt, J=11.4, 7.4 Hz, 1H), 2.88-2.76 (m, 2H), 2.24 (d, J=1.8 Hz, 3H), 2.00-1.93 (m, 1H), 1.88-1.79 (m, 1H).
Example 275 (S)-3-[4-Chloro-2-(4-chloro-phenoxy)-phenoxy]-pyrrolidineMS (ESI): mass calcd. for C16H15O2NO2, 323.1; m/z found, 324.1 [M+H]+. 1H NMR (CDCl3): 7.27-7.22 (m, 2H), 7.09 (dd, J=8.7, 2.5 Hz, 1H), 7.03 (d, J=2.5 Hz, 1H), 6.88 (d, J=8.7 Hz, 1H), 6.86-6.75 (m, 2H), 4.76 (dd, J=5.7, 4.5 Hz, 1H), 3.01 (d, J=12.8 Hz, 1H), 2.96-2.74 (m, 3H), 2.01-1.89 (m, 1H), 1.85-1.71 (m, 1H).
Example 276 (S)-3-[4-Chloro-2-(3-chloro-phenoxy)-phenoxy]-pyrrolidineMS (ESI): mass calcd. for C16H15O2NO2, 323.1; m/z found, 324.1 [M+H]+. 1H NMR (CDCl3): 7.21 (t, J=8.1 Hz, 1H), 7.12 (dd, J=8.7, 2.6 Hz, 1H), 7.08 (d, J=2.5 Hz, 1H), 7.03 (ddd, J=8.0, 1.9, 0.9 Hz, 1H), 6.89 (d, J=8.7 Hz, 1H), 6.85 (t, J=2.2 Hz, 1H), 6.80 (ddd, J=8.3, 2.4, 0.9 Hz, 1H), 4.87-4.51 (m, 1H), 3.00 (d, J=12.8 Hz, 1H), 2.94-2.70 (m, 3H), 2.00-1.89 (m, 1H), 1.82-1.71 (m, 1H).
Example 277 (S)-3-[2-(4-Bromo-phenoxy)-4-chloro-phenoxy]-pyrrolidineMS (ESI): mass calcd. for C16H15BrClNO2, 367.0; m/z found, 368.1 [M+H]+. 1H NMR (CDCl3): 7.43-7.35 (m, 2H), 7.10 (dd, J=8.7, 2.6 Hz, 1H), 7.03 (dd, J=8.7, 2.5 Hz, 1H), 6.88 (d, J=8.7 Hz, 1H), 6.80-6.73 (m, 2H), 4.76 (dd, J=5.9, 4.4 Hz, 1H), 3.01 (d, J=12.8 Hz, 1H), 2.92 (dt, J=11.4, 7.4 Hz, 1H), 2.87-2.72 (m, 2H), 2.02-1.89 (m, 1H), 1.84-1.72 (m, 1H).
Example 278 (S)-3-[4-Chloro-2-(4-isopropyl-phenoxy)-phenoxy]-pyrrolidineMS (ESI): mass calcd. for C19H22ClNO2, 331.1; m/z found, 332.2 [M+H]+. 1H NMR (CDCl3): 7.15 (d, J=8.5 Hz, 2H), 7.07-7.00 (m, 2H), 6.85 (dd, J=11.0, 8.6 Hz, 3H), 4.77 (d, J=4.6 Hz, 1H), 3.04 (d, J=12.8 Hz, 1H), 2.92-2.81 (m, 2H), 2.76-2.70 (m, 2H), 1.95-1.87 (m, 1H), 1.82-1.73 (m, 1H), 1.24 (d, J=6.9 Hz, 6H).
Example 279 (±)-3-[5-Bromo-2-(4-bromo-phenoxy)-phenoxy]-1-ethyl-pyrrolidinePrepared using 5-bromo-2-(3-bromo-phenoxy)-phenol and (±)-1-ethyl-pyrrolidin-3-ol according to general procedure 7. MS (ESI): mass calcd. for C18H19Br2NO2, 439.1; m/z found, 441.0 [M+H]+. 1H NMR (CDCl3): 7.16-7.12 (m, 2H), 7.08 (dd, J=8.4, 2.2 Hz, 1H), 7.02 (d, J=2.2 Hz, 1H), 7.01-6.98 (m, 1H), 6.93 (d, J=8.5 Hz, 1H), 6.87-6.82 (m, 1H), 4.74 (m, 1H), 3.02 (dd, J=10.7, 6.2 Hz, 1H), 2.69-2.54 (m, 1H), 2.44 (m, 4H), 2.17 (m, 1H), 1.88-1.77 (m, 1H), 1.07 (t, J=7.2 Hz, 3H).
Example 280 2-(Azetidin-3-yloxy)-4-bromo-phenyl]-phenyl-methanoneTo a solution of 3-(5-bromo-2-formyl-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (0.25 g, 0.70 mmol) in CH2Cl2 (10 mL) was added a solution of PhMgBr (1M in THF, 1 mL). The reaction was allowed to stir for 15 h then quenched with 1N HCl (4 mL). After 10 min, the mixture was made basic with 1N NaOH (10 mL), and extracted with CH2Cl2 (3×20 mL). The organic layers were combined and dried. Chromatography of the resulting residue (SiO2; EtOAc/Hexanes) gave the title compound (0.24 g, 79%). MS (ESI): mass calcd. for C21H24BrNO4, 433.1; m/z found, 434.4 [M+H]+. 1H NMR (CDCl3): 7.41-7.23 (m, 6H), 7.17 (dd, J=8.2, 1.7, 1H), 6.61 (d, J=1.7, 1H), 6.04 (s, 1H), 4.90-4.68 (m, 1H), 4.32-4.01 (m, 2H), 3.95-3.68 (m, 2H), 2.04-2.10, 1H), 1.44 (s, 9H).
Step B: Preparation of 3-(2-Benzoyl-5-bromo-phenoxy)-azetidine-1-carboxylic acid tert-butyl esterA solution of the title compound of Step A (0.12 g, 0.28 mmol) and Dess-Martin periodane (0.17 g, 0.39 mmol) in CH2Cl2 (15 mL) was stirred at rt for 15 h and filtered. The resulting filtrate was concentrated and purified (SiO2; EtOAc/Hexanes) providing the title compound (0.10 g, 84%). MS (ESI): mass calcd. for C21H22BrNO4, 431.1; m/z found, 432.4 [M+H]+. 1H NMR (CDCl3): 7.70-7.64 (m, 2H), 7.55-7.45 (m, 1H), 7.40-7.31 (m, 2H), 7.27 (d, J=8.1 Hz, 1H), 7.18 (dd, J=8.0, 1.7 Hz, 1H), 6.69 (d, J=1.6 Hz, 1H), 4.72 (tt, J=6.4, 4.2 Hz, 1H), 4.16-3.97 (m, 2H), 3.59 (dd, J=10.6, 4.1 Hz, 2H), 1.46-1.25 (m, 9H).
Step C: Preparation of 2-(azetidin-3-yloxy)-4-bromo-phenyl]-phenyl-methanoneTo a solution of 3-(2-benzoyl-5-bromo-phenoxy)-azetidine-1-carboxylic acid tert-butyl ester (0.10 g, 0.23 mmol) in CH2Cl2 (10 mL) was added 2M HCl in Et2O (0.5 mL). After 15 h, the reaction was concentrated to give the title compound as the hydrochloride salt which was neutralized with 1N NaOH (5 mL) and extracted with CH2Cl2 (3×15 mL). The organic layers were combined and dried to give the title compound (0.07 g, 90%). MS (ESI): mass calcd. for C16H14BrNO2, 331.0; m/z found 332.2, [M+H]+. 1H NMR (CD3OD): 7.82-7.74 (m, 2H), 7.67 (t, J=7.4 Hz, 1H), 7.54 (t, J=7.8 Hz, 2H), 7.43-7.32 (m, 2H), 5.47-5.36 (m, 1H), 4.46 (dd, J=12.4, 6.7 Hz, 2H), 3.94-3.81 (m, 2H).
Examples 275-292 were synthesized according to Example 274 using the appropriately substituted aryl magnesium halide and aldehyde.
Example 281 [2-(Azetidin-3-yloxy)-4-bromo-phenyl]-(4-chloro-phenyl)-methanoneMS (ESI): mass calcd. for C16H13BrClNO2, 365.0; m/z found, 366.0 [M+H]+. 1H NMR (CD3OD): 7.91-7.79 (m, 2H), 7.68-7.55 (m, 2H), 7.52-7.41 (m, 2H), 5.39-5.26 (m, 1H), 4.65-4.47 (m, 2H), 4.01 (d, J=7.4 Hz, 2H).
Example 282 [2-(Azetidin-3-yloxy)-4-bromo-phenyl]-(3-chloro-phenyl)-methanoneMS (ESI): mass calcd. for C16H13BrClNO2, 365.0; m/z found, 366.0 [M+H]+. 1H NMR (CD3OD): 7.77 (t, J=1.8, 1H), 7.71-7.61 (m, 2H), 7.51 (t, J=7.9, 1H), 7.44-7.34 (m, 2H), 7.17 (d, J=1.3, 1H), 5.19 (t, J=4.9, 1H), 4.45 (dd, J=12.7, 6.6, 2H), 3.89 (dd, J=12.6, 4.8, 2H).
Example 283 [4-Bromo-2-(1-methyl-azetidin-3-yloxy)-phenyl]-(3-chloro-phenyl)-methanonePrepared according to general procedure 5 using the title compound from Example 276. MS (ESI): mass calcd. for C17H15BrClNO2, 379.0; m/z found, 380.1 [M+H]+. 1H NMR (CD3OD): 7.74 (t, J=1.7, 1H), 7.71-7.60 (m, 2H), 7.51 (t, J=7.9, 1H), 7.44-7.34 (m, 2H), 7.17 (d, J=1.3, 1H), 5.19 (t, J=4.9, 1H), 4.50-4.40 (m, 2H), 3.90-3.82 (m, 2H). 2.19 (s, 3H).
Example 284 [2-(Azetidin-3-yloxy)-4-bromo-phenyl]-m-tolyl-methanoneMS (ESI): mass calcd. for C17H16BrNO2, 345.0; m/z found, 346.1 [M+H]+. 1H NMR (CDCl3): 7.67-7.48 (m, 2H), 7.43-7.13 (m, 4H), 6.90-6.74 (m, 1H), 4.98-4.86 (m, 1H), 3.80 (s, 1H), 3.52 (s, 1H), 2.40 (s, 2H), 2.02 (s, 3H).
Example 285 [2-(Azetidin-3-yloxy)-4-bromo-phenyl]-o-tolyl-methanoneMS (ESI): mass calcd. for C17H16BrNO2, 345.0; m/z found, 346.1 [M+H]+. 1H NMR (CDCl3): 7.46 (d, J=8.2, 1H), 7.36 (s, 1H), 7.27 (s, 3H), 7.23-7.10 (m, 2H), 6.75 (s, 1H), 4.81 (s, 1H), 3.69 (s, 2H), 3.32 (s, 2H), 2.44 (s, 3H).
Example 286 [2-(Azetidin-3-yloxy)-4-bromo-phenyl]-(3-methoxy-phenyl)-methanoneMS (ESI): mass calcd. for C17H16BrNO3, 361.0; m/z found, 362.1 [M+H]+. 1H NMR (CDCl3): 7.39-7.07 (m, 6H), 6.91-6.79 (m, 1H), 4.66 (s, 1H), 3.84 (s, 3H), 3.50 (s, 2H), 2.97 (s, 2H).
Example 287 [2-(Azetidin-3-yloxy)-4-bromo-phenyl]-naphthalen-2-yl-methanoneMS (ESI): mass calcd. for C20H16BrNO2, 381.0; m/z found, 382.1 [M+H]+. 1H NMR (CDCl3): 8.19 (s, 1H), 7.96-7.85 (m, 4H), 7.65-7.50 (m, 2H), 7.39-7.21 (m, 2H), 6.85 (d, J=1.6 Hz, 1H), 4.95-4.89 m, 1H), 3.77-3.66 (m, 2H), 3.51-3.40 (m, 2H).
Example 288 [4-Bromo-2-(1-isopropyl-azetidin-3-yloxy)-phenyl]-naphthalen-2-yl-methanonePrepared according to general procedure 3 or 4 using the title compound from Example 281. MS (ESI): mass calcd. for C23H22BrNO2, 423.1; m/z found, 426.1 [M+H]+. 1H NMR (CDCl3): 8.16-8.10 (m, 1H), 7.95-7.85 (m, 4H), 7.65-7.50 (m, 2H), 7.39-7.21 (m, 2H), 6.90-6.82 (m, 1H), 4.96-4.80 (m, 1H), 3.77-3.66 (m, 2H), 3.51-3.40 (m, 2H), 2.34-2.20 (m, 1H), 0.91 (d, J=6.1 Hz, 6H).
Example 289 [2-(Azetidin-3-yloxy)-4-bromo-phenyl]-benzo[1,3]dioxol-5-yl-methanoneMS (ESI): mass calcd. for C17H14BrNO4, 375.1; m/z found, 376.1 [M+H]+. 1H NMR (CDCl3): 7.38-7.11 (m, 4H), 6.81 (d, J=8.0 Hz, 2H), 6.06 (s, 2H), 4.94 (s, 1H), 3.81 (s, 2H), 3.59 (s, 2H).
Example 290 Benzo[1,3]dioxol-5-yl-[4-bromo-2-(1-isopropyl-azetidin-3-yloxy)-phenyl]-methanonePrepared according to general procedure 3 or 4 using the title compound from Example 283. MS (ESI): mass calcd. for C20H20BrNO4, 417.1; m/z found, 418.1 [M+H]+. 1H NMR (CDCl3): 7.36-7.15 (m, 4H), 6.76-6.61 (m, 2H), 6.06 (d, J=4.1 Hz, 2H), 4.76-4.61 (m, 1H), 3.79-3.63 (m, 2H), 2.87-2.75 (m, 2H), 2.34-2.18 (m, 1H), 0.90 (d, J=6.2 Hz, 6H).
Example 291 [2-(Azetidin-3-yloxy)-4-bromo-phenyl]-(4-methoxy-phenyl)-methanoneMS (ESI): mass calcd. for C17H16BrNO3, 361.0; m/z found, 362.1 [M+H]+. 1H NMR (CDCl3): 7.38-7.12 (m, 6H), 6.96-6.83 (m, 1H), 4.65 (s, 1H), 3.84 (s, 3H), 3.54 (s, 2H), 2.99 (s, 2H).
Example 292 [2-(Azetidin-3-yloxy)-4-bromo-phenyl]-(4-chloro-3-fluoro-phenyl)-methanoneMS (ESI): mass calcd. for C16H12BrClFNO2, 383.0; m/z found, 384.2 [M+H]+. 1H NMR (CDCl3): 7.63-7.40 (m, 3H), 7.38-7.15 (m, 2H), 6.88-6.67 (m, 1H), 4.91 (s, 1H), 3.80 (s, 2H), 3.50 (s, 2H).
Example 293 [2-(Azetidin-3-yloxy)-4-bromo-phenyl]-(3,4-dichloro-phenyl)-methanoneMS (ESI): mass calcd. for C16H12BrCl2NO2, 399.0; m/z found, 400.1 [M+H]+. 1H NMR (CDCl3): 7.83 (d, J=1.9 Hz, 1H), 7.63-7.51 (m, 2H), 7.35-7.19 (m, 2H), 6.82 (d, J=1.6 Hz, 1H), 5.00-4.85 (m, 1H), 4.02-3.31 (m, 4H).
Example 294 [2-(Azetidin-3-yloxy)-4-chloro-phenyl]-naphthalen-2-yl-methanoneMS (ESI): mass calcd. for C20H16ClNO2, 337.1; m/z found, 338.2 [M+H]+. 1H NMR (CDCl3): 8.19 (s, 1H), 7.98-7.85 (m, 3H), 7.63-7.37 (m, 4H), 7.10 (dd, J=8.1, 1.7 Hz, 1H), 6.70 (d, J=1.6 Hz, 1H), 4.97-4.84 (m, 1H), 3.74 (s, 2H), 3.50-3.37 (m, 2H).
Example 295 [2-(Azetidin-3-yloxy)-4-chloro-phenyl]-benzo[1,3]dioxol-5-yl-methanoneMS (ESI): mass calcd. for C17H14ClNO4, 331.1; m/z found, 332.2 [M+H]+. 1H NMR (CDCl3): 7.35-7.21 (m, 3H), 7.04 (dd, J=8.1, 1.8 Hz, 1H), 6.82 (d, J=8.1 Hz, 1H), 6.65 (d, J=1.7 Hz, 1H), 6.05 (d, J=8.9 Hz, 2H), 5.02-4.87 (m, 1H), 3.86 (s, 2H), 3.62 (s, 2H).
Example 296 Benzo[1,3]dioxol-5-yl-[4-chloro-2-(1-isopropyl-azetidin-3-yloxy)-phenyl]-methanonePrepared according to general procedure 3 or 4 using the title compound from Example 289. MS (ESI): mass calcd. for C20H20ClNO4, 373.1; m/z found, 374.2 [M+H]+. 1H NMR (CDCl3): 7.40-7.25 (m, 4H), 6.76-6.61 (m, 2H), 6.10-6.04 (m, 2H), 4.81-4.64 (m, 1H), 3.75-3.63 (m, 2H), 2.85-2.74 (m, 2H), 2.28-2.18 (m, 1H), 0.96 (d, J=6.1 Hz, 6H).
Example 297 [2-(Azetidin-3-yloxy)-4-chloro-phenyl]-(4-chloro-phenyl)-methanoneMS (ESI): mass calcd. for C16H13O2NO2, 321.0; m/z found, 322.2 [M+H]+. 1H NMR (CD3OD): 7.79-7.62 (m, 2H), 7.56-7.35 (m, 3H), 7.16 (s, 1H), 7.00-6.76 (m, 1H), 5.19-5.08 (m, 1H), 4.16 (s, 2H), 3.87 (s, 1H), 3.49 (s, 1H).
Example 298 [2-(Azetidin-3-yloxy)-4-chloro-phenyl]-(3-chloro-phenyl)-methanoneMS (ESI): mass calcd. for C16H13O2NO2, 321.0; m/z found, 322.2 [M+H]+. 1H NMR (CDCl3): 7.70 (t, J=1.7, 1 H), 7.62 (dd, J=7.8, 1.3 Hz, 1H), 7.58-7.51 (m, 1H), 7.47-7.34 (m, 2H), 7.12 (dd, J=8.2, 1.8 Hz, 1H), 6.61 (d, J=1.7 Hz, 1H), 4.87-4.68 (m, 1H), 4.21-4.13 (m, 2H), 3.67 (dd, J=9.9, 4.0 Hz, 2H).
Biological Assaysr5-HT7 Binding Assay
Receptor binding was performed using membrane fractions prepared from the HEK-293 cell line recombinantly expressing rat 5-HT7 receptors (NCBI accession NM—022938). Compound affinity for the rat 5-HT7 receptor subtype was evaluated by competitive radioligand binding assays using 5-carboxamido[3H]tryptamine ([3H]5-CT) (Amersham Biosciences, cat. 90000403) detection. HitHunter™ cAMP assays are in-vitro based competitive immunoassays. The assay was performed on the HEK-293 cell line stably transfected with r5-HT7 receptor. Cells were pre-incubated with test compounds for 10 minutes. For antagonist testing, the cells were then challenged with 100 nM 5-CT for 20 minutes. Cells were then lysed and cAMP measured according to manufacturers protocol (Amersham, cat. NET791250UC) or [3H]mesulergine (Amersham, cat. TRK1041). The assay was performed on membranes prepared from HEK-293 cells stably transfected with h5-HT6. Following centrifugation, membranes were resuspended and incubated for 60 min at room temperature with 1.7 nM [3H]LSD in the presence of increasing concentration of test compounds. Nonspecific binding was defined in the presence of 10 μM clozapine (Tocris, cat. TRK1068). Homogenized HEK-293 membranes expressing the human SERT were incubated in 50 mM Tris-HCl (pH 7.5), 120 mM NaCl, 5 mM KCl with [3H]-citalopram (3 nM) with or without test compounds. Nonspecific binding was determined in the presence of 10 μM fluoxetine. Radioactivity readouts and Ki values were performed as previously described for r5-HT7. Table 1 shows assay results for exemplified compounds of the invention. Compounds were assayed in their free form or as salts, as indicated in the Examples section above.
While the invention has been illustrated by reference to exemplary and preferred embodiments, it will be understood that the invention is intended not to be limited by the foregoing detailed description, but to be defined by the appended claims as properly construed under principles of patent law.
Claims
1. A compound selected from the group consisting of (a) compounds of Formula (I):
- wherein
- R1 is —H, monocyclic cycloalkyl, phenyl, or benzyl;
- m is 2 or 3;
- n is 1 or 2;
- R2 and R3 are each independently —H or —C1-4alkyl;
- R4 is —H, F, C1-4alkyl, or R4 is —OH when L is —CH2—, —CF2—, —CHF—, —OCH2—, or —OCH(CH3)—;
- L is —O—, —CH2—, —OCH2—, —OCH(CH3)—, —CH2O—, —CF2—, or —CHF—;
- Z is —O—, —C(O)—, —OCH(Rb)—, or —OCH2C(Rc)(Rd)—; where Rb is —H; a —C1-4alkyl group unsubstituted or substituted with OH or halo; —CO2C1-4alkyl; or —CO2H; and Rc and Rd are each independently —H, —O—C1-4alkyl, or halo; or Rc and Rd taken together form an oxime, a C1-4alkyl oxime, or a carbonyl group; or Rc and Rd taken together with the carbon to which they are attached form a C3-6cycloalkyl group;
- R5 is: i) a phenyl group, unsubstituted or substituted with one, two, or three Rg substituents; where each Rg substituent is selected from the group consisting of: —C1-6alkyl, —OH, —OC1-6alkyl, —CN, —NO2, —C(O)C1-6alkyl, S(O)0-2—C1-6alkyl, —OS(O)0-2—C1-6alkyl, —SO2CF3, —SCF3, halo, —CF3, —OCF3, —CO2H, —CO2C1-6alkyl, —CH2OH, monocyclic cycloalkyl, phenyl, thiophenyl, benzhydryl, and oxadiazolyl; or two Rg substituents taken together form —OCH2O—, —OCF2O—, or —OCH2CH2O—; ii) a naphthyl group, unsubstituted or substituted with C1-4alkyl or halo; iii) a monocyclic heteroaryl group, unsubstituted or substituted with one, two, or three Rg substituents; iv) a fused bicyclic heteroaryl group, unsubstituted or substituted with C1-4alkyl or halo; v) a monocyclic cycloalkyl group, optionally fused to a phenyl ring, and unsubstituted or substituted with one or two substituents selected from the group consisting of: —C1-4alkyl, —OC1-4alkyl, halo, —CF3, oxime, —C1-4alkyl oxime, or phenyl; and vi) a monocyclic heterocycloalkyl group, optionally fused to or substituted with phenyl; X is C or N, R6 or R7 are each independently —H, halo, —CF3, thiophene, or —C(O)N(Rx)Ry; wherein Rx and Ry are each independently —H or —C1-4alkyl; and (b) pharmaceutically acceptable salts of the compounds of Formula (I).
2. A compound as defined in claim 1, wherein R1 is —H, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —C(CH3)3, cyclopropyl, cyclobutyl, or benzyl.
3. A compound as defined in claim 2, wherein R1 is —H.
4. (canceled)
5. A compound as defined in claim 1, wherein m and n are each 2.
6. A compound as defined in claim 1, wherein m is 1 and n is 2.
7. A compound as defined in claim 1, wherein m is 3 and n is 1.
8. A compound as defined in claim 1, wherein R2 is —H or —CH3.
9. A compound as defined in claim 1, wherein R3 is —H or —CH3.
10. A compound as defined in claim 1, wherein R2 and R3 are each —H.
11. A compound as defined in claim 1, wherein R4 is —H.
12. A compound as defined in claim 1, wherein L is —O—, —CH2—, —OCH2—, —OCH(CH3)—, —CH2O—, —CHF—, or —CF2—.
13. A compound as defined in claim 1, wherein L is —O—.
14. A compound as defined in claim 1, wherein Z is —O—, —C(O)—, —OCH2—, —OCH(CH3)—, —OCH(CH2CH3)—, —OCH(CH2OH)—, —OCH(CO2H)—, —OCH(CH2F)—, —OCH2CH2—, —OCH2CH(F)—, —OCH2CH(OCH3)—, —OCH2C(NOH)—, —OCH2C(NOCH3)—, —OCH2CF2—, —OCH2C(O)—, or
15. A compound as defined in claim 1, wherein Z is —O—, —OCH2—, —OCH2CH2—, or —OCH(CH3)—.
16. A compound as defined in claim 1, wherein R5 is phenyl, optionally substituted with halo, —OCH3, —OSO2CH3, CF3,
17. A compound as defined in claim 1, wherein R5 is cyclohexyl, 2-indanyl, or furanyl optionally substituted with one or more substituents individually selected from halo, —CH3, —CF3, —OCF3, or —CN.
18. A compound as defined in claim 1, wherein R5 is selected from the group consisting of: and 5-methyl-isoxazole-3-yl.
- i) cyclopropyl, cyclobutyl, 3-phenyl-cyclobutyl, cyclopentyl, cyclohexyl, phenyl, 3- or 4-bromo-phenyl, 2-, 3- or 4-chloro-phenyl, 3,4-dichloro-phenyl, 3- or 4-cyano-phenyl, 2-, 3- or 4-fluoro-phenyl, 3-chloro-4-fluoro-phenyl, 4-chloro-3-fluoro-phenyl, 4-chloro-3-trifluoromethyl-phenyl, 3-chloro-4-trifluoromethoxy-phenyl, 2,4-difluoro-phenyl, 2-fluoro-4-trifluoromethyl-phenyl, 3-fluoro-4-trifluoromethyl-phenyl, 4-fluoro-3-trifluoromethyl-phenyl, 3- or 4-methyl-phenyl, 3- or 4-methylsulfanyl-phenyl, 3- or 4-methoxy-phenyl, 3-chloro-4-methoxy-phenyl, 3-methanesulfonyloxy-phenyl, 3- or 4-methoxy-phenyl, 3-trifluoromethoxy-phenyl, 2-, 3- or 4-trifluoromethyl-phenyl, 4-fluoro-3-trifluoromethyl-phenyl, 3- or 4-trifluoromethylsulfanyl-phenyl, 3-trifluoromethoxy-phenyl,
- ii) 3-azetidinyl, 1-benzyl-azetidin-3-yl, 1-benzhydryl-azetidin-3-yl, 1-isopropyl-azetidin-3-yl, benzo[1,3]dioxol-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 2-benzofuranyl, 5-benzofuranyl, 2,3-dihydro-benzofuran-2-yl, 2-benzothiazolyl, 6-benzothiazolyl, 1H-benzotriazole-6-yl, 1-methyl-1H-benzotriazole-6-yl, 2- or 3-chromanyl, 2- or 3-furanyl, 5-trifluoromethyl-2-furanyl, 2-indanyl, tetrahydro-3-furanyl, 1-Hydroxyimino-indan-2-yl, 4-methoxy-2-indanyl, 5-fluoro-1-indanyl, 5-methyl-1-indanyl, 5- or 6-chloro-1-indanyl, 6-fluoro-1-indanyl, 6-trifluoromethyl-1-indanyl, 6-methyl-1-indanyl, 5-fluoro-2-indanyl, 5-methoxy-2-indanyl, [1,2,4]oxadiazole-5-yl, 3-cyclopropyl-[1,2,4]oxadiazole-5-yl, 3-cyclobutyl-[1,2,4]oxadiazole-5-yl, 3-isopropyl-[1,2,4]oxadiazole-5-yl, phenoxy, 4-piperidinyl, 2- or 3-pyrrolidinyl, 3-methyl-[1,2,4]oxadiazole-5-yl, 5-oxazolyl, 3-, 4- or 5-pyrazolyl, 4-trifluoromethyl-2-pyridinyl, 2-, 3- or 4-pyridinyl, 6-trifluoromethyl-2-pyridinyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, 1,2,3,4-tetrahydro-naphthalen-2-yl, 1-phenyl-3-azetidinyl, 4- or 5-thiazolyl, 2-methyl-thiazole-4-yl, 2-thiophen-2-yl-thiazole-4-yl,
19. A compound as defined in claim 1, wherein R6 and R7 are each independently —H, halo, —CF3, thiophene-3-yl, or N,N-dimethyl-formamidyl.
20. A compound as defined in claim 1, wherein R6 is —H or halo.
21. A compound as defined in claim 1, wherein R6 is —H or halo and R7 is —H, halo, —CF3, thiophene-3-yl, or N,N-dimethyl-formamidyl.
22. A compound as defined in claim 1, wherein X is C.
23. A compound as defined in claim 1, wherein X is N.
24. A compound as defined in claim 1, selected from the group consisting of:
- (R)-3-[5-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-pyrrolidine;
- (R)-3-[5-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-pyrrolidine;
- (R)-3-[5-Chloro-2-(2-chloro-benzyloxy)-phenoxy]-pyrrolidine;
- (R)-3-[5-Chloro-2-(2-chloro-benzyloxy)-phenoxy]-1-methyl-pyrrolidine;
- 4-(2-Benzyloxy-5-chloro-phenoxy)-piperidine;
- 4-[5-Chloro-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-piperidine;
- 4-[5-Bromo-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-piperidine;
- 4-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-piperidine;
- 4-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-piperidine;
- 4-[5-Bromo-2-(2-fluoro-benzyloxy)-phenoxy]-piperidine;
- 4-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-piperidine;
- (±)-3-[5-Chloro-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-piperidine;
- (±)-3-(2-Benzyloxy-5-chloro-phenoxy)piperidine;
- (±)-3-[5-Chloro-2-(3-trifluoromethyl-benzyloxy)-phenoxy]-piperidine;
- (R)-3-(2-Benzyloxy-4-chloro-phenoxy)-pyrrolidine;
- (R)-3-(2-Benzyloxy-4-chloro-phenoxy)-1-methyl-pyrrolidine;
- (R)-3-[4-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-pyrrolidine;
- (R)-3-[4-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-pyrrolidine;
- (S)-3-[4-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-pyrrolidine;
- (±)-3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-pyrrolidine;
- (±)-3-[5-Bromo-2-(3-methoxy-benzyloxy)-phenoxy]-1-methyl-pyrrolidine;
- (±)-3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-1-methyl-pyrrolidine;
- (±)-3-(2-Benzyloxy-5-bromo-phenoxy)-1-methyl-pyrrolidine;
- (±)-Methanesulfonic acid 3-[4-bromo-2-(1-methyl-pyrrolidin-3-yloxy)-phenoxymethyl]-phenyl ester;
- (±)-Methanesulfonic acid 3-[2-(1-methyl-pyrrolidin-3-yloxy)-phenoxymethyl]-phenyl ester;
- (R)-4-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-piperidine;
- (±)-4-[5-Chloro-2-[1-(3-chloro-phenyl)-ethoxy]-phenoxy]-piperidine;
- (±)-4-[5-Chloro-2-[1-(3-trifluoromethoxy-phenyl)-ethoxy]-phenoxy]-piperidine;
- (±)-4-[5-Chloro-2-[1-(2-fluoro-phenyl)-ethoxy]-phenoxy]-piperidine;
- (R,S)-3-[5-Chloro-2-[1-((R)-3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-piperidine;
- (±)-4-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-propoxy]-phenoxy]-piperidine;
- (±)-4-[5-Chloro-2-(2-fluoro-1-phenyl-ethoxy)-phenoxy]-piperidine;
- 4-(5-Chloro-2-phenoxy-phenoxy)-piperidine;
- (S)-3-(4-Chloro-2-p-tolyloxy-phenoxy)-pyrrolidine;
- (R)-3-(4-Chloro-2-p-tolyloxy-phenoxy)-pyrrolidine;
- (R)-3-(4-Chloro-2-p-tolyloxy-phenoxy)-1-methyl-pyrrolidine;
- (S)-3-[4-Chloro-2-(4-fluoro-phenoxy)-phenoxy]-pyrrolidine;
- (R)-3-[4-Chloro-2-(4-fluoro-phenoxy)-phenoxy]-pyrrolidine;
- (R)-3-[4-Chloro-2-(4-fluoro-phenoxy)-phenoxy]-1-methyl-pyrrolidine;
- (S)-3-(4-Chloro-2-o-tolyloxy-phenoxy)-pyrrolidine;
- (S)-3-(4-Chloro-2-m-tolyloxy-phenoxy)-pyrrolidine;
- (S)-3-[4-Chloro-2-(4-fluoro-3-methyl-phenoxy)-phenoxy]-pyrrolidine;
- (S)-3-[4-Chloro-2-(4-chloro-phenoxy)-phenoxy]-pyrrolidine;
- (S)-3-[4-Chloro-2-(3-chloro-phenoxy)-phenoxy]-pyrrolidine;
- (S)-3-[2-(4-Bromo-phenoxy)-4-chloro-phenoxy]-pyrrolidine;
- (S)-3-[4-Chloro-2-(4-isopropyl-phenoxy)-phenoxy]-pyrrolidine; and
- (±)-3-[5-Bromo-2-(4-bromo-phenoxy)-phenoxy]-1-ethyl-pyrrolidine;
- and pharmaceutically acceptable salts thereof.
25. A pharmaceutical composition comprising an effective amount of at least one compound selected from compounds of Formula (I):
- wherein
- R1 is —H, monocyclic cycloalkyl, phenyl, or benzyl;
- m is 2 or 3;
- n is 1 or 2;
- R2 and R3 are each independently —H or —C1-4alkyl;
- R4 is —H, F, C1-4alkyl, or R4 is —OH when L is —CH2—, —CF2—, —CHF—, —OCH2—, or —OCH(CH3)—;
- L is —O—, —CH2—, —OCH2—, —OCH(CH3)—, —CH2O—, —CF2—, or —CHF—;
- Z is —O—, —C(O)—, —OCH(Rb)—, or —OCH2C(Rc)(Rd)—; where where Rb is —H; a —C1-4alkyl group unsubstituted or substituted with OH or halo; —CO2C1-4alkyl; or —CO2H; and Rc and Rd are each independently —H, —O—C1-4alkyl, or halo; or Rc and Rd taken together form an oxime, a C1-4alkyl oxime, or a carbonyl group; or Rc and Rd taken together with the carbon to which they are attached form a C3-6cycloalkyl group;
- R5 is: i) a phenyl group, unsubstituted or substituted with one, two, or three Rg substituents; where each Rg substituent is selected from the group consisting of: —C1-6alkyl, —OH, —OC1-6alkyl, —CN, —NO2, —C(O)C1-6alkyl, —S(O)0-2—C1-6alkyl, —OS(O)0-2—C1-6alkyl, —SO2CF3, —SCF3, halo, —CF3, —OCF3, —CO2H, —CO2C1-6alkyl, —CH2OH, monocyclic cycloalkyl, phenyl, thiophenyl, benzhydryl, and oxadiazolyl; or two Rg substituents taken together form —OCH2O—, —OCF2O—, or —OCH2CH2O—; ii) a naphthyl group, unsubstituted or substituted with C1-4alkyl or halo; iii) a monocyclic heteroaryl group, unsubstituted or substituted with one, two, or three Rg substituents; iv) a fused bicyclic heteroaryl group, unsubstituted or substituted with C1-4alkyl or halo; v) a monocyclic cycloalkyl group, optionally fused to a phenyl ring, and unsubstituted or substituted with one or two substituents selected from the group consisting of: —C1-4alkyl, —OC1-4alkyl, halo, —CF3, oxime, —C1-4alkyl oxime, or phenyl; and vi) a monocyclic heterocycloalkyl group, optionally fused to or substituted with phenyl; X is C or N, R6 or R7 are each independently —H, halo, —CF3, thiophene, or —C(O)N(Rx)Ry; wherein Rx and Ry are each independently —H or —C1-4alkyl; and (b) pharmaceutically acceptable salts of the compounds of Formula (I).
26. A pharmaceutical composition according to claim 25, wherein said at least one compound is selected from the group consisting of:
- (R)-3-[5-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-pyrrolidine;
- (R)-3-[5-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-pyrrolidine;
- (R)-3-[5-Chloro-2-(2-chloro-benzyloxy)-phenoxy]-pyrrolidine;
- (R)-3-[5-Chloro-2-(2-chloro-benzyloxy)-phenoxy]-1-methyl-pyrrolidine;
- 4-(2-Benzyloxy-5-chloro-phenoxy)-piperidine;
- 4-[5-Chloro-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-piperidine;
- 4-[5-Bromo-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-piperidine;
- 4-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-piperidine;
- 4-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-piperidine;
- 4-[5-Bromo-2-(2-fluoro-benzyloxy)-phenoxy]-piperidine;
- 4-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-piperidine;
- (±)-3-[5-Chloro-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-piperidine;
- (±)-3-(2-Benzyloxy-5-chloro-phenoxy)piperidine;
- (±)-3-[5-Chloro-2-(3-trifluoromethyl-benzyloxy)-phenoxy]-piperidine;
- (R)-3-(2-Benzyloxy-4-chloro-phenoxy)-pyrrolidine;
- (R)-3-(2-Benzyloxy-4-chloro-phenoxy)-1-methyl-pyrrolidine;
- (R)-3-[4-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-pyrrolidine;
- (R)-3-[4-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-pyrrolidine;
- (S)-3-[4-Chloro-2-(3-chloro-benzyloxy)-phenoxy]-pyrrolidine;
- (±)-3-[5-Bromo-2-(3-chloro-benzyloxy)-phenoxy]-1-methyl-pyrrolidine;
- (±)-3-[5-Bromo-2-(3-methoxy-benzyloxy)-phenoxy]-1-methyl-pyrrolidine;
- (±)-3-[5-Bromo-2-(3-fluoro-benzyloxy)-phenoxy]-1-methyl-pyrrolidine;
- (±)-3-(2-Benzyloxy-5-bromo-phenoxy)-1-methyl-pyrrolidine;
- (±)-Methanesulfonic acid 3-[4-bromo-2-(1-methyl-pyrrolidin-3-yloxy)-phenoxymethyl]-phenyl ester;
- (±)-Methanesulfonic acid 3-[2-(1-methyl-pyrrolidin-3-yloxy)-phenoxymethyl]-phenyl ester;
- (R)-4-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-piperidine;
- (±)-4-[5-Chloro-2-[1-(3-chloro-phenyl)-ethoxy]-phenoxy]-piperidine;
- (±)-4-[5-Chloro-2-[1-(3-trifluoromethoxy-phenyl)-ethoxy]-phenoxy]-piperidine;
- (±)-4-[5-Chloro-2-[1-(2-fluoro-phenyl)-ethoxy]-phenoxy]-piperidine;
- (R,S)-3-[5-Chloro-2-[14-(R)-3-trifluoromethyl-phenyl)-ethoxy]-phenoxy]-piperidine;
- (±)-4-[5-Chloro-2-[1-(3-trifluoromethyl-phenyl)-propoxy]-phenoxy]-piperidine;
- (±)-4-[5-Chloro-2-(2-fluoro-1-phenyl-ethoxy)-phenoxy]-piperidine;
- 4-(5-Chloro-2-phenoxy-phenoxy)-piperidine;
- (S)-3-(4-Chloro-2-p-tolyloxy-phenoxy)-pyrrolidine;
- (R)-3-(4-Chloro-2-p-tolyloxy-phenoxy)-pyrrolidine;
- (R)-3-(4-Chloro-2-p-tolyloxy-phenoxy)-1-methyl-pyrrolidine;
- (S)-3-[4-Chloro-2-(4-fluoro-phenoxy)-phenoxy]-pyrrolidine;
- (R)-3-[4-Chloro-2-(4-fluoro-phenoxy)-phenoxy]-pyrrolidine;
- (R)-3-[4-Chloro-2-(4-fluoro-phenoxy)-phenoxy]-1-methyl-pyrrolidine;
- (S)-3-(4-Chloro-2-o-tolyloxy-phenoxy)-pyrrolidine;
- (S)-3-(4-Chloro-2-m-tolyloxy-phenoxy)-pyrrolidine;
- (S)-3-[4-Chloro-2-(4-fluoro-3-methyl-phenoxy)-phenoxy]-pyrrolidine;
- (S)-3-[4-Chloro-2-(4-chloro-phenoxy)-phenoxy]-pyrrolidine;
- (S)-3-[4-Chloro-2-(3-chloro-phenoxy)-phenoxy]-pyrrolidine;
- (S)-3-[2-(4-Bromo-phenoxy)-4-chloro-phenoxy]-pyrrolidine;
- (S)-3-[4-Chloro-2-(4-isopropyl-phenoxy)-phenoxy]-pyrrolidine; and
- (±)-3-[5-Bromo-2-(4-bromo-phenoxy)-phenoxy]-1-ethyl-pyrrolidine;
- and pharmaceutically acceptable salts, thereof.
27. A pharmaceutical composition according to claim 25, further comprising: an active ingredient selected from the group consisting of an additional active ingredient selected from the group consisting of: H1 receptor antagonists, H2 receptor antagonists, H3 receptor antagonists, topiramate, norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, noradrenergic reuptake inhibitors, non-selective serotonin re-uptake inhibitors, acetylcholinesterase inhibitors, modafinil, anti-psychotics, sedatives, monoamine oxidase inhibitors, and tricyclic antidepressants.
28. A method of treating a subject suffering from or diagnosed with a disease or disorder selected from the group consisting of: depression, anxiety, schizophrenia, bipolar disorders, Alzheimer's disease, Parkinson's disease, hypotension, peripheral vascular disorders, cardiovascular shock, renal disorders, gastric motility, diarrhea, spastic colon, irritable bowel disorders, ischemias, septic shock, urinary incontinence, glaucoma, optic neuritis, diabetic retinopathy, retinal edema and age related macular degeneration, comprising administering to the subject an effective amount of at least one agent selected from compounds of Formula (I) and pharmaceutically acceptable salts of said compounds of Formula (I):
- wherein
- R1 is —H, monocyclic cycloalkyl, phenyl, or benzyl;
- m is 2 or 3;
- n is 1 or 2;
- R2 and R3 are each independently —H or —C1-4alkyl;
- R4 is —H, F, C1-4alkyl, or R4 is —OH when L is —CH2—, —CF2—, —CHF—, —OCH2—, or —OCH(CH3)—;
- L is —O—, —CH2—, —OCH2—, —OCH(CH3)—, —CH2O—, —CF2—, or —CHF—;
- Z is —O—, —C(O)—, —OCH(Rb)—, or —OCH2C(Rc)(Rd)—; where where Rb is —H; a —C1-4alkyl group unsubstituted or substituted with OH or halo; —CO2C1-4alkyl; or —CO2H; and Rc and Rd are each independently —H, —O—C1-4alkyl, or halo; or Rc and Rd taken together form an oxime, a C1-4alkyl oxime, or a carbonyl group; or Rc and Rd taken together with the carbon to which they are attached form a C3-6cycloalkyl group;
- R5 is: i) a phenyl group, unsubstituted or substituted with one, two, or three Rg substituents; where each Rg substituent is selected from the group consisting of: —C1-6alkyl, —OH, —OC1-6alkyl, —CN, —NO2, —C(O)C1-6alkyl, —S(O)0-2—C1-6alkyl, —OS(O)0-2—C1-6alkyl, —SO2CF3, —SCF3, halo, —CF3, —OCF3, —CO2H, —CO2C1-6alkyl, —CH2OH, monocyclic cycloalkyl, phenyl, thiophenyl, benzhydryl, and oxadiazolyl; or two Rg substituents taken together form —OCH2O—, —OCF2O—, or —OCH2CH2O—; ii) a naphthyl group, unsubstituted or substituted with C1-4alkyl or halo; iii) a monocyclic heteroaryl group, unsubstituted or substituted with one, two, or three Rg substituents; iv) a fused bicyclic heteroaryl group, unsubstituted or substituted with C1-4alkyl or halo; v) a monocyclic cycloalkyl group, optionally fused to a phenyl ring, and unsubstituted or substituted with one or two substituents selected from the group consisting of: —C1-4alkyl, —OC1-4alkyl, halo, —CF3, oxime, oxime, or phenyl; and vi) a monocyclic heterocycloalkyl group, optionally fused to or substituted with phenyl; X is C or N, R6 or R7 are each independently —H, halo, —CF3, thiophene, or —C(O)N(Rx)Ry; wherein Rx and Ry are each independently —H or —C1-4alkyl; and (b) pharmaceutically acceptable salts of the compounds of Formula (I).
29. A method according to claim 28, wherein the disease, disorder, or condition is selected from the group consisting of: sleep disorders, depression/anxiety, generalized anxiety disorder, schizophrenia, bipolar disorders, cognitive disorders, mild cognitive impairment, Alzheimer's disease, Parkinson's disease, psychotic disorders, phobic disorders, obsessive-compulsive disorder, mood disorders, post-traumatic stress and other stress-related disorders, migraine, pain, eating disorders, obesity, sexual dysfunction, metabolic disturbances, hormonal imbalance, hot flushes associated with menopause, alcohol abuse, drug abuse, addictive disorders including drug addiction and alcohol addiction, nausea, inflammation, centrally mediated hypertension, sleep/wake disturbances, jetlag, and circadian rhythm abnormalities.
30. A method according to claim 28, wherein the disease, disorder, or condition is selected from the group consisting of: hypotension, peripheral vascular disorders, cardiovascular shock, renal disorders, gastric motility, diarrhea, spastic colon, irritable bowel disorders, ischemias, septic shock, and urinary incontinence.
31. The method according to claim 28, wherein the disease, disorder, or medical condition is selected from the group consisting of: glaucoma, optic neuritis, diabetic retinopathy, retinal edema, and age-related macular degeneration.
Type: Application
Filed: Oct 10, 2013
Publication Date: Feb 6, 2014
Applicant: Janssen Pharmaceutica NV (New Brunswick, CA)
Inventors: Nicholas I. Carruthers (Poway, CA), Wenying Chai (San Diego, CA), Jill A. Jablonowski (San Diego, CA), Chandravadan R. Shah (San Diego, CA), Brock T. Shireman (Poway, CA), Devin M. Swanson (San Diego, CA), Vi Tran (New York, NY), Victoria Wong (San Diego, CA)
Application Number: 14/051,199
International Classification: C07D 205/04 (20060101); C07D 405/12 (20060101); A61K 31/423 (20060101); A61K 31/4465 (20060101); A61K 31/428 (20060101); A61K 31/40 (20060101); C07D 471/04 (20060101); C07D 401/12 (20060101); C07D 211/94 (20060101); C07D 417/12 (20060101); C07D 413/12 (20060101); C07D 207/12 (20060101); A61K 45/06 (20060101); C07D 403/12 (20060101); A61K 31/4375 (20060101); A61K 31/4725 (20060101); A61K 31/397 (20060101);
